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I. PRD Risk Title: Risk Factor of Inadequate Nutrition 
 
Description: It is critical that crewmembers be adequately nourished before, during, and after 
space missions (1, 2). Required research areas within this risk include validation of the correct 
nutritional needs, assessment of the stability of nutrients during long-duration flight, correct 
packaging and preservation techniques, effects of countermeasures on nutrition, and use of 
nutrients as countermeasures. 
 
Risk Statement: Given that adequate nutrition is a key factor in all physiological functions, that 
spaceflight has been shown to alter many physiological functions in humans, and that 
countermeasures for individual systems may alter nutritional status, there is a possibility that 
inadequate and/or suboptimal nutrition will compromise crew health, including endurance, 
muscle mass and strength, immune system function, bone mass and strength, cardiovascular 
performance, gastrointestinal function, endocrine function, ocular health, psychological health, 
behavior and performance, and ability to mitigate oxidative damage. 
 
 
 
 
II. Executive Summary 
 
 The importance of nutrition in exploration has been documented repeatedly throughout 
history, where, for example, in the period between Columbus’ voyage in 1492 and the invention 
of the steam engine, scurvy resulted in more sailor deaths than all other causes of death 
combined (3). Because nutrients are required for the structure and function of every cell and 
every system in the body, defining the nutrient requirements for spaceflight and ensuring 
provision and intake of those nutrients are primary issues for crew health and mission success. 
Unique aspects of nutrition during space travel include the overarching physiological adaptation 
to weightlessness, psychological adaptation to extreme and remote environments, and the ability 
of nutrition and nutrients to serve as countermeasures to ameliorate the negative effects of 
spaceflight on the human body. Key areas of clinical concern for long-duration spaceflight 
include loss of body mass (general inadequate food intake), bone and muscle loss, cardiovascular 
and immune system decrements, increased radiation exposure and oxidative stress, vision and 
ophthalmic changes, behavior and performance, nutrient supply during extravehicular activity, 
and general depletion of body nutrient stores because of inadequate food supply, inadequate food 
intake, increased metabolism, and/or irreversible loss of nutrients.  These topics are reviewed 
herein, based on the current gap structure. 
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III. Introduction 
 
This document is based on many sources of information, including the nutritional 
requirements defined in 1991 for Space Station Freedom missions (2, 4), the updated set of 
requirements developed in 1995 (in collaboration with Russian partners) for Mir flights (5), the 
available published data from short-duration Space Shuttle flights, and longer Skylab, Mir, and 
International Space Station (ISS) flights.  
The initial Human Research Program (HRP) Nutrition Evidence Book was completed in 
2008, and a modified version of that document was published in 2009 (2) (available for free 
download at http://go.nasa.gov/QS1KW1). What follows is an update completed in 2014, which 
has been reorganized to reflect updates and changes to the approved Nutrition Discipline Gaps. 
For full disclosure – Almost all of the text of this document is directly taken from these two 
original publications (2, 6).  Any thought that the document herein is “original” writing 
should be abandoned at this point. While the 2009 book (2) took more of a nutrient-based 
approach, the 2014 book (6) took a systems-based approach.  Both approaches are included 
herein, as the knowledge gaps also follow these two paths.  
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IV. Gap Structure 
 The Nutrition Discipline is part of the Human Health Countermeasures Element of the 
NASA Human Research Program (HRP). The Nutrition Discipline currently manages several 
Gaps relating to nutrition within the Risk Factor of Inadequate Nutrition. As of this writing in 
late 2014, the approved Gap structure is as follows: 
N3.1: Determine the macronutrient requirements for spaceflight. 
N3.2: Determine the micronutrient requirements for spaceflight. 
N3.3: We need to determine changes in nutritional status due to spaceflight. 
N4: Does mission architecture and/or available countermeasures impact nutritional status 
of crewmembers during spaceflight? 
N6: What impact does the spaceflight environment have on oxidative damage? 
N7.1: We need to identify the most important nutritional factors for musculoskeletal 
health. 
N7.2: We need to identify the most important nutritional factors for cardiovascular 
health. 
N7.3: We need to identify the most important nutritional factors for ophthalmic health. 
N7.4: We need to identify the most important nutritional factors for behavior and 
performance. 
N7.5: We need to identify the most important nutritional factors for immune health. 
N13: Can renal stone risk be decreased using nutritional countermeasures? 
N15: We need to identify the most important nutritional factors for oxidative damage 
during spaceflight. 
 
 The Nutrition Gaps, Integrated Research Plan Rev F, and Human Research Roadmap 
structure are focused to define progress to gap closure and risk mitigation. Gaps N3.1, 3.2, 3.3, 
and 4 are the core gaps that are aimed at directly mitigating the risk factor of nutrition by 
addressing nutritional status and requirements, and the impact of countermeasures on nutrition. 
The remaining gaps are focused on nutrition as a major risk factor for other HRP Risks or 
physiological systems such as Oxidative stress, Muscle/Bone, Immune, Cardiovascular, Visual 
Impairment/Intracranial Pressure, and Behavior and Performance. A Gap addressing issues of 
drug and nutrient interaction needs to be added to the Integrated Research Plan with the next 
update. 
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V. Gap N3.1: Determine the macronutrient requirements for spaceflight. 
 
A. Food and Energy 
 
1. Background  
 
Ensuring that the spacecraft food systems provide palatable, safe, and nutritious foods is 
obviously critical for any space mission. The longer space station missions have included semi-
closed food systems, with periodic resupply and transient exposure to unique and fresh foods (7-
10). Exploration missions will have a more closed food system, with the potential for 
supplementation with food sources grown in situ (7, 8, 10). 
From the early days of the U.S. space program (11-16), development of foods for 
spaceflight has proven a significant challenge, yet the design criteria have changed little since 
then: minimal crumbling, ease of preparation and consumption in microgravity, minimal trash 
volume, and high palatability. With one exception, the food systems used in every space program 
to date have been entirely shelf-stable, and they are composed primarily of rehydratable or 
thermostabilized food items (7, 10). Although these foods are known to have lower hedonistic 
value (palatability) than fresh or frozen foods, ground-based studies have clearly shown that the 
Shuttle food system can adequately support most nutritional requirements (17). Skylab is the 
only U.S. program that has included frozen foods (7, 10).  
Energy itself is not readily stored in the body, but the substrates for energy are. Energy in 
the form of heat is obtained by oxidizing carbohydrates, fats, proteins, and alcohol; it is also 
known as the heat of combustion. Fat provides the most energy of these sources, at about 9 
kcal/gram. Carbohydrates and proteins provide about 4 kcal/gram, and alcohol provides about 7 
kcal/gram. Because the body can adapt to different energy sources, large variations in 
macronutrient intake are generally well tolerated. Adipose tissue is the only viable long-term 
source of stored energy. Carbohydrate stored as glycogen in liver and muscle provides a transient 
(hours) source of carbohydrate. Protein can be broken down to release amino acids, but this is 
done at the expense of muscle tissue.  
The estimated energy requirements (EER) for space missions are based on total energy 
expenditure (TEE), as calculated from the 2002 Institute of Medicine Dietary Reference Intake 
reports (18), using an activity factor of 1.25 (active) along with the individual’s age, body mass 
(kg), and height (m) in the following calculations: 
 
EER for men 19 years and older 
  EER = 622 – 9.53  Age [y] + 1.25  (15.9  Mass [kg] + 539.6  Ht [m]) 
 
EER for women 19 years and older 
  EER = 354 – 6.91  Age [y] + 1.25  (9.36  Mass [kg] + 726  Ht [m]) 
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2. Evidence 
 
Energy Expenditure 
 
 Energy expenditure is often hypothesized to be lower during flight than on the ground, 
because of the presumed relative hypokinesia in space (13). An early example of this is that 
lower energy expenditure was observed during extravehicular activity (EVA) on the lunar 
surface than during similar activities at 1g (19). This was determined through indirect 
calorimetry in the space suit. However, Space Shuttle crewmembers did not have any change in 
energy expenditure during EVA relative to before flight (20). 
 Studies of total energy expenditure of Shuttle astronauts documented that in-flight energy 
expenditure was unchanged from preflight levels (21), or in cases where these crews performed 
intensive exercise during the mission, energy expenditure during flight was higher than before 
flight (22). For these studies, the doubly-labeled water (water enriched with deuterium and 18O) 
technique was used to determine oxygen consumption (23). The benefits of this technique are 
that it is noninvasive and it takes into account the energy cost of all activities over a period of 
several days. The drawback of the method is that information about the individual components of 
total energy expenditure (TEE), such as resting, sleep, and exercise, is not available. The range 
of differences between preflight and in-flight TEE makes it important to have information about 
the components of TEE. Although it is assumed that moving the body mass around the cabin 
requires less expenditure of energy during weightlessness than at 1g, other metabolic activities, 
such as maintaining resting metabolic rate and responding to stress, may require increased 
energy expenditure during weightlessness.  
 In ground-based bed rest studies, an analog of spaceflight, resting energy expenditure did not 
change, but TEE was less during bed rest than before bed rest (24). Because TEE during flight is 
unchanged (21) or increased (22) from preflight levels, the lower TEE during bed rest may 
indicate that bed rest is not an appropriate model for studies of energy metabolism during flight. 
One possible explanation for this difference between bed rest and spaceflight is the lack of a 
metabolic response to stress during bed rest (25). Attempts have been made to improve the utility 
of bed rest studies by administering a metabolic stressor (such as triiodothyronine or cortisol) to 
provide a better ground-based model than bed rest alone for the metabolic effects of spaceflight 
on energy and fuel metabolism (26). 
 Energy requirements are typically estimated using standard equations, including the World 
Health Organization (WHO) (27) and dietary reference intake (DRI) equations (18), using a 
“moderately active” or “active” adjustment for activity level for these 2 equations, respectively. 
The DRI equation factors in age, sex, weight, and height in estimating energy requirements. 
While it would be more accurate to determine actual resting energy expenditure before flight for 
each astronaut, this testing has not been possible except in cases where these data were required 
for specific experiments. 
 The aforementioned studies of energy expenditure on Space Shuttle missions were performed 
on flights of 10 to 14 days’ duration. The objective of a European Space Agency (ESA)-
sponsored experiment initiated in 2012 is to determine energy expenditure during 6-month 
missions to the International Space Station. These data will help investigators understand 
whether any adaptation effect occurs on these longer missions, and thus may be important in 
estimating energy requirements for exploration missions (missions beyond low Earth orbit). 
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Energy Intake 
 Historically, inadequate energy intake and subsequent body mass loss have been considered 
hallmarks of spaceflight, and have occurred on many missions and programs (2, 9, 21, 28-37). 
From Apollo through the Shuttle program, crewmember dietary intakes during flight have 
averaged about 70% of predicted requirements (31), with ISS intakes on average about 80% of 
requirements (Figure 1). There are exceptions to this finding, including the Skylab missions of 
the early 1970s (38, 39), European flights to the Mir space station (40), and more recently some 
of the ISS missions (41). In the Skylab and Mir examples, crew participation in metabolic 
experiments has required consumption of balanced, controlled, eucaloric diets. As a result, 
crewmembers met their recommended energy intake requirements. It is difficult to determine 
whether the intakes on Skylab were related more to the requirement to consume the food or to 
the fact that the food was more palatable because of the additional variety available with frozen 
foods; however, increased palatability is obviously beneficial. 
 The International Space Station has accommodated 4- to 6-month missions dating back to 
2000. During this time, many aspects of these missions have evolved and new exercise 
equipment, reformulations of many space food items, and international foods from all partner 
agencies have debuted. These factors, coupled with the passage of lessons learned from one crew 
to the next, may have been responsible for our observation that many ISS crewmembers now 
consume recommended dietary intakes of energy, and also maintain body mass (31, 41). 
 
 
 
Figure 1. In-flight dietary intake of crewmembers in different 
space programs. Data are expressed as percentage of energy 
requirements predicted by the World Health Organization (WHO) 
(27). Apollo N=33, Skylab N=9, Shuttle N=32, Mir N=7, ISS E1-
18 N=26, E19-36 N=31. E = expedition. Apollo and Skylab data 
are from Bourland et al (7). Figure from (6), adapted from earlier 
publications (2, 42), with additional published data included (1, 
31, 41).  
 
 
 In cases where energy intakes do not meet 
requirements, absent definitive causes, many potential 
explanations have been proposed (13, 33, 43). Anecdotal reports of appetite vary significantly, as 
indicated in a Russian study in which 40% of Mir crewmembers reported decreased appetite, 
40% reported no change, and 20% reported increased appetite (44).  
 Food palatability is occasionally reported as a cause of reduced in-flight intake, and many 
anecdotal reports exist of changes in taste and aroma of food during flight (45-47). One 
hypothesis to explain these changes is that fluid shifts and congestion associated with the first 
days of microgravity can alter taste and odor perception. Other possibilities exist as well, 
including effects of atmospheric contaminants, stress, radiation, and psychological factors (45). 
Experimental research has not been able to clearly document changes in taste or olfaction during 
spaceflight or head-down-tilt bed rest (45, 48, 49), but it is hoped that ongoing ground-based and 
in-flight research on ISS will provide clarity. 
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 When tongue taste perception was measured before, during, and after a 30-day –6° head-
down bed rest period, subjects reported decreased appetite and lack of taste early in the bed rest 
phase (49, 50). By day 13 of the bed rest phase, for all tastes (sweet, salt, acidic, bitter), the 
threshold for taste sensitivity had increased. In contrast, in the 1990s no changes in odor or taste 
perception were found after 14 days of head-down bed rest (51), suggesting that multiple factors 
are likely involved in this process. Additional studies of taste and smell changes during bed rest 
are ongoing, and will help expand the evidence base for this area. 
 Flight-related changes in gastrointestinal function may also occur. Fluid shifts, in 
combination with reduced fluid intake, would tend to decrease gastrointestinal motility. 
Gastrointestinal transit time has not been systematically studied during flight, but during 10 days 
of –6° head-down bed rest, mouth-to-cecum transit time was significantly longer than it was 
during ambulatory control periods (52). However, because the Skylab astronauts and others were 
able to maintain a eucaloric diet in space, hypotheses about inability to consume the requisite 
amount of food because of stomach fullness or other factors are not likely to fully explain 
decreased dietary intake during flight. Russian studies of gastrointestinal function during actual 
and simulated spaceflight, in humans and in animal models, have previously been reviewed (53). 
A common cause of reduced dietary intake during the first days of a mission (54) is space motion 
sickness (47, 54-57). The effects of space motion sickness typically pass after the first several 
days of flight, but the decreased dietary intake can extend well beyond the first week (43). 
Anecdotal reports from long-duration crewmembers indicate that a rebound body mass gain 
occurred after flights on which on-orbit loss of body mass was significant, but in general, the 
data do not support this finding (Figure 2) (2). 
 
 
 
Figure 2. Postflight body weight (BW) in Mir and 
ISS crewmembers (N=20). Data are expressed as the 
mean ± SD of the percentage change from preflight 
body weight. R+0 = landing day, and AME1 and 
AME2 = first and second annual medical exams after 
return from the mission, respectively. (2) 
 
 
 
 
 
  Implications for Inadequate Energy Intake 
 
The obvious and immediate reason for concern about reduced dietary intake is the risk of 
body mass loss, and more specifically, loss of lean mass and bone tissue. Body mass losses of 
1% to 5% of preflight body mass have been a typical finding in the history of spaceflight, 
although some crewmembers have been able to maintain body mass (31, 41, 58). Indeed, all 
crewmembers on Gemini, Apollo (Figure 3), Skylab (Figure 4), and Apollo-Soyuz Test Project 
missions lost body mass (59); thus, ingestion of the prescribed energy intake on the U.S. Skylab 
missions did not ensure maintenance of body mass (38). In-flight and postflight losses of body 
mass are shown in Figure 4 and Figure 5. Documented weight losses have occurred on short- and 
long-duration flights in both the U.S. and Russian space programs (14, 33, 60-62). In one study 
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of 13 male Shuttle crewmembers, body mass losses ranged from 0 to 3.9 kg (21). Body mass loss 
has been observed to reach 10% to 15% of preflight body mass (63). Crewmembers on ISS 
(Figure 4 and Figure 5) have shown similar patterns of mass loss during and after flight (60). 
 
 
 
 
Figure 3. Body weight in Apollo crewmembers 
(Apollo 7 through 17) before (F-0) and after (R+0) 
flight (64). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. In-flight body mass measurement data from 55 ISS 
crewmembers. Data are expressed as percentage change from 
preflight values. Figure and data adapted from Zwart et al (60). 
 
 
 
 
 
 
 
 
 
Figure 5. Body mass on 
landing day expressed as 
percentage change from 
preflight. Each symbol 
represents a crewmember 
from a mission on the Space 
Shuttle (green, N=25), Skylab 
(red, N=9), Mir (blue squares, 
N=19), ISS Expeditions 1-18 
(dark purple, N=26), or 
Expeditions 19-36 (light 
purple, N=31). Some 
durations have been adjusted 
slightly to ensure anonymity. 
Data updated from initial 
publications (2, 6, 10). 
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Data relating reduced dietary intake to loss of body mass were collected from two ground-
based studies, not related to spaceflight, in which subjects were semi-starved. In the first study 
(65), subjects who consumed 580 kcal/d lost 7% of their body mass in 12 days and subjects who 
consumed 1010 kcal/d lost 11% of their body mass in 24 days. In the other study, starved 
subjects lost 9% of their body mass after 11 days, 15% by day 18, and 18% by day 43 (66).  
 
Data from Apollo missions clearly document the relationship between energy intake and 
weight loss (Figure 6). The mechanism for this energy-weight/mass connection has been 
hypothesized to involve multiple functions of many endocrine factors, including insulin, leptin, 
and growth hormone (67). 
 
 
 
Figure 6. Relationship between energy intake (kcal/kg body 
mass/d) and weight loss (change in body mass/d, kg) during 
Apollo missions. N=33. Data are courtesy of William Carpentier, 
as originally presented in (6). 
 
 
 
 
Only about 1% of the loss of body mass can be explained by loss of body water (28); 
most of the observed loss of body mass is accounted for by loss of muscle and fat tissue (20, 68). 
The water loss may be confounded by lean tissue loss, as metabolic water loss will be associated 
with depletion of glycogen stores and protein catabolism, both of which occur with inadequate 
intake. Inadequate energy intake is associated not only with loss of fat tissue (Figure 7), but also 
with decreased protein synthesis (69) (during spaceflight), increased protein catabolism (70) 
(during bed rest), and subsequent loss of lean tissue mass.  
 
 
 
 
Figure 7. In-flight oxidation of body fat related to in-flight 
energy deficit. Adapted from (22). 
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Besides the obvious concerns about body mass loss and dehydration (71), existing data 
suggest that many systems are affected by inadequate nutrient intake, including the muscle, bone, 
cardiovascular, and immune systems. The German Institute of Aerospace Medicine at the 
German Aerospace Center conducted a study jointly with ESA to evaluate the impact of 
hypocaloric nutrition on multiple systems. A crossover design was used, with hypocaloric and 
eucaloric phases, and bed rest and ambulatory phases. Results for body mass and protein 
metabolism, calcium loss, and LBNP “survival” are shown in Figure 8, Figure 9, Figure 10, and 
Figure 11. These clearly document the negative effects of undernutrition, exacerbating the 
negative effects of bed rest. These data document the fact that undernutrition exacerbates the 
negative effects of bed rest on human physiology (2, 6, 70). 
 
 
 
 
Figure 8. Body weight changes in a crossover-design bed 
rest study to evaluate the hypocaloric impact of nutrition on 
integrated physiology. Data are expressed as the change 
from the group average body weight before bed rest (6). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Leucine oxidation (an index of net protein 
catabolism) in a crossover-design bed rest study to 
evaluate the impact of hypocaloric nutrition on 
integrated physiology. There was a significant 
(P=0.04) interaction between bed rest and diet 
(adapted from (70)). 
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Figure 10. Urinary calcium in a crossover-design bed rest 
study to evaluate the impact of hypocaloric nutrition on 
integrated physiology.  Data are expressed as mmol Ca 
excreted per 24 hours before, during, and after bed rest. From 
inset legend: Up, ambulatory phase; HDT, head-down-tilt bed 
rest phase. 
 
 
 
 
 
 
 
 
 
Figure 11. Lower-body negative pressure (LBNP) 
“survival” in a crossover-design bed rest study to evaluate 
the impact of hypocaloric nutrition on integrated 
physiology.  Data are expressed as the number of subjects 
who were able to tolerate different amounts (minutes) of 
LBNP (72). 
 
 
 
 
 
 
3. Risk 
 
It is imperative that adequate resources be provided to support food consumption. A reliable 
food system must include a variety of palatable foods and the means to process them (such as 
rehydration, heating, and cooling). Time (for meal preparation, consumption, and cleanup) is 
another limited resource that often hinders dietary intake during spaceflight. 
The availability of freezers and refrigerators for food storage and preparation would provide 
a more palatable food system, which would increase dietary intake as well as provide added 
psychological support.  
Deficiency of energy leads to wasting and ultimately tissue breakdown, or even death. An 
excess of energy may lead to excess body mass if metabolic rate does not increase. The loss of 
lean body mass during spaceflight is significant and is associated with increased proteolysis and 
catabolism related to metabolic stress (73).  
The small amount of starvation data available suggest that for every 500 kcal consumed per 
day, about 1% of body mass can be conserved every 12 days. It would not be acceptable, 
however, to use these numbers for a long-term (>21 days) prediction of body mass loss or 
conserved body mass loss because after 21 days of starvation, the basal metabolic rate of the 
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body decreases (65, 74). This can be and has been accounted for using a mathematical model to 
predict body mass loss given changes in the basal metabolic rate (74), with results estimating that 
survival on 1000 kcal/d could exceed 3 years (compared with only 6 months without accounting 
for a decreased metabolic rate).  
It is difficult to predict the impact of suboptimal (or lack of) energy intake in otherwise 
healthy individuals. One issue is that the energy equivalent of the mass lost changes with time, as 
different body fuels are used at different times during semi-starvation (65, 74). With partial 
rations available (1000 calories per day), it is reasonable to expect that a person could survive for 
more than 4 to 6 months, potentially longer if the metabolic rate were to decrease because of 
decreased intake. Greater restrictions in energy availability would be expected to yield 
survivability ranging between this amount of time and the 1 to 2 months possible with no food. 
These projections obviously include many assumptions, unknowns, and extrapolations. Data 
from 10 Irish Republican Army hunger strikers, who consumed water ad libitum but no energy, 
vitamins, or minerals, indicate that an average 25-year-old male could survive no longer than 60 
days without energy (75, 76).  
Other possible effects of long-term low calorie intake include decreased motor and 
cognitive function, both of which could impair an astronaut’s ability to perform work-related 
tasks necessary for landing. According to military survival studies, astronauts would be expected 
to experience decreased endurance early on, and the decrease in strength would parallel the 
decrease in lean body mass (77). During total fasting, degradation of coordination, speed, and 
cognitive function would be evident within the first 2 weeks (77). 
The metabolic condition of ketosis, which would be expected to result from starvation, not 
only would have metabolic effects (including decreased appetite), but might also affect other 
aspects of the mission (for example, the life-support systems might not be able to remove the 
ketones from the air).  
It is speculated that a crew could survive on a spacecraft or planetary base for 40-60 days 
without food. With limited rations (1000 calories/d), a crew could survive 4 to 6 months 
(although physical performance capability might be severely degraded). The high-stress 
environment of a contingency during transit or on a planetary surface would likely exacerbate the 
basic effects of limited rations and would shorten projections of survivability estimated from 
ground-based studies. 
Insufficient dietary intake and subsequent body mass loss are significant not only for crew 
health, but also for medical operations and research studies, in which clear interpretation of 
essentially all other physiological data is impossible when subjects are malnourished; that is, 
virtually all spaceflight data collected on Shuttle, Mir, and ISS missions are confounded by 
inadequate dietary intake. Investigators who have studied bone and muscle, cardiovascular 
function, immune response, and other systems during spaceflight cannot say to what degree 
undernutrition affected their findings.  
 
 
 
 
 
 
 
 
Risk Factor of Inadequate Nutrition 
 
 21
4. Gaps 
 
Studies of energy expenditure have been conducted only on short-duration (Shuttle) flights 
(21, 22). Whether the same trends continue on longer flights is not known (an ESA-sponsored 
study of energy expenditure on ISS missions is currently being conducted on ISS. The health 
implications of this phenomenon need to be determined, and ways to prevent both in-flight body 
mass loss and postflight body mass gain need to be evaluated.  
While research may be warranted to better understand why astronauts typically do not 
consume 100% of their recommended intakes, recent data from ISS crewmembers clearly 
document that intakes can be met during spaceflight (41). In addition to maintaining energy 
intake and vitamin D status, in conjunction with exercise, these crewmembers maintained body 
mass; came home leaner, with less fat; and maintained bone mineral density at preflight levels 
(41). Additional details are provided in the Bone section. 
Although energy requirements are currently estimated using published equations (see 
above), valuable and more accurate information would be provided by actually determining 
resting metabolic rate in astronauts before (if not during) flight. The recent Pro K study (see 
Bone section) included provision of controlled diets based on estimated energy requirements. 
While these provisions were adequate for some crews, for others they seemed to provide excess 
calories, and for others insufficient calories. These differences are likely to be generally due to 
variability in individuals; again, this could be determined through preflight indirect calorimetry. 
Such measurements are included in the Integrated Nutrition experiment, but as of this writing 
(October 2014) there is debate as to whether this experiment will be manifested by the Human 
Research Program.  
With respect to the provision of energy in bed rest studies, the issues of whether and how to 
account for energy intake in this ground analog are separate. At least two approaches exist to 
controlling body mass and composition while studying human adaptation to bed rest: either 
maintaining body mass (as is typically done in the U.S.) or allowing subjects to lose total mass 
while keeping fat mass constant (and thus losing lean tissue). While this latter approach sounds 
intriguing, implementing it effectively has not been possible (to date), given the difficulties in 
measuring fat mass and adapting intake in a timely manner. In one case, there were significant 
differences in weight loss between groups, and even between subjects, which confounds 
interpretation of the findings (78-81).  In view of the difference between these two approaches, it 
has been proposed that a bed rest study of energy expenditure is required to determine the impact 
of this difference. This yielded nutrition knowledge gap 11 (identified by the Small Assessment 
Team in 2006) (82), “What model of bed rest energy expenditure is best?”  
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B. Protein 
 
 
1. Background  
 
As the major structural component of all cells in the body, protein includes molecules that 
perform many essential physiological functions, serving as enzymes, hormones, transport 
carriers, and other important molecules. The total energy contribution of protein to the average 
diet is about 15%. The nitrogen in their amino-acid building blocks makes protein, along with 
nucleic acids, one of the major nitrogen-containing macromolecules. The type of protein, such as 
animal or vegetable protein, that is incorporated into the diet may be an important factor to 
consider in determining protein requirements. 
Protein is one of the most critical limiting factors when the body is deprived of energy 
because essential amino acids are not stored in the body. A complete depletion of energy and 
protein reserves is said to be the cause of death from starvation. It is estimated that when 33-50% 
of total body protein is lost, death results (83). Total body mass loss in excess of 40-50% of 
initial body mass is not compatible with life (77, 84). In one case report, individuals on a hunger 
strike lost 30% of their total body mass and 19% of total body protein before they died (75, 76).  
 
 
 
 
2. Evidence 
 
  Protein Intake 
Maintaining a proper protein intake is vital, as both low-protein and high-protein diets can 
cause harm (and, at the extreme, death). A low-protein diet (below the recommended dietary 
allowance) for up to 4 weeks can decrease calcium absorption and cause increased secretion of 
parathyroid hormone in otherwise healthy subjects (85, 86). The impact of chronically low 
protein intake is not well understood; however, several studies suggest that low-protein diets are 
associated with loss of bone density (87, 88). 
Actual intakes of protein during spaceflight typically exceed these recommendations, as 
shown in Appendix A and (2). European studies have shown that on long missions, reaching (or 
exceeding) nominal protein intakes is common, but that on short flights (Shuttle missions), 
protein intake is less than the recommended amount because of insufficient food intake (9). On 
ISS missions, on average, protein intake is more than adequate (Figure 12). 
Some data suggest that during the recovery period after short-duration Shuttle flights, protein 
is a limiting nutrient, and that competition for substrate to replenish plasma proteins and muscle 
mass strains the system (89). This has not been tested experimentally, but it is clear that good 
nutrition is required for rapid return to optimal health. 
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Figure 12. Protein intake during spaceflight on ISS missions 
(N=56). Each point represents an individual crewmember, and 
is their reported average intake over the course of the mission. 
Dashed lines represent spaceflight (and ground-based) protein 
intake requirements of 0.8 g protein/kg body mass, and the 
range of protein intakes (1.2.-1.7 g/kg) recommended by the 
American Dietetic Association, Dietitians of Canada, and 
American College of Sports Medicine for high-intensity 
athletes (90). The blue lines represent the mean ± SD. Figure 
from (6). 
 
 
 
 
  Protein Status and Nitrogen Balance 
Basic clinical testing includes determinations of circulating proteins. Blood concentrations 
of total protein and albumin were elevated at landing after Skylab missions (Figure 13). Urinary 
albumin has been shown to be reduced during spaceflight and bed rest (91-93). Measurements of 
urinary albumin excretion, which is typically low in healthy individuals, have not been reported 
after landing. Potassium and nitrogen balances became increasingly negative throughout the 
Skylab flights, but urinary creatinine (a measure of muscle mass) did not change (39, 94) despite 
losses of leg volume (38, 95). Nitrogen balance has also been shown to be negative during 
Shuttle flights (96) 
 
 
 
 
 
 
 
 
 
 
Figure 13. Plasma total protein and albumin in Skylab crewmembers before flight and after landing (R+0, 
landing day) (39). 
 
 
 
3. Risk 
 
The risks associated with protein are twofold: deficiency and excess. Deficiency of protein 
leads to muscle loss, weakness, wasting, tissue breakdown, inability to perform one’s job 
(including egress from the spacecraft), and ultimately death. Excess protein exacerbates 
hypercalciuria and the risk of renal stone formation, and is detrimental to bone. Furthermore, 
specific amino acids may additionally increase these risks.  This is reviewed in much more detail 
Skylab
Pr
efl
igh
t
R+
0
R+
1
R+
3/4
R+
14
6.0
6.5
7.0
7.5
8.0
Pr
ot
ei
n 
(g
 %
)
Skylab
Pr
efl
igh
t
R+
0
R+
1
R+
3/4
R+
14
3.5
4.0
4.5
5.0
A
lb
um
in
 (g
 %
)
Pr
ot
ei
n 
in
ta
ke
(g
 p
ro
te
in
/k
g 
B
W
)
Risk Factor of Inadequate Nutrition 
 
 24
under Gap N7.1, “We need to identify the most important nutritional factors for musculoskeletal 
health.” 
 
 
4. Gaps 
 
Research continues on the effects of amino acid supplementation as a means to mitigate 
muscle loss. This research needs to continue to refine the details (such as dose and timing) and 
assess the viability of this countermeasure. 
Further research is also required to better understand the effects of protein source (animal 
vs. vegetable, and the effect of sulfur amino acid content) on bone loss and renal stone risk.  This 
has been advocated in context of spaceflight (97-99), and general health (100, 101). 
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C.   Carbohydrate 
 
1. Background 
 
Carbohydrates play an important role in the body because they supply the primary source of 
energy as well as a readily available source. This energy is oxidized and used by various organs 
and cells in the body, particularly the brain and red blood cells, which depend solely on 
carbohydrate for energy. The human body stores about 150 to 500 g of carbohydrate as 
glycogen, in the liver and skeletal muscle (102). Most of the body’s glycogen is in skeletal 
muscle. Muscle glycogen stores are used mainly by muscle, whereas the smaller glycogen stores 
in the liver are used to maintain, store, and export blood glucose. Glycogen stores, especially 
those in the liver, fluctuate greatly during the day in response to food intake, and these 
fluctuations may be involved in the regulation of food intake (103). Liver stores of glycogen are 
depleted after 12 to 18 hours of fasting (102). In skeletal muscle, glycogen synthesis is triggered 
by a rise in insulin after the consumption of carbohydrates. De novo synthesis of glucose from 
non-carbohydrate precursors can and does occur in the body, if needed. This allows the liver to 
maintain adequate blood glucose concentrations. Insulin is required for the uptake of glucose into 
cells, and various transporter systems are found in different types of tissues that utilize glucose.  
Requirements for carbohydrate in space are thought to be similar to those on Earth. 
However, to date, few investigations have been conducted on the effects of microgravity on the 
metabolism of dietary carbohydrate, and those studies have had conflicting results. 
 
 
2. Evidence 
 
Early studies documented both increased insulin and glucose at landing in Apollo (Figure 
14) and Skylab ( 
 
Figure 15, Figure 16) flights. 
 
 
 
 
 
Figure 14. Plasma insulin (N=22) and glucose 
(N=33) in Apollo crewmembers before and after 
flight (104). 
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Figure 15. Plasma glucose in Skylab crewmembers 
before, during, and after flight (39). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16. Plasma insulin in Skylab 
crewmembers before, during, and after flight 
(39). 
 
 
 
 
 
 
 
 On the Shuttle, studies by German investigators showed no impact of 7 days of flight on 
glucose tolerance tests (105). Additionally, a Russian study documented a reduction in fasting 
plasma glucose after 60 or 88 days of flight on a Salyut-Soyuz spacecraft complex, and a 
reduced peak of blood glucose in glucose tolerance tests (106, 107). Insulin resistance (lack of 
sensitivity to insulin) has been found to result from simulated weightlessness (bed rest) (108-
111). Using C-peptide excretion as a proxy, Stein et al found evidence of insulin resistance 
during actual and simulated spaceflight (112). Heer et al documented that after 3 weeks of bed 
rest, glucose tolerance was altered for more than 4 days after reambulation (113). Efforts to 
maintain muscle mass (and presumably correct the insulin resistance) continue, but little research 
has been done to pursue this as a nutritional issue. 
 Suboptimal carbohydrate intake before and during spaceflight may have consequences for 
the crew’s productivity and impede their ability to respond in emergency situations (114). 
Deficiency of carbohydrate leads to ketosis. A ketotic state would likely impair performance of 
crewmembers, as seen in studies conducted by the military (77), as well as increase renal stone 
risk secondary to reduced urinary pH (115-117). Other aspects of the mission would also be at 
risk (for example, the life-support systems may not be able to remove exhaled ketones from the 
air). Toxicity of carbohydrate has not been well studied, and would likely be an issue only 
because it would displace other nutrients (protein and fat) from the diet. 
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 Few data are currently available to assess the impact of spaceflight on carbohydrate 
metabolism. Observations from spaceflight as well as ground-based bed rest studies show subtle 
changes in insulin secretion, insulin resistance, and glucose intolerance (109, 110, 118, 119). 
Even subtle changes in such important metabolic processes make it critically important to 
consider the likelihood, nature, and consequences of altered carbohydrate and insulin metabolism 
for exploration missions.  
 
  Requirements 
The current documented requirement for carbohydrate intake during spaceflight is 50% to 
55% of the total daily energy intake. In the U.S., acceptable daily intake of dietary carbohydrate 
is defined as intake between 55% and 75% of the total dietary energy (120). A minimum intake 
of 140 g/d is required to maintain the needs of organs that require carbohydrate for energy 
production (121). For reference, the daily carbohydrate requirement for male and female 
astronauts was originally defined in 1991 for missions of 30-120 days as 50% of the total energy 
intake (4) and in 1995 for missions up to 360 days as 50% to 55% of the total energy intake (5), 
with a caveat that most of the carbohydrate should be provided as complex carbohydrates and 
less than 10% of the total carbohydrate should be provided as simple sugars.  
Macronutrient intake by space crews tends to reflect a relatively high protein and 
carbohydrate intake (close to 60% of calories) (2, 6, 43). Some researchers have speculated that 
this may represent a shift in macronutrient preferences, but it may also simply be related to the 
high sugar content of many of the available beverages in the U.S. food supply. 
 
3. Risk 
 
Suboptimal carbohydrate intake before and during spaceflight may have consequences for 
the crew’s productivity and impede their ability to respond in emergency situations (114). 
Deficiency of carbohydrate leads to ketosis. A ketotic state would likely impair 
performance of crewmembers, as seen in studies conducted by the military (77), as well as 
increase renal stone risk secondary to reduced pH (115-117). Other aspects of the mission would 
also be at risk (for example, the life-support systems may not be able to remove the ketones from 
the air). Toxicity of carbohydrate has not been well studied and would likely be an issue only 
with regard to displacement of other nutrients (protein and fat). 
 
 
4. Gaps 
 
Few data are currently available to assess the impact of spaceflight on carbohydrate 
metabolism. Observations from spaceflight as well as ground-based bed rest studies show subtle 
changes in insulin secretion, insulin resistance, and glucose intolerance (109, 110, 118, 119). 
Even subtle changes in such important metabolic processes make it critically important to 
consider the possibilities of altered carbohydrate and insulin metabolism for exploration 
missions.  
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D.   Dietary Fiber 
 
1. Background 
 
Dietary fiber consists of non-digestible food components that are typically carbohydrate 
and plant based. Non-starch polysaccharides, including cellulose, gums, pectins, mixed-linkage 
β-glucans, and hemicelluloses, are the major components of dietary fiber. Lignan is also included 
even though it is a non-carbohydrate component.  
A role for dietary fiber has been implicated in decreases in plasma cholesterol, modification 
of the response of blood glucose to food (the glycemic response), improvements in large bowel 
function, and decreases in the bioavailability of some nutrients. Epidemiological evidence also 
points to relationships between diets high in fiber and decreased incidence of cardiovascular 
disease and bowel cancer (122).  
 
2. Evidence 
 
Changes have been described in gastrointestinal function and gut transit time during 
spaceflight. Adequate dietary fiber will be essential to maintaining gastrointestinal function and 
decrease the incidence of constipation because mouth-to-cecum transit times are slower on orbit 
(114).  
The current documented requirement for dietary fiber intake in spaceflight is 10-14 g/1000 
kcal. In the U.S., acceptable daily intake requirements for dietary fiber are provided (18) for 
individuals aged 19-50 years (men 38 g/d and women 25 g/d) and for individuals aged 51-70 
years (men 30 g/d and women 21 g/d).  
For reference, the daily total fiber requirements for male and female astronauts were 
defined in 1991 for missions of 30-120 days as 10-15 g, in soluble and insoluble forms (4), and 
in 1995 for missions up to 360 days as 10-25 g, in soluble and insoluble forms (5). 
 
3. Risk 
 
Inadequate dietary fiber, in combination with low fluid intake, may lead to constipation. 
There is an open question about the effectiveness of vitamin K synthesis by colonic microflora 
(and its availability) during spaceflight (see vitamin K section).  
 
4. Gaps 
 
Several studies have shown that specific dietary fatty acids and types of dietary fiber can 
reduce animals’ risk of developing radiation-induced cancer (123, 124). Further research is 
warranted to investigate the potential protective effects of fiber on radiation-induced cancer risk 
in humans exposed to high-linear energy transfer radiation during spaceflight.  
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E.   Fat 
 
1. Background 
 
Fat is the most energy-dense of all the nutrients, and therefore is a major energy source for 
the body. Chemically, dietary fat is mainly in the form of triacylglycerols, which contain a 
glycerol backbone with as many as 3 fatty acids attached. Many types of fatty acids exist, 
including saturated, monounsaturated, polyunsaturated, and trans. Dietary fat assists in the 
absorption of fat-soluble vitamins and supplies the body with the 2 essential fatty acids, linoleic 
acid and linolenic acid. These essential fatty acids are necessary for growth and development as 
well as many other biochemical processes, including production of eicosanoids (physiologically 
active substances derived from arachidonic acid). Lipids, in the form of phospholipids, make up 
a large proportion of the structural components of the cellular membrane bilayer. Energy stored 
as fat is released in the process of fatty acid oxidation, and fat supplies more energy than any 
other macronutrient because of its higher content of carbon-to-hydrogen bonds. Body stores of 
fat are located mainly in adipose tissue as triacylglycerols. Adipose tissue is dispersed 
throughout the human body, with its distribution patterns differing between sexes.  
According to case studies, people following fat-free diets can exhibit symptoms of essential 
fatty acid deficiencies after only 1 month. In one study, an infant consuming fat-free total 
parenteral nutrition for 3 months developed skin lesions and had polyunsaturated fatty acid levels 
of less than 10% of control values (125). In another study, an adult consumed fat-free total 
parenteral nutrition for 7 months and developed severe dermatitis by the end of the first month. 
Omega-3 (n-3) fatty acids constituted 0.01% of the fatty acids of this person’s plasma 
phospholipids, which means that the patient was almost completely depleted of n-3 fatty acids 
(126). 
 
2. Evidence 
 
While few (if any) studies have been conducted to investigate dietary fat, plasma lipid levels, and 
related factors during spaceflight, numerous data exist from routine medical exams conducted 
before and after flight, along with annual medical examinations (Figure 17, Figure 18, Figure 
19). 
 
 
 
 
 
Figure 17. Plasma triglycerides in Skylab 
crewmembers before and after flight (39). 
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Figure 18. Serum high-density lipoproteins (HDLs) in ISS 
crewmembers before and after flight. Unless otherwise noted, data 
are from R+0/1. Because HDLs are not routinely measured at 
landing, some data were available only at the next medical exam. 
In these cases, the date is denoted on the chart as R+X days (2). 
 
 
 
 
 
 
 
 
Figure 19. Serum low-density lipoproteins (LDLs) in ISS 
crewmembers before and after flight. Because LSLs are not 
routinely measured at landing, some data were available only at 
the next medical exam. In these cases, the date is denoted on the 
chart as R+X days (2). 
 
 
 
 
Contrary to the typical lipoprotein response to weight loss, LDL concentrations tended to 
increase in long-duration crewmembers who lost weight during the flight. This relationship 
seems to return to normal by the subsequent medical exam (based on available data, 50-257 days 
after landing) (Figure 20) (2, 6). 
 
 
 
 
Figure 20. Relationship between the loss 
of body mass post flight and the change in 
serum LDLs in ISS crewmembers. 
Because LDLs are not routinely measured 
at landing, some data were available only 
at the next medical exam, which ranged 
from 50 to 257 days after landing. 
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 Alterations in fuel homeostasis and regulatory hormones have been noted in spaceflight and 
ground-based studies. Bed rest studies have documented alterations in fuel homeostasis (127), 
including sex differences (111). Specifically, lipogenesis increased during bed rest, to a greater 
extent in women than in men. Additionally, men had increased carbohydrate oxidation (111). 
Other studies have shown inflammatory changes during bed rest, along with insulin resistance, 
leading to increased body fat and altered fatty acid metabolism (128). Given these data, and the 
insulin, leptin, and other endocrine changes noted in bed rest and spaceflight (25, 129, 130), 
changes in fuel homeostasis in bed rest clearly warrant additional investigation. 
 The role of omega-3 fatty acids in cancer prevention has been investigated in animal models 
of spaceflight radiation effects (123, 124). Not only do omega-3 fatty acids (in combination with 
pectin) show promise in alleviating cancer risk (123, 124, 131-133), but these fatty acids also 
have well-documented cardiovascular benefits. Abundant data show that eicosapentaenoic acid 
can successfully prevent muscle atrophy in other muscle-wasting circumstances, such as cancer 
or sepsis (134-143), indicating the likelihood is high that eicosapentaenoic acid will have the 
same beneficial effects on muscle atrophy during spaceflight or in ground-based analogs 
including bed rest.  
 Omega-3 fatty acids also have been shown to protect bone, in the general population (144-
146) as well as in spaceflight analog studies, including bed rest and cell culture (147). Although 
omega-3 fatty acids have not been studied in a controlled fashion during actual spaceflight, a 
positive correlation was found between fish intake and bone loss in astronauts (147). That is, 
those who ate more fish lost less bone (Figure 21). These data provide additional evidence of the 
potential importance of fish oils as a countermeasure for muscle, bone, and radiation risks of 
spaceflight. Studies showing positive effects of omega-3 fatty acids typically look at intake of 
fish or other food sources of these nutrients (148-150). Studies of fish oil supplements added to 
typical diets often fail to document any benefit (151-153), thus highlighting the need for dietary 
modification, and not simply supplementation. 
 
 
 
Figure 21. Relationship between fish intake during flight 
and whole-body bone mineral density loss after flight. 
Figure adapted from (147). 
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  Requirements 
 
The current documented spaceflight requirement is for dietary intake of fat to constitute 
25% to 35% of the total daily energy intake (97). Dietary intake of n-6 and n-3 fatty acids should 
be 14 g/d and 1.1-1.6 g/d, respectively. Consumption of saturated fat should be <7% of calories, 
consumption of trans fatty acids <1% of total calories, and consumption of cholesterol <300 
mg/d. In the U.S., no recommended dietary allowance or adequate intake level has been set for 
total fat because data are insufficient to determine the level of dietary fat that may put one at risk 
for inadequacy or may contribute to the prevention of chronic disease (18). The acceptable 
distribution range for fat intake is 20% to 35% of the total energy intake (18). For reference, the 
daily total fat requirement for male and female astronauts was defined in 1991 for missions of 
30-120 days to be 30% to 35% of the total energy intake (4) and in 1995 for missions up to 360 
days to be 30% to 35% of the total energy intake (5).  
 
3. Risk 
 
Deficiency of fat leads to essential fatty acid deficiency and ultimately death. Toxic levels 
of fat lead to high serum cholesterol, obesity, atherosclerotic plaques, and, ultimately, coronary 
heart disease, or even death. 
 
4. Gaps 
 
The role of n-3 fatty acids in many systems has been investigated to one degree or another. 
Studies of n-3 fatty acids and cancer prevention have been investigated in animal models of 
spaceflight radiation effects (124). Not only do n-3 fatty acids (in combination with pectin) show 
promise in alleviating cancer risk (123, 124, 131-133), but these fatty acids also have well-
documented cardiovascular benefits. Abundant data show that eicosapentaenoic acid can 
successfully prevent muscle atrophy in other muscle-wasting conditions, such as cancer or sepsis 
(134-140, 143), indicating the likelihood is high that eicosapentaenoic acid will have the same 
beneficial effects on muscle atrophy during spaceflight or ground-based analogs, including bed 
rest (98). As mentioned above, fish intake and omega-3 fatty acids are also documented to 
protect bone in ground research, ground analog research, and preliminary spaceflight analyses. 
Thus, further research on omega-3 fatty acids, and eicosapentaenoic acid specifically, is 
warranted. 
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F.   Fluid Homeostasis and Renal Stone Risk 
 
1. Background 
 
 Adequate fluid intake is necessary to maintain the body’s normal hemodynamic state and 
normal fluid osmolality, which are important for cardiovascular health and for maintenance of 
fluid and electrolyte homeostasis. Water is a structural component of the body and the solvent for 
transportation of nutrients and waste. Fluid and electrolytes may be lost from the body by a 
variety of routes and for a variety of reasons. They are excreted in sweat, urine, and feces, and in 
abnormal situations excessive amounts can be lost by these routes and others. Significant losses 
may occur through the gastrointestinal tract as a result of diarrhea, vomiting, or gastric drainage. 
Loss through the skin increases with fever, increased metabolism, sweating, and burns (154). 
 Total body water makes up about 50% to 70% of body mass (155). Fluid requirements 
increase with metabolic rate and heat stress. Death from dehydration can occur within weeks of 
depriving the body of all water (156). 
 
 
2. Evidence 
 
Fluid and electrolyte homeostasis is significantly altered during spaceflight, and this has 
been extensively reviewed (28, 40, 157-164). The hypothesis originally proposed to explain this 
was that upon entering weightlessness, the human body would experience a headward shift of 
fluids, with subsequent diuresis and dehydration. A series of flight experiments was conducted to 
assess fluid and electrolyte homeostasis during spaceflight; the most comprehensive of these 
took place on the 2 Spacelab Life Sciences missions in the early 1990s. Despite much research, 
the hypothesis of diuresis and subsequent dehydration secondary to the headward fluid shift has 
never been confirmed during actual spaceflight (28, 158, 163, 165-167). 
Within hours of the onset of weightlessness (the earliest available data point), a reduction in 
both plasma volume and extracellular fluid volume had occurred, accompanied by the “puffy” 
faces typically observed early in flight (28, 168). Initially, the decrement in plasma volume 
(~17%) was larger than the decrement in extracellular fluid volume (~10%), suggesting that 
interstitial fluid volume (the other four-fifths of extracellular fluid) is conserved proportionally 
more than plasma volume (28). The idea that interstitial fluid volume is conserved is supported 
by rapid decreases in total circulating protein, specifically albumin (28), indicating that protein, 
and associated oncotic pressure, shifted from the intravascular to the extravascular space. This 
would have facilitated the initial changes in plasma volume (28). 
Following the initial adaptation, extracellular fluid volume further decreased between the 
first days of flight and 8 to 12 days after launch, from the initial ~10% below preflight levels to 
~15% below preflight levels (28). Plasma volume was partially restored during this period, from 
the initial ~17% below preflight levels to ~11% below preflight levels (28), and it has been found 
to remain 10% to 15% below preflight levels even for extended-duration flights (169).  
Leach et al (28) and Norsk et al (165) have hypothesized that the shift of protein and fluid 
to the extravascular space represents an adaptation to weightlessness, and that after several days, 
some of the extravascular albumin has been metabolized, with a loss of oncotic force and a 
resulting decreased extracellular fluid volume and increased plasma volume. This loss of 
extracellular protein (intra- and extravascular) and the associated decreased oncotic potential 
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probably play a role in postflight orthostatic intolerance, which has been considered to result 
partly from reduced plasma volume at landing (170). Furthermore, the loss of protein may in part 
explain why fluid loading alone does not restore circulatory volume (171, 172), as no additional 
solute load exists to maintain the fluid volume. Another potential (or perhaps partial) explanation 
for the failure of fluid loading is that because astronauts’ diets are high in sodium, additional salt 
cannot help increase plasma volume or extracellular fluid volume. This explanation has been 
documented in bed rest (173). 
The effect of spaceflight on total body water has been evaluated to assess hydration. Shuttle 
and Skylab astronauts had decreases of about 1% in total body water during flight (28, 174, 175), 
and the percentage of body mass represented by water did not change. Thus, the often-proposed 
weightlessness-induced dehydration does not exist. This has also been shown by European 
investigators on Shuttle and Mir missions (163, 165, 167, 176, 177). 
Diuresis is also typically not observed during flight (68, 157, 158, 165, 167, 176, 178-180), 
for a number of possible reasons. Operational constraints have made it difficult to document 
urine volume accurately on the first day of spaceflight. However, on the Spacelab Life Sciences 
missions, urine volume on the first 3 days of flight was significantly less than preflight volume, 
and urine volume tended to be less than preflight volume throughout the flight (28). Urine 
volumes on a week-long flight to Mir were also less than preflight volumes (179). During the 
first week of the 59- and 84-day Skylab flights (39), urine volume was less than it was before 
flight, and for the remainder of the missions it was unchanged from preflight levels. Decreased 
fluid intake likely accounts for the decreased urine volume, which was accompanied by little or 
no change in total body water. Adequate urine volume during flight is important for reducing the 
risk of renal stone formation (181-184).  
As mentioned above, the percentage of body mass represented by total body water is 
relatively unchanged during flight (28). However, on a volume basis, the change in extracellular 
fluid volume was found to be greater than the change (or lack of change) in total body water 
(28). Thus, by difference, intracellular fluid volume increased during spaceflight. This had been 
previously hypothesized from ground-based studies (185) and observed in postflight studies of 
Apollo crewmembers (68). The mechanism for a spaceflight-induced increase in intracellular 
fluid volume is unknown. One possible explanation is that a shift in fuel utilization results in 
increased glycogen storage, a condition known to increase cellular water content. 
Diuresis has been documented to occur in bed rest studies (186-188). Urinary albumin, a 
marker of kidney function, has been shown to be reduced in both spaceflight (relative to before 
flight) and bed rest (relative to the ambulatory state) (91-93). However, spaceflight, but not bed 
rest, results in reduced urine flow rates (167). Taken together, these data suggest that differences 
in fluid metabolism exist between analog studies and actual spaceflight (163, 165-167, 177, 180, 
188). Such differences do not seem to be a simple effect of abnormal renal function, and thus 
require further investigation (189).  
Although no spaceflight-induced dehydration occurs, care must be taken to ensure adequate 
fluid intake and hydration status. Inadequate fluid intake increases the risk of dehydration and 
renal stone formation. Fluid intake during flight is typically less than preflight intake, and is 
often below the recommended quantity. In closed flight vehicles, water is often a limiting 
resource, but rationing of water should be avoided. 
Deficiency of fluid leads to dehydration and ultimately death. Likewise, an excess of fluid 
intake leads to water intoxication and ultimately death. Obviously, the risk of this occurring 
during spaceflight, where water is a limited commodity, is extremely low. 
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Decreased fluid intake during spaceflight may be a consequence of reduced thirst during 
flight (114), but the reason for reduced thirst is unknown. 
Studies described above have documented that total body water is unchanged during flight, 
but apparently a shift of fluid from the extracellular to the intracellular compartment occurs. The 
effect of this shift on cell size and cell function (such as the effect of a change in the density of 
receptors on cell membranes) has not been evaluated. A change in cell size and function might 
be responsible for some of the microgravity-induced changes noted in other systems (such as the 
endocrine, cardiovascular, and immune systems). 
In the U.S., the recommended total water intake (including the water contained in food, 
beverages, and drinking water) is 3.7 L/d for men (19 y and older) and 2.7 L/d for women (19 y 
and older) (190). This is considered “adequate intake.” Since 1991 (4, 5), the spaceflight 
requirement for fluid has been 1-1.5 mL/kcal, with a minimum intake of 2000 mL/d. Actual fluid 
intakes on average meet this minimum (>2 L) requirement, but not often enough (2, 191). 
Diuresis has been documented in bed rest studies (186), suggesting that differences in fluid 
metabolism exist between analog studies and actual spaceflight (163, 166, 180). 
 
 
3. Risk 
 
Although no spaceflight-induced dehydration occurs, care must be taken to ensure adequate 
fluid intake and hydration status. Inadequate fluid intake increases the risk of dehydration and 
renal stone formation. Fluid intake during flight is typically less than preflight intake and often 
below the recommended quantity. In closed flight vehicles, water is often a limiting resource, but 
rationing of water should be avoided wherever possible. 
Deficiency of fluid leads to dehydration and ultimately death. Likewise, an excess of fluid 
intake leads to water intoxication or even death. 
 
 
4. Gaps 
 
Decreased fluid intake during spaceflight may be a consequence of reduced thirst during 
flight (114), but the reason for reduced thirst is unknown. 
The studies described above have documented that total body water is unchanged during 
flight, but there is an apparent shift of fluid from the extracellular to the intracellular 
compartment. The effect of this on cell size and cell function (such as the effect of a change in 
the density of receptors on cell membranes) has not been evaluated. This might be responsible 
for some of the microgravity-induced changes noted in other systems (such as the endocrine, 
cardiovascular, and immune systems). 
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G. Sodium and Chloride 
 
1. Background 
 
Sodium is the major cation of extracellular fluid (154). Together with chloride, sodium is 
used by the body to maintain normal water distribution, osmotic pressure, and anion-cation 
balance in the extracellular fluid compartment (192). Electrolyte concentrations in the body are 
essential for proper cardiovascular function and are under renal and hormonal control (193). 
Increases in blood sodium levels can be caused by diabetes, renal polyuria, diarrhea, insufficient 
water intake, excessive sweating, or increased dietary sodium intake. Sodium levels decrease 
with edema, excessive water intake, vomiting, diarrhea, diuretic therapy, renal tubular damage, 
hyperaldosteronism, or lower dietary intake. 
For the normal adult, total body sodium averages about 60 mmol/kg body weight. Forty to 
45 percent of total sodium resides in bone, with the balance found in extracellular and 
intracellular fluid. These sodium stores are classified as either exchangeable (42 mmol/kg body 
weight) or nonexchangeable, the exchangeable stores being composed of all cellular sodium and 
less than half of bone sodium (194). Exchangeable sodium becomes available by diffusion when 
plasma sodium levels become low, and in states of edema, the exchangeable sodium stores 
absorb sodium. 
Animal studies show that symptoms of sodium deficiency occur after 3 to 4 weeks of 
dietary sodium restriction (195). During acute starvation, urinary sodium excretion decreases to 
less than 0.2 g within 10 days (196), and can be affected by the amount of sweat (197). Plasma 
sodium levels are maintained fairly well during acute starvation: an initial decrease is followed 
by a return toward normal values (198). Maintenance of blood sodium is also observed during 
semi-starvation. During the Minnesota Experiment, plasma sodium levels in samples taken after 
the 6-month semi-starvation period were 0.6 ± 7.3% higher than baseline levels (N=4) (197). Six 
days of undernutrition resulted in large negative balances of sodium chloride (–12.8 ± 3.6 g/d), 
likely related to changes in water balance (197). 
 
 
 
2. Evidence 
 
Pre-, in-, and postflight plasma sodium and chloride data are available from Apollo (Figure 
22, Figure 23), Skylab (Figure 24, Figure 25), and Shuttle flights (Figure 26), and have been 
reviewed extensively (2, 9, 158, 165, 166, 199). In-flight sodium intakes during Skylab and 
Shuttle missions averaged 4 to 5 g, and were similar to the astronauts’ preflight intakes (7). The 
current food system is high in dietary sodium, and typical intakes on ISS have been in excess of 
4.5 g, even with suboptimal food intake (31). Intakes as high as 7 to 10 g of sodium per day have 
been observed. Sodium homeostasis and blood sodium levels are maintained during real and 
simulated spaceflight (200), but the high sodium content of the current space food system makes 
it important to monitor and restrict dietary sodium intake of astronauts to maintain their bone and 
renal health.  
European studies with Mir crewmembers documented positive sodium balance during 
spaceflight, in a non-osmotic fashion (that is, without a concomitant increase in fluid 
compartments) (9, 40, 165, 166, 173, 176). These data were confirmed in a series of ground-
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based studies, documenting an increase in messenger RNA (mRNA) expression of some of the 
enzymes required for glycosaminoglycan syntheses in the skin, the displacement of sodium by 
hydrogen in the glycosaminoglycans, and a subsequent acidosis (173, 201-206). These findings 
of increased sodium-proteoglycan binding had already been observed in animal studies by 
Ivanova in the 1970s (207). The skin here functions as a reservoir that stores sodium in case of 
overconsumption and releases sodium when it is insufficiently supplied. In recent studies carried 
out by the group of Titze et al (201, 202, 204) in animals and summarized in a mini-review 
(204), the group demonstrated the involvement of the lymph capillary system in the clearance of 
sodium and chloride from the skin. Increasing density of lymph capillaries in the skin seemed to 
play one of the key roles in this clearance, and when hyperplasia of the cutaneous lymph 
capillary system was inhibited, skin sodium and chloride retention was augmented and led to 
increased blood pressure. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22. Serum (N=33) and urinary (N=30) sodium from Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). 
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Figure 23. Serum (N=33) and urinary (N=30) 
chloride from Apollo crewmembers. Numbers in 
bars represent the percentage change from preflight 
values. Adapted from (104). 
 
 
 
 
 
 
 
 
 
 
Figure 24. Plasma sodium of Skylab 
crewmembers (N=9) before, during, and after 
flight (39). 
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Figure 25. Plasma chloride of Skylab 
crewmembers (N=9) before, during, and after 
flight (39). 
 
 
 
 
 
 
 
 
 
 
 
Figure 26. Serum sodium (left panel) and chloride (right panel) of Shuttle crewmembers (N=2-6) during and after 
flight, expressed as a percentage change from preflight values (208). 
 
 
 
 
 
In-flight sodium intakes (Figure 27) during Skylab and Shuttle missions averaged 4-5 g and 
were not dissimilar from the astronauts’ preflight intakes (7). The current food system is high in 
dietary sodium, and typical intakes on ISS have been in excess of 4.5 g, even with suboptimal 
food intake (1, 2, 6, 31). Intakes as high as 7-10 g of sodium per day have been observed. 
Sodium homeostasis and blood sodium levels are maintained during real and simulated 
spaceflight (200), but the high sodium content of the current space food system makes it 
important to monitor and restrict dietary sodium intake of astronauts to maintain their bone and 
renal health.  
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Figure 27. Inflight dietary sodium intake (mg/d) 
across space programs. 
 
 
 
 
 
 
 
 
Sodium is also stored in bone; however, sodium stored in bone does not seem to be 
exchangeable and therefore does not take part in day-to-day sodium regulation. However, on 
Earth, excessive sodium intake has been associated with increased bone turnover (209-212). 
Dietary sodium is known to affect calcium homeostasis (212-218). A predictable relationship 
exists between urinary sodium and calcium; that is, for each 100 mmol of sodium excreted in 
urine, 1 mmol of calcium is excreted (219). This phenomenon is expressed at high levels of 
dietary sodium. More than 90% of dietary sodium is absorbed, even when intake is high (220). 
Sodium is excreted mostly in the urine, but about two-thirds of the sodium filtered by the kidney 
is reabsorbed by mechanisms thought to involve solvent drag and electrochemical gradients. The 
sodium-dependent calcium transport system uses the energy stored in the electrochemical 
gradient of sodium to drive calcium into the lumen of the proximal renal tubule, and ultimately 
the presence of calcium in this location leads to increased calcium loss secondary to increased 
sodium excretion. In the distal tubule, calcium is preferentially reabsorbed, an event stimulated 
by parathyroid hormone (PTH) and cyclic adenosine monophosphate (cyclic AMP) (221). Cyclic 
AMP also influences reabsorption of sodium (222). 
A small amount of sodium is excreted in feces. When 550 mmol sodium was ingested each 
day for 7 d, the average fecal excretion was 1.8 ± 0.4% of the total dose, and when smaller 
amounts of sodium were ingested (50 mmol/d), an average of 6.0 ± 1.0% was excreted in the 
feces. 
Salt loading alone increases intestinal calcium absorption. In hypoparathyroid patients, 
dietary salt increased intestinal calcium absorption in one study by Meyer (223) but not in 
another study by Breslau (224). In Breslau’s study, calcium absorption correlated with serum 
1,25-dihydroxyvitamin D. Thus, conclusions about the role of PTH in the increase in intestinal 
calcium absorption after a sodium load are speculative. 
Studies in premenopausal women suggest that increased intestinal calcium absorption, 
rather than increased bone resorption, compensates for sodium-induced hypercalciuria in 
subjects whose adaptive processes related to bone metabolism are intact (225, 226). Ginty et al 
(225) examined the effects of 7 days of high or low dietary sodium on bone markers in young 
women. Although urinary calcium was increased with high (180 mmol/d) sodium intakes, the 
effect of high sodium on markers of bone resorption was not different from the effect of low (80 
mmol/d) sodium intakes. Lietz et al (226) also found no effect of intakes of 170 mmol/d or 60 
mmol/d of sodium for 8 days on bone resorption markers in postmenopausal women. However, 
Evans et al (211) reported that postmenopausal women ingesting 300 mmol sodium per day for 7 
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days had greater excretion of bone resorption markers than those ingesting 50 mmol sodium per 
day. These differences were not observed in a premenopausal group (211). These results suggest 
that bone resorption is increased in situations where the adaptive responses of bone are limited or 
altered, as they are after menopause. It might also suggest that at levels above 200 mmol sodium 
intake per day, the regulatory processes are different.  
Data from human and animal studies suggest that high dietary sodium chloride leads to 
bone loss due to increased bone resorption (227-233), and they further suggest that restriction of 
dietary sodium will reduce bone resorption (234). In a review of the interactions between dietary 
salt, calcium, and bone, Massey and Whiting (232) suggested that habitual excessive salt intake 
contributes to bone loss. Other reviewers have come to the conclusion that increased dietary 
sodium chloride intake negatively affects acid-base balance, with subsequent loss of calcium 
(101, 235).  
Massey and Whiting (232) found that the effect of excessive salt intake on bone loss is 
modulated in specific subpopulations. For example, people who tend to form renal calcium 
stones are more responsive to changes in dietary salt than are non-stone formers. Although 
sodium intakes of stone formers are typically similar to those of controls (236, 237), the 
detrimental effects of high sodium intakes on renal stone risk have been well documented (227, 
233, 235). Increasing sodium intake from 50 mmol/d to 300 mmol/d increased renal stone risk by 
elevating urinary saturation of calcium phosphate and monosodium urate, and reducing 
inhibition of calcium oxalate crystallization (238). 
Work by Goulding (209, 210) and Matkovic (239) has generated interest in the effect of 
dietary sodium on bone mass. High levels of dietary sodium are not only major predictors of 
urinary calcium and hydroxyproline excretion, but are also associated with greater loss of bone 
with age, unless dietary calcium is supplemented (240). Work by Dr. Heer’s group has also 
documented the resorptive response to high dietary sodium, and the role of acid-base balance in 
this process (241, 242). 
Dietary sodium also seems to exacerbate the calciuric responses to musculoskeletal 
unloading in weightlessness. Bed rest subjects consuming a low-sodium diet (100 mmol/d) had 
no change in urinary calcium, while those on a high-sodium diet (190 mmol/d) had 
hypercalciuria (243). A more recent bed rest study by Heer et al documented that the high-
sodium-induced increase in bone resorption exceeded the bed rest-induced increase (Figure 28), 
through a mechanism mediated by acid-base balance (241, 242). Figure 29 shows a proposed 
mechanism for the effects of dietary sodium on bone (6). Additionally, the mechanism could be 
that metabolic acidosis causes an increase in urinary corticosterone (244). Increased sodium 
intake and consequent low-grade metabolic acidosis caused an increase in bioactive 
glucocorticoids (203, 245). In turn, the increase in glucocorticoid concentration caused rapid 
bone loss (246-249). Applying an alkaline salt together with high sodium intake (245) reduced 
bioactive glucocorticoid excretion, which result supports the idea that acid-base balance plays a 
role in the effects of high sodium intake. A symposium was held recently in Germany (its 
proceedings were published in 2008) regarding the impact of acid-base balance on health issues 
(250), including the role of sodium in bone loss (212, 251, 252).  
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Figure 28. Urinary C-telopeptide (CTX) 
excretion in bed rest subjects on high-sodium 
(open triangles) or low-sodium (filled squares) 
diets. Bed rest began on day 4, indicated by the 
vertical line. Adapted from (241, 242). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29. Proposed mechanism of the effects of high dietary sodium on bone loss (6). 
 
 
In the U.S., the recommendation for adequate intake of sodium is 1.5 g/d for men and 
women ages 19-50 years and 1.3 g/d for men and women ages 51-70 years (190). The current 
documented spaceflight requirement for dietary sodium is 1500-2300 mg/d for both women and 
men. 
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3. Risk 
 
High sodium intakes during spaceflight can exacerbate bone loss and lead to increased risk 
of renal stone formation. In and of itself, excess sodium can lead to hypernatremia, hypertension, 
and even death. Although it has not been a concern to date, too little sodium or a deficiency of 
this electrolyte during flight could lead to hyponatremia, hypotension, and even death. 
 
4. Gaps 
 
Further research is required to investigate potential effects of high sodium intake during 
spaceflight, as the space food system currently has very high sodium levels. The impact of high 
sodium intake on bone, calcium, and pH is not well understood, but adjustments in sodium intake 
may serve as a viable countermeasure to bone loss. Furthermore, the role of a high-sodium diet 
in potassium homeostasis is not well understood. This may prove to be an area where nutrition 
and cardiovascular effects of spaceflight interact, and study of the interaction may produce a 
dietary countermeasure. 
 
 
 
H.   Potassium 
 
1. Background 
 
As the most plentiful intracellular cation, potassium has a significant role in several 
physiological processes (193). It is crucial to regulation of acid-base balance, energy 
metabolism, blood pressure, membrane transport, and distribution of fluid within the body. It is 
also involved in the transmission of nerve impulses and cardiac function (253). Potassium 
metabolism that is disordered because of excessive or deficient circulating levels has negative 
consequences for cardiac, muscle, and neurological function. 
Total body potassium averages 45 mmol/kg body weight, totaling about 3150 mmol (1230 
g) of potassium in a reference 70-kg person. Two percent of body potassium (~60 mmol) is 
distributed in the extracellular fluid, and intracellular fluid levels are typically maintained at 140-
150 mmol/L). 
Potassium levels cannot be maintained at intakes under 10-20 mmol/d (254). Moderate 
depletion of potassium in humans is associated with clinically significant impaired active 
relaxation of the left ventricle (255). In the referenced study, healthy adults were placed on a 
potassium-depletion diet for 7 days. At the end of 7 days, isovolumic relaxation time and 
deceleration time of flow through the mitral valve were significantly increased. 
Increased levels of urinary potassium may be related to muscle disuse atrophy and 
inadequate intake during spaceflight (200). 
Deficiency of potassium leads to hypokalemia, muscle weakness, constipation, fatigue, or 
even death. There is no evidence of adverse effects associated with ingestion of excessive 
amounts of potassium from naturally occurring sources. However, supplemental intake may 
cause hyperkalemia (and associated weakness, cardiac arrest, and paralysis), metabolic acidosis, 
decreased neuromuscular functions, or even death. 
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2. Evidence 
 
Both serum and urinary levels of potassium decreased after spaceflight in the Apollo 
program (Figure 30) (104), and there is evidence of a similar decrease on Skylab (Figure 31) and 
Shuttle (Figure 32) missions (39, 208). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 30. Serum (N=33) and urinary (N=30) potassium of Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). 
 
 
Potassium loss (both total body potassium and exchangeable potassium) was observed in 
Apollo crewmembers (Figure 31) (104). 
 
 
 
 
 
Figure 31. Exchangeable potassium of Apollo 15, 16, 
and 17 crewmembers after flight, as the percentage 
change from preflight values (104).  
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Figure 32. Plasma potassium of Skylab 
crewmembers (N=9) before, during, and after 
flight (39). 
 
 
 
 
 
 
 
 
 
 
 
Figure 33. Serum potassium of Shuttle crewmembers (N=2-6) 
during and after flight, expressed as the percentage change from 
preflight values (208). 
 
 
 
 
 
Excess dietary sodium has been shown to be potassium-depleting during bed rest (Heer et 
al, unpublished observations). 
The current documented spaceflight requirement for potassium is 4.7 g/d, the same as the 
U.S. recommendation for adequate intake of potassium for men and women aged 19-70 years 
(190).  
 
3. Risk 
 
The loss of lean body mass, along with high sodium intake, may result in potassium 
depletion. The implications of potassium depletion for cardiac, musculoskeletal, and other 
systems are profound. 
 
4. Gaps 
 
The relationship between bone health and the protein:potassium ratio is currently being 
investigated on ISS.  The role of potassium in cardiovascular health during flight requires 
additional study.  
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VI. Gap N3.2: Determine the micronutrient requirements for spaceflight. 
 
 
A. Vitamin A 
 
1. Background 
 
One of the vitamins important to vision health is vitamin A. Vitamin A and the structurally 
related carotenoids can be found in dark green leafy vegetables and in vegetables and fruits that 
are yellow, orange, or red. Vitamin A plays a fundamental role in the retinal response to light. 
Inadequate vitamin A can result in night blindness, delayed light and dark adaptation, and dry 
eye (256). 
Beyond its essential role in the visual process, vitamin A is directly involved in gene 
expression, reproduction, embryonic development, and immunity. Vitamin A and β-carotene 
serve as biological antioxidants and have been shown in multiple studies to reduce the risk of 
cancer and coronary heart disease (257, 258). Vitamin A also plays a role, albeit sometimes 
indirectly, in the function of almost all of the body’s organs (259). 
Vitamin A is one of the fat-soluble vitamins. Less concern is expressed about the adequacy 
of fat-soluble vitamin intake than about the intake of water-soluble vitamins because the body 
can store larger quantities of fat-soluble vitamins. However, recent findings about previously 
unknown functions of some of these vitamins, as well as unique aspects of spaceflight, provide 
specific challenges for maintaining optimum status of these nutrients.  
Vitamin A is a general term for a family of fat-soluble compounds that are structurally 
similar to retinol and share its biological activity. Among these are retinol, -carotene, -
carotene, and retinyl palmitate. Trans-retinol is the primary biologically active form of vitamin 
A. Many carotenoids, including -carotene, can be converted to trans-retinol and thus contribute 
to vitamin A activity. Collectively, these carotenoids are termed provitamin A carotenoids and 
are measured in retinol equivalents (REs).  
Vitamin A is stored mainly (80%) in the liver, with the remainder stored in peripheral 
organs and tissues. Total body stores range from 1.05 to 3.14 nmol (300-900 mg) in normal 
adults (260). Liver stores of vitamin A are severely depleted when levels are less than 20 g 
(261). A study of vitamin A depletion in baboons showed a 59% decrease in hepatic vitamin A 
after 4 months of a chronic ethanol diet (262). After 24-48 months, the researchers found a 95% 
decrease in hepatic vitamin A stores, which was accompanied by fibrosis and cirrhosis of the 
liver. Alcoholism is often associated with vitamin A deficiency because retinol and ethanol are 
competing substrates for the same enzymes (263). 
Deficiency of vitamin A leads to xerophthalmia, loss of appetite, drying and keratinization 
of membranes, infection, or even death. Acute toxicity of vitamin A leads to nausea, vomiting, 
headache, blurred vision, and muscular incoordination. Chronic toxicity of vitamin A leads to 
rapid reduction in bone mineral density, liver abnormalities, or even death. 
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2. Evidence 
 
Oxidative stress is increased during spaceflight, and this could affect cardiovascular health 
and cancer risk, as described in other sections of this book. Vitamin A status may play a critical 
role in maintaining antioxidant health during spaceflight; however, as with many antioxidants, 
the desire to supplement with high doses in the hope of staving off one disease is high, but 
unwarranted and potentially counterproductive. Excess vitamin A, in amounts on the order of 
twice the recommended daily intake, has been shown to increase bone resorption and fracture 
risk (264-267). Furthermore, supplementation with β-carotene should be done with caution 
(either alone or with vitamin A, or in combination with vitamin E), because of the unanticipated 
outcome of an increased risk of lung cancer in smokers (268, 269). This increased risk among 
smokers might be related to pro-oxidant actions of β-carotene in the lung. 
When considering pre- and postflight spaceflight data, a significant interaction occurs 
between the effects of landing site and spaceflight on serum levels of both retinol and retinol-
binding protein (Figure 34) (31). Russian landings are different from U.S. landings in that blood 
samples are usually collected several hours later because of the logistics of the landing site.  
 
 
 
 
 
  
 
 
 
 
 
 
Figure 34. Serum retinol and retinol-binding protein in ISS crewmembers before and after long-duration 
spaceflight.  Adapted from (31). 
 
 Serum retinol decreased from 0.73 ± 0.17 µg/mL before flight to 0.59 ± 0.13 µg/mL after 
landing when landings were in Russia, and increased from 0.52 ± 0.09 µg/mL to 0.63 ± 0.12 
µg/mL when landings were in the U.S. Similarly, retinol-binding protein decreased from 61.4 ± 
5.6 to 50.92 ± 8.41 mg/L when landings were in Russia, and increased from 49.2 ± 9.2 to 53.0 ± 
8.7 mg/L when landings were in the U.S. These differences associated with landing sites could 
be related to the time delay in sample collection, the fact that crewmembers might have 
consumed food during the time delay, or even a difference in the stress response at different 
sites. These data, however, do not provide evidence that there is a deficiency of any sort for 
vitamin A. 
 
 In-flight vitamin A data have been collected as part of nutrition experiments on ISS, and 
Figure 35 shows that no significant changes in retinol or β-carotene occur during spaceflight. 
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Figure 35. Serum retinol (left) and β-carotene (right) in ISS crewmembers before, during, and after long-
duration spaceflight.  Dashed lines represent the normal range for retinal.  Figure from (6).  
 
 
In addition to the vision-related changes observed in some astronauts after long-duration 
spaceflight, several studies have confirmed that astronauts and cosmonauts have an increased 
risk of cataract formation after spaceflight (270-273). Cucinotta et al (271) identified an 
increased risk of all types of cataracts (including posterior subcapsular, cortical, and nuclear) 
among astronauts with greater exposure to radiation. Longitudinal follow-up studies have been 
conducted and it was determined that progression of cortical cataracts, but not posterior 
subcapsular or nuclear cataracts, is related to space radiation exposure (272, 274). Although 
radiation exposure is a large driving force for the oxidative damage that leads to some types of 
cataracts, the longitudinal study provided evidence that intake of specific nutrients may provide 
some protective effects (272). In the first report of the NASA Study of Cataract in Astronauts, 
nutritional intake estimates were obtained from a questionnaire, and the data provided evidence 
that β-carotene and lycopene intake had a protective effect for some types of cataracts in 
astronauts (272). As reviewed by Agte and Tarwadi, numerous ground-based studies have 
provided evidence for associations between micronutrients and antioxidants (either blood levels 
or estimated intakes) and cataracts (275). A recent meta-analysis provided similar results 
supporting an inverse association with α-carotene (and vitamin E, lutein, and zeaxanthin) and 
age-related cataract (276).  
Although epidemiological data support the idea that lower vitamin A status is associated with 
cataract incidence, it is not known whether altered micronutrient and antioxidant intake during 
spaceflight could minimize cataract incidence related to space radiation, as this requires further 
interventional study and better estimates of in-flight nutrient intake along with nutrient status 
assessments. 
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3. Risk 
 
Oxidative stress is increased during spaceflight, which could affect cardiovascular health 
and cancer risk. Vitamin A status may play a critical role in maintaining antioxidant health 
during spaceflight. 
As with many antioxidants, the desire to supplement with high doses in the hope of staving 
off one disease is high but can be unwarranted and potentially counterproductive; for example, 
excess vitamin A, in amounts on the order of twice the recommended daily intake, has been 
shown to increase bone resorption and fracture risk (264-267). 
In the U.S., the recommended dietary allowance for vitamin A is 900 g RE/d for men aged 
19 and older and 700 g RE/d for women aged 19 and older (277). Upper limits also exist for 
vitamin A (3000 g RE/d), and -carotene supplementation is advised only in situations where 
there is a risk of vitamin A deficiency. The current documented spaceflight requirement for 
vitamin A intake is 700-900 g/d. 
 
 
4. Gaps 
 
Vitamin A content and stability in the space food supply should be determined. The role of 
vitamin A as an antioxidant has not been investigated.  
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B. Vitamin D 
 
1. Background 
 
The best-understood role of vitamin D is its involvement in calcium metabolism. One of the 
major functions of this vitamin—its calcitropic function—is to maintain normal blood levels of 
calcium and phosphorus. A component of sunlight acts on 7,8-dehydrocholesterol in the skin to 
form pre-vitamin D, which is converted to vitamin D. The liver converts vitamin D to 
25-hydroxyvitamin D, which is typically the gold standard measurement for determining vitamin 
D status (Figure 36). In the kidney, 25-hydroxyvitamin D is converted to 1,25-dihydroxyvitamin 
D, which is transported from the kidney systemically to target organs. Classic target organs 
include bone, intestine, and kidney.  
 
 
Figure 36. Vitamin D synthesis, activation, and catabolism. Adapted from (278). 
 
The Institute of Medicine (IOM) conducted an extensive review of the literature in 2010 
and increased the recommended dietary allowance (RDA) for vitamin D to 600 IU/d for healthy 
males and females 9-70 years old, and 800 IU/d for those older than 70 years (279, 280). The 
main factors that were taken into account were changes in bone density and fracture risk. The 
IOM review committee did not find conclusive evidence that vitamin D plays a role in 
extraskeletal health outcomes. Even though a considerable number of papers published in the 
past 10 to 15 years have shown associations between low vitamin D status and adverse health 
outcomes such as cancer, autoimmune diseases, diabetes, cognitive decline, and all-cause 
mortality, the evidence that vitamin D status causes any of these outcomes is inconclusive, and 
insufficient to inform nutritional recommendations (281-286). The non-calcitropic functions of 
vitamin D may help explain why a robust set of reproducible data shows an inverse correlation 
7,8-dehydrocholesterol               pre-vitamin D                vitamin D 
skin 
25(OH)D 
1,25(OH)2D                  1,25(OH)2D 
kidney 
prostate, breast, 
colon, immune 
cells, β cells, skin 
liver 
Endocrine actions
Intestinal Ca transport 
Bone metabolism 
Renal Ca absorption 
Blood pressure 
Insulin secretion 
Autocrine/paracrine actions
Inhibition of cell proliferation 
Promotion of cell differentiation 
Immune regulation 
Risk Factor of Inadequate Nutrition 
 
 51
between sun exposure and several types of cancer (287-289). Although 1,25-dihydroxyvitamin D 
is the biologically active form for the noncalcitropic functions also, 25-hydroxyvitamin D must 
be available in sufficient quantities for the 1-hydroxylase enzyme in nonrenal tissues to 
synthesize 1,25-dihydroxyvitamin D. Besides kidney cells, other cell types, including bone cells, 
epithelial cells, monocytes, and antigen-presenting cells, also synthesize 1,25-dihydroxyvitamin 
D (290). Numerous tissues are affected by vitamin D status because their cell nuclei contain 
receptors for 1,25-dihydroxyvitamin D (284). Some of these tissues are adipose tissue, bone 
marrow, brain, breast, cancer cells, cartilage, lung, muscle, ovary, placenta, prostate, stomach, 
testis, thymus, and uterus (291).  
People who are normally exposed to sunlight make vitamin D in their skin (Figure 36). 
Ultraviolet B (UV-B) light, a component of sunlight, converts 7-dehydrocholesterol to 25-
hydroxyvitamin D3 in the skin (292). Although sunlight has a positive effect on health through its 
role in making vitamin D, caution must still be exercised to avoid too much sun exposure (293-
295).  
 
 
Evidence 
 
Spacecraft typically shield crewmembers from the UV-B radiation that forms 25-
hydroxyvitamin D3 in the skin (the only exception to shielding being the rare quartz windows). 
Crewmembers on the longest Skylab mission (Skylab 4, 84 days), but not the shorter missions 
(28 and 59 days), had decreased serum 25-hydroxyvitamin D at landing (39) despite taking daily 
vitamin D supplements (Figure 37). Provision of 400 IU/d vitamin D supplements did not 
prevent a decrease in vitamin D status during flight in ISS crewmembers (31). 
 
 
 
 
Figure 37. Plasma 25-hydroxyvitamin D of 
Skylab crewmembers (N=9) before and after 
flight (39). 
 
 
 
 
 
 
Decreased vitamin D status is one of the most striking nutritional changes that has occurred 
during spaceflight (30, 31). The mean preflight serum 25-hydroxyvitamin D for early U.S. ISS 
crewmembers is 62 ± 14 nmol/L (Figure 38). In several studies, crewmembers on the Russian 
space station Mir had serum 25-hydroxyvitamin D3 concentrations that were 32% to 36% less 
during and after long-duration (3- to 4-month) missions than before the missions (30, 63). ISS 
astronauts had serum 25-hydroxyvitamin D concentrations that were typically 25% to 30% lower 
after 4- to 6-month spaceflights (31), and in several ISS crewmembers, serum 25-
hydroxyvitamin D decreased to levels considered clinically significant (Figure 38) (31).  
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Figure 38. Serum 25-hydroxyvitamin D concentrations before 
and after 4- to 6-month spaceflights on the International Space 
Station. Each line represents one crewmember. The “Pre Mean” 
point on each line is the average of data collected about 6 months 
and 6 weeks before launch. R+0 = Recovery plus zero days, that 
is, landing day. These samples are typically collected 2-8 hours 
after landing. The dashed line shows the (outdated) lower limit of 
normal range, and the solid horizontal line shows what many 
considered to be the “optimal” concentration of vitamin D in the 
circulation. From (1, 31). 
 
 
 
 
Another important observation from ISS nutritional status assessment was related to the 
relationship between parathyroid hormone (PTH) and 25-hydroxyvitamin D before and after ISS 
missions. Before launch, 25-hydroxyvitamin D was inversely correlated with PTH (r = –0.72, P 
< 0.05) (Figure 39), but this relationship was not evident after landing, suggesting that the body’s 
normal response to changes in vitamin D was altered (31).  
 
 
Figure 39. Serum 25-hydroxyvitamin D and parathyroid hormone (PTH) concentrations before (average of 
data from samples collected about 6 months and 6 weeks before launch) and after (landing day, typically 
collected 2-8 hours after landing) 4 to 6-month spaceflights on the International Space Station. Each 
symbol represents one crewmember. From (1, 31). 
 
 
Results from ground-based studies of bed rest subjects (296) and subjects living in closed-
chamber facilities for extended periods suggest that these subjects are also at high risk of having 
vitamin D deficiency (29). Ground-based models with limited sunlight exposure are valuable for 
performing vitamin D supplementation trials.  
Perhaps an ideal ground-based model for individuals lacking UV-B light exposure is the 
Antarctic, where winter levels of UV-B radiation are essentially zero. We recently completed a 
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study at McMurdo Station, Antarctica, to determine the daily dose of vitamin D needed to 
sustain serum levels of 25-hydroxyvitamin D during a 5- to 6-month period when there is little to 
no UV-B exposure.  
The environment in the Antarctic is quite unique. Seasonal changes in UV-B light exposure 
are more extreme than in any other part of the world. The sun does not rise for 42 days during 
winter (June 1 – July 12), and the sun does not set for 60 days during the summer months (Nov 
22 – Jan 20). During the Antarctic winter, scientists and visitors are typically isolated, and no 
fresh fruits or vegetables are available. As a result of close quarters and limited food choices 
throughout the year, most scientists at a particular research station have homogeneous food 
intakes and physical activities. Not only is Antarctica a good model for studying vitamin D 
metabolism because of the limited sunlight exposure, but also the Antarctic science station model 
has been used successfully as a ground-based analog for spaceflight in studies of behavior, 
immune response, and latent virus reactivation (297-299). 
It is well documented that vitamin D status is decreased among subjects who live in 
Antarctica for an extended period (300-304). One research group examined 25-hydroxyvitamin 
D status of 31 members of an Antarctic wintering team who stayed at the Japanese Antarctic 
station, Syowa, for 14 months. For one week in May and one week in July, food items were 
weighed before they were cooked and vitamin D intake was estimated to be 488 IU/d. Serum 25-
hydroxyvitamin D was lowest during April – October (~19.0  4.4 ng/mL, or ~47.5 nmol/L) 
(301). Because there was no source of UV-B during the winter months, it can be concluded from 
this study that 488 IU/d is not enough vitamin D to prevent a decrease in serum 25-
hydroxyvitamin D levels. Olvieri and colleagues studied bone metabolism in wintering 
individuals for 1 year and found that the mean 25-hydroxyvitamin D level in Argentine Antarctic 
wintering researchers was 10 ng/mL (25 nmol/L) during the winter months (300). On a different 
1-year expedition to Antarctica, both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D were 
significantly decreased by about 25% during the winter months (303).  
To our knowledge, only one supplementation trial has successfully maintained serum 25-
hydroxyvitamin D in subjects living in Antarctica during the summer (302). Despite the sunlight 
in the summer, temperatures still keep skin exposure to the sun at a minimum. Twenty-two 
healthy males were randomly divided into two groups: individuals supplemented with 1000 IU 
vitamin D3 per day and non-supplemented controls. Both groups ingested less than 500 mg/d 
calcium. Blood was sampled at intervals of 22 days during the Antarctic summer months. Serum 
25-hydroxyvitamin D levels were significantly decreased in the control group but did not change 
in the supplemented group. In the latter group, however, a significant decrease in PTH occurred. 
This study showed that 1000 IU/d vitamin D was enough to maintain vitamin D status during the 
summer months in Antarctica.  
Although these data suggest that 1000 IU/d vitamin D may be enough to offset changes in 
vitamin D status in subjects with limited sun exposure such as astronauts, they shed no light on 
the efficacy of 1000 IU/d vitamin D during the winter months in Antarctica, the time when 
Antarctica most closely models spaceflight. In the winter months, there is little to no UV-B 
exposure. The mean monthly amount of total UV-B radiation at the Syowa station in Antarctica 
is greatest in December (49,540 J/m2) and smallest in June and July (0 J/m2) (301). In Tsukuba, 
Japan, which is similar in latitude to the Midwest in the United States, the maximum total daily 
UV-B is about 20,550 J/m2 and the lowest is about 5,010 J/m2 (301). Astronauts aboard the 
International Space Station and those who will travel to Mars will not be exposed to any UV-B 
radiation because spacecraft successfully block UV-B radiation (305). The zero UV-B radiation 
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exposure and zero availability of fresh fruits and vegetables due to forced isolation make the 
winter months in Antarctica a better model for spaceflight than the summer months, when many 
researchers work outdoors (temperatures range from -5 to +6 C). 
In addition to a decrease in vitamin D status, wintering residents in Antarctica show signs 
of impaired cognitive function and changes in psychosocial behavior (306, 307). Although there 
is some evidence that a vitamin D deficiency may be related to changes in cognitive function 
(308), further research is needed to determine whether these changes are related to nutritional 
issues or other reasons. 
Glerup and colleagues compared vitamin D status in sunlight-deprived individuals (veiled 
Arab women living in Denmark, veiled Danish Muslim women, and non-veiled Danish women) 
and found a severe vitamin D deficiency among veiled Arab women (serum 25-hydroxyvitamin 
D was 7.1  1.1 nmol/L) (309). Twenty-six percent of the veiled Arab women reported a change 
in gait compared with 9% of non-veiled Danish controls, and muscle pain was felt by 88% of 
Arab women. These women had a very low vitamin D intake (1.04 g/d) and limited sun 
exposure. Veiled Danish Muslims had a high vitamin D intake [13.53 g/d (~600 IU/d)] but 
limited sun exposure, and they were still vitamin D deficient (serum 25-hydroxyvitamin D was 
17.5  2.3 nmol/L). These data suggest that 600 IU/d vitamin D is not enough to maintain 
25-hydroxyvitamin D levels in individuals with little or no sun exposure. In another study with 
51 submariners on deployment, 400 IU vitamin D was not enough to prevent a decrease in 
vitamin D status after 76 days (310). 
Before 2006, when ISS crews were first provided 400 IU vitamin D/d, it was well 
documented that vitamin D status (serum 25-hydroxyvitamin D) decreased after long-duration 
spaceflight (30, 31, 39, 63). The absence of UV-B light during spaceflight diminishes vitamin D 
stores in the body, as observed during the 84-day Skylab mission (39), space station Mir 
missions (30, 63), and early ISS expeditions (31). Despite the reported use of vitamin D 
supplements by some of the astronauts on early ISS expeditions (average supplement use was 3.0 
± 2.8 per week of a 400-IU vitamin D supplement), the mean serum concentration of 25-
hydroxyvitamin D for the ISS crewmembers was about 25% less after landing than before 
launch.  
In 2006, vitamin D supplement recommendations to crews increased from 400 IU vitamin 
D/d to 800 IU vitamin D /d. In-flight 25-hydroxyvitamin D data from the Nutritional Status 
Assessment Supplemental Medical Objective provide evidence that 800 IU vitamin D/d is 
enough to maintain vitamin D status during long-duration spaceflight (Figure 40) (41). 
Furthermore, recent data show that crewmembers who exercised with the Advanced Resistance 
Exercise Device, maintained energy intake at recommended levels, and took 800 IU/d vitamin D 
during flight maintained bone mineral density during 4- to 6-month spaceflights (41). 
An ideal ground-based model for individuals lacking UV-B light exposure is the Antarctic, 
where winter levels of UV-B radiation are essentially zero. Two studies have been conducted at 
McMurdo Station, Antarctica, to determine the dose of vitamin D needed to sustain serum levels 
of 25-hydroxyvitamin D during a 5- to 6-month period when there is little to no UV-B exposure, 
without increasing risks of hypercalcemia (311, 312). Several ground-based studies (performed 
in Antarctica and at the Johnson Space Center) provide evidence that a vitamin D dose in the 
range of 800-2000 IU/d is tolerable, safe, and can maintain vitamin D status for 3 to 6 months 
even in environments with no UV light exposure (311-313). This recommendation is in line with 
the recent Institute of Medicine recommendations for vitamin D intake for North Americans 
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(279).  
One of the vitamin D studies conducted at McMurdo Station showed an interactive effect of 
serum cortisol and vitamin D status on immune function (312). In that study, subjects with 
higher serum cortisol and lower vitamin D status had greater latent virus reactivation in their 
saliva. It is clear that vitamin D may have an effect on other systems besides bone, but further 
research is required before evidence-based recommendations can be made for other systems. 
 
 
 
Figure 40. Pre- and postflight data from testing 
required for medical operations show that vitamin D 
status decreased after long-duration spaceflight, despite 
vitamin D supplementation with 400 IU/d (black dashed 
line, N=16). In-flight data (purple line) show that 800 
IU/d is enough vitamin D3 to maintain status during 
long-duration spaceflight (N=26). Red lines depict 
Institute of Medicine-defined lower acceptable limits 
(with respect to bone health), and upper advised limit 
(279). The green line at 80 nmol/L reflects what many 
perceive as an optimal level with respect to parathyroid 
hormone suppression and non-bone health outcomes. 
Figure adapted, and data updated, from Smith et al 
(314). 
 
 
 
 
 
 As noted above, vitamin D deficiency is linked to calcium metabolism, and in severe cases 
leads to osteomalacia and osteoporosis in adults (and rickets in children). Throughout the ISS 
program, supplemental vitamin D has been provided to astronauts to ensure optimal vitamin D 
status.  
 Efforts to provide vitamin D supplements are misinterpreted to infer that this might be a 
viable bone loss countermeasure, but this is not the case. Even when vitamin D stores during 
flight are adequate, the circulating concentration of the active form of vitamin D, 1,25-
dihydroxyvitamin D, is decreased (30, 63). This is likely the result of the increased release of 
calcium from resorbed bone (see subsection N, “Calcium,” in this section), and results in 
decreased intestinal absorption of calcium. Adequate stores of 25-hydroxyvitamin D will not 
affect this. Any attempt to directly provide the 1,25-dihydroxyvitamin D, or as in some cases on 
Earth, excess 25-hydroxyvitamin D levels, may lead to hypercalcemia, renal stones, soft-tissue 
calcification, or even death. Controlled trials in bedridden subjects have also proven that several 
months of supplementation fail to affect bone metabolism. In one trial, bedridden elderly people 
took supplemental vitamin D (400 or 1200 IU/d compared to placebo) for 6 months. Little effect 
was found on PTH, and no effect on bone markers (315). In a similar 40-week trial of 1000 IU of 
vitamin D2 or D3 (2 groups), neither had an effect on bone markers (316). The problem of 
weightlessness-induced bone loss must be solved, but vitamin D is not the answer. Nevertheless, 
even if bone loss is not stemmed, ensuring an adequate amount of vitamin D will remain 
important. 
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3. Risk 
 
 The current documented spaceflight requirement for dietary intake of vitamin D is 25 µg per 
day. Because astronauts in space are shielded from sunlight, considering them to be in a high-
risk group seems appropriate. It is currently recommended that ISS crewmembers consume 800 
IU of vitamin D per day during long-duration spaceflight. As the current space food system 
includes very few dietary sources of vitamin D, and vitamin D cannot be synthesized 
endogenously due to lack of UV light, decreased vitamin D status is a serious concern for 
exploration missions that could last 1000 days. 
 Toxicity of vitamin D is typically less likely to occur than a deficiency (317-320), but use of 
supplements would increase its likelihood. Excessive blood levels of vitamin D can lead to 
hypercalcemia, which can lead to nephrocalcinosis, arteriosclerosis, and irreversible soft tissue 
calcification. In one study conducted in Houston in healthy individuals, a 50,000-IU/wk dose of 
vitamin D for 4 weeks and then monthly increased mean urinary calcium excretion to numbers 
higher than the normal range (313). In that study, a daily dose of 2000 IU or a single weekly 
dose of 10000 IU did not increase the incidence of hypercalciuria. 
 
 
 
4. Gaps 
 
Vitamin D levels in the food system need to be determined, and the stability of vitamin D in 
the food system needs to be investigated. The interaction of vitamin D, stress, and immune 
system function during spaceflight requires further study. Monitoring of vitamin D status should 
continue, along with efforts to inform stakeholders about the importance of adequate vitamin D 
status and risks of vitamin D toxicity. 
 
 
 
 
  
Risk Factor of Inadequate Nutrition 
 
 57
 
C. Vitamin E 
 
1. Background 
 
Vitamin E is a lipid-soluble, chain-breaking antioxidant found in body tissues, and it is also 
the first line of defense against lipid peroxidation reactions. Eight naturally occurring compounds 
have vitamin E activity: four tocopherol derivatives (α-, γ-, δ-, and β-tocopherol) and four 
tocotrienol derivatives (α-, γ-, δ-, and β-tocotrienol) (321). The tocopherols that are most 
abundant in biological systems are α- and γ-tocopherol, but small amounts of δ-tocopherol and α-
tocopheryl quinine are also present. About 90% of the tocopherol found in human plasma is in 
the form of α-tocopherol (322).  
Vitamin E helps protect cell membranes in the early stages of free-radical attack because of 
its free-radical-quenching activity. Free radicals attack polyunsaturated fatty acids found in 
membrane phospholipids, causing damage to cellular membranes and possibly cell death. The 
interception of a free radical by vitamin E produces a tocopheroxyl radical that can be reduced 
by vitamin C or another reducing agent to return vitamin E to its reduced state. The extent of 
regeneration and recycling of vitamin E in human tissue has not been well established (321). 
Vitamin E has important roles related to immune system function (see Gap N7.5 below). 
Vitamin E is stored mainly in adipose tissue and is also found in phospholipid membranes. 
Results of studies conducted to determine vitamin E tissue levels have shown that tissue α-
tocopherol concentrations are largely reflected by changes in plasma α-tocopherol concentrations 
(323).  
Vitamin E deficiencies in humans are rare; however, fat malabsorption syndromes, genetic 
abnormalities, and protein-energy malnutrition are specific cases when a vitamin E deficiency is 
likely to occur (324). Symptoms include neurological problems associated with nerve 
degeneration in the extremities (322). Vitamin E depletion has been detected when markers of 
lipid peroxidation were elevated. However, the lowering of levels of these lipid peroxidation 
markers has not been shown to have any health benefits, and, therefore, they have not been used 
to establish α-tocopherol requirements.  
Deficiency of vitamin E leads to neurological disorders, hemolytic anemia, retinopathy, 
abnormal platelets and lymphocytes, or even death. Toxicity of vitamin E from naturally 
occurring sources has not been shown to occur. 
 
2. Evidence 
 
After ISS crewmembers had spent 4 to 6 months in space, their plasma -tocopherol was 
50% less than preflight levels (31). No change in α-tocopherol occurred in these subjects. 
Preliminary data collected during spaceflight show similar changes, that is, a decrease in 
circulating -tocopherol and no change in circulating α-tocopherol (6).  This is true for 
circulating tocopherols, whether they are normalized to lipid concentrations or not. The change 
in -tocopherol likely reflects differences in sources of vitamin E from the space food system. 
Animal hindlimb unloading studies have shown that supplemental vitamin E can have a positive 
influence on bone, potentially through antioxidant properties (325). 
The current documented spaceflight requirement for dietary intake of vitamin E is 15 mg/d 
for men and women, the same as the U.S. recommendation for adequate intake of vitamin E. No 
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upper limit has been established because the highest level of daily intake is not likely to pose 
serious health risks to the majority of individuals (322). Although no striking changes occurred 
in plasma vitamin E concentrations, the spaceflight menus provide only about 60% of the 
documented requirement for vitamin E. 
 
 
3. Risk 
 
Oxidative stress can increase in microgravity and high-radiation environments (326-328), 
and the antioxidant properties of vitamin E may help to counteract the free-radical damage 
caused by high-linear energy transfer radiation in space. Pretreatment with antioxidants may help 
decrease radiation damage during missions (329), and it may be necessary to provide enough 
vitamin E for astronauts’ blood levels of the vitamin to be higher during spaceflight than on 
Earth. However, knowledge gaps weaken the evidence for use of vitamin E as a countermeasure 
(see below). 
 
4. Gaps 
 
Vitamin E content of space foods, along with the stability of vitamin E in these foods, needs 
to be determined. After learning about the promising antioxidant effects of supplemental vitamin 
E, many people on Earth did not hesitate to take vitamin E supplements to prevent cancer. The 
protective effects were not borne out in controlled studies, highlighting the difficulties of 
defining a specific antioxidant countermeasure for space travelers without the luxury of having 
data from epidemiological studies to provide an evidence base for spaceflight. 
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D. Vitamin K 
 
1. Background 
 
Vitamin K occurs naturally in two forms: phylloquinone (vitamin K1) and menaquinone 
(vitamin K2). Menaquinones are produced by bacteria, while phylloquinone is synthesized in 
plants. Phylloquinone represents the main source of dietary vitamin K in Western countries (330, 
331). 
The function of vitamin K was originally assumed to be strictly limited to involvement in 
blood coagulation, but an increasing amount of evidence indicates that this vitamin affects 
multiple physiological systems. Vitamin K is a cofactor in the post-translational synthesis of γ-
carboxyglutamic acid (GLA) (332). Gamma-carboxyglutamic acid is common to all vitamin K-
dependent proteins, and its role is related to increasing the affinity of the proteins for calcium 
(333). Vitamin K-dependent proteins include blood coagulation proteins (prothrombin; factors 
VII, IX, and X; and proteins C and S) and bone proteins (osteocalcin, matrix GLA protein, and 
protein S).  
The main storage depot for vitamin K in the body is the liver. Large amounts of vitamin K 
are also present in cortical and trabecular bone (334). However, vitamin K stores are very small 
compared to those of other fat-soluble vitamins, and hepatic vitamin K is rapidly depleted when 
dietary vitamin K is restricted (335).  
Anticoagulants such as warfarin, a coumarin-based anticoagulant, are administered to create 
a partial vitamin K deficiency to reduce risks of abnormal blood clotting (336). Dosing with 
warfarin must be closely monitored for optimal efficacy and safety. Generous or poor intake of 
vitamin K can interact with the actions of warfarin to yield non-therapeutic anticoagulation or 
life-threatening hemorrhagic complications (337, 338).  
 
2. Evidence 
 
Data from 11 U.S. astronauts on ISS Expeditions 1-8 (mission durations of 128-195 days 
during 2000-2004) revealed that on landing day, their serum phylloquinone (vitamin K1) was 
42% lower than it was before flight (Figure 41), whereas urinary -carboxyglutamic acid did not 
change (31). In one study, undercarboxylated osteocalcin was elevated (a sign of vitamin K 
insufficiency) as early as the 8th day of spaceflight and remained high during 21- and 180-day 
missions (339). Studies on the EuroMir 95 mission showed that markers of vitamin K status were 
decreased after 12.5 weeks of spaceflight, and vitamin K supplementation (10 mg/d for 6 weeks) 
reversed these effects (340). Vitamin K supplementation elevated urinary -carboxyglutamic acid 
and decreased urinary undercarboxylated osteocalcin (a bone protein), suggesting that vitamin K 
status was lower during spaceflight and was improved by supplementation (339, 340).  
 
Monitoring vitamin K status during flight for the Nutrition Status Assessment Supplemental 
Medical Objective project (aka, Nutrition SMO) has documented a lack of evidence that vitamin 
K status is decreased during spaceflight, a finding earlier reported from a single case study on 
Mir (339, 340).  Nutrition SMO data from the first 15 participating crewmembers showed no 
major changes in phylloquinone, urinary GLA, or undercarboxylated osteocalcin (Figure 41) 
(341).  This was an important finding, to document that a vitamin K countermeasure to mitigate a 
vitamin K deficiency during spaceflight is not needed and therefore likely would not have an 
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effect on bone. 
 
 
 
Figure 41. Effect of long-duration 
spaceflight on vitamin K status of 
15 ISS crewmembers. 
Undercarboxylated osteocalcin 
(left) and urinary -
carboxyglutamic acid (GLA, right) 
are shown here. There were no 
significant changes as a result of 
spaceflight (341). 
 
 
 
The current documented spaceflight requirements for dietary intake of vitamin K are 90 and 
120 µg/d for women and men, respectively. These are the same as the U.S. adequate intake 
recommendations for vitamin K (277). No upper limit has been established. 
 
3. Risk 
 
Decreased vitamin K status has serious implications for spaceflight because it is related to 
bone health. Although spaceflight data, including data from Mir (339) and ISS crewmembers 
(31), suggest that vitamin K status during long-duration spaceflight was suboptimal, more recent 
data do not support this contention (6, 341). Elevated undercarboxylated osteocalcin has been 
associated with increased fracture risk in certain populations, and evidence exists that vitamin K 
antagonists increase the risk of fracturing vertebrae and ribs in a time-dependent manner (342, 
343).  
 
 
4. Gaps 
 
Deficiency of vitamin K is not common in adults, as the intestinal microflora synthesize 
vitamin K. The reliability of this source of vitamin K during flight is unknown, and expert panels 
have recommended having higher intake requirements because of this uncertainty (97). It has 
been hypothesized that microflora production of vitamin K may be altered in space, but few or 
no data are available to support this. The vitamin K content in the space food system and its 
stability should be determined. 
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Water-soluble vitamins are a key concern for space travelers, given the limited endogenous 
storage of many of these nutrients. They must be replenished from food that may have been 
stored for a long time (9-18 months) under suboptimal conditions, including the space radiation 
environment. 
 
 
E. Folate 
 
1. Background 
 
Folate is the general term used to describe folic acid and compounds that have activity 
similar to that of folic acid. Folic acid is the form of the vitamin used in vitamin supplements and 
fortified food products, but it is rarely found to occur naturally in food.  
The reduction of folic acid and dihydrofolate by a cytosolic enzyme produces the active 
form of folate, tetrahydrofolate (THF). Tetrahydrofolate accepts single-carbon groups from 
reactions in amino acid metabolism to form active derivatives of THF (344). These derivatives 
function in amino acid metabolism, specifically in the reversible reactions of serine synthesis 
from glycine, methionine synthesis from homocysteine, and histidine metabolism. Folate is 
essential in cell division because the THF derivatives play important roles in purine and 
pyrimidine synthesis. Tetrahydrofolate derivatives play a major role in the formation of 
thymidylate, which is a substrate needed for DNA synthesis (344).  
Deficiency of folate leads to megaloblastic anemia. Low folate intake will cause red blood 
cell (RBC) folate concentrations to diminish within 4 months. Bone marrow cells become 
megaloblastic (that is, they take on a nucleated, embryonic form), and anemia occurs after 4 to 5 
months of low folate intake (345). Folate deficiency in humans has been described as a 4-stage 
process (346, 347), including changes in serum folate (Stage 1), changes in RBC folate (Stage 2), 
defective DNA synthesis and elevated homocysteine (Stage 3), and clinical folate deficiency 
(Stage 4), manifested by macroovalocytosis (many large, oval cells in the blood), elevated mean 
corpuscular (red blood cell) volume, and large, nucleated embryonic cells. Radiation exposure 
and inadequate dietary consumption can lead to inadequate intake of folate (348). 
 
 
2. Evidence 
 
Early ISS flight data showed a reduction in RBC folate after long-duration missions (29, 
31). Serum folate is variable among crewmembers, but generally does not change during flight 
(Figure 42). Interestingly, serum folate was lower during spaceflight in crewmembers with 
vision-related issues (349). 
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Figure 42. Red blood cell (RBC) (left) and serum folate (right) before, during, and after long-duration 
spaceflight (data are mean ± SD). Note: RBC folate data are not available during flight because of 
sample processing requirements. 
 
 
As with many nutrients, folate deficiency on an exploration mission could be catastrophic. 
Animal studies have shown that low folate status increases chromosome damage resulting from 
radiation exposure (350-353); however, it should be noted that excessive folate supplementation 
provided no additional benefit (350). Similarly, cell models have shown that folic acid deficiency 
increases sensitivity to chromosome breakage from ionizing radiation (352). Antioxidant 
properties of folate have been studied, and folate was found to scavenge a diverse array of 
reactive oxygen species efficiently (354). Cell models also show the ability of folate to reduce 
iron toxicity in cases of iron overload, by oxidizing free or chelated iron (354). Evidence exists 
that in subjects living in saturation diving conditions with increased partial pressure of oxygen 
for 10 to 14 days, folate status decreases, which may be related to its antioxidant properties 
(355). Folate status may be even more important during exploration missions than on ISS 
because of known increases in iron storage during long-duration spaceflight (31) and exposure to 
ionizing radiation. Recent bed rest studies did not document any change in RBC folate status 
during or after short (3-week (356)) or long (60-90-day (357)) bed rest. A 14-day exposure to 
increased atmospheric pressure (i.e., saturation diving) did not significantly affect RBC folate 
(358). 
The current documented spaceflight requirement for folate intake is 400 g/d (97). In the 
U.S., the recommended dietary allowance (RDA) for all individuals aged 14 and older is 400 
μg/d of dietary folate equivalents (DFEs). Using DFEs adjusts for the 50% reduction in food 
folate bioavailability compared with that of folic acid: 1 μg/d DFE = 0.6 μg of folic acid from 
fortified food, or as a supplement taken with meals; 1 μg DFE = 1 μg of food folate = 0.5 μg of a 
supplement taken on an empty stomach. An upper limit of folate intake during spaceflight is set 
at 1000 μg/d. 
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3. Risk 
 
As with many nutrients, folate deficiency on an exploration mission would be catastrophic. 
Animal studies have shown that low folate status increases chromosomal damage resulting from 
radiation exposure (350-353); however, it should be noted that excessive folate supplementation 
provided no additional benefit (350). Similarly, cell models have shown that folic acid deficiency 
increases sensitivity to radiation-induced chromosome breakage from ionizing radiation (352). 
Antioxidant properties of folate have been studied, and it was found to efficiently scavenge a 
diverse array of reactive oxygen species (354). Cell models also show the ability of folate to 
reduce iron toxicity in cases of iron overload by oxidizing free or chelated iron (354). Folate 
status during exploration missions may be even more important because of known increases in 
iron storage during long-duration spaceflight (31) and exposure to ionizing radiation.   
 
4. Gaps 
 
Ongoing evaluation of one-carbon metabolism pathways, vitamins, and polymorphisms are 
required for better understanding of the role of vitamin B12 in astronaut vision issues. Folate 
levels in the space food system need to be determined. If the diet does in fact provide 400 g/d, 
further research should be conducted to understand the stability of folate following radiation 
exposure. 
 
 
 
 
 
F. Thiamin 
 
1. Background 
 
Thiamin functions as a coenzyme in the metabolism of carbohydrates and branched-chain 
amino acids. The coenzyme form of thiamin, thiamin pyrophosphate (TPP), functions in the 
decarboxylation of pyruvate and α-ketoglutarate. Without these decarboxylations, synthesis of 
both adenosine triphosphate (ATP) and acetyl-CoA would be inhibited. TPP also functions as 
part of a major enzyme involved in the hexose monophosphate shunt, the pathway by which 6-
carbon sugars are converted to pentoses and NADPH. Thiamin pyrophosphate is also believed to 
be involved in nerve conduction and nerve membrane function, although its role is not 
completely clear (345).  
About 30 mg of thiamin is stored in the human body (348). About half of the body’s 
thiamin is stored in the skeletal muscle, with the rest being stored in the heart, liver, kidney, and 
brain. Thiamin in excess of tissue needs and storage capacity is excreted in the urine. The 
biological half-life of thiamin is in the range of 9-18 days. 
Deficiency of thiamin ultimately leads to beriberi (enlarged heart, muscle weakness, 
anorexia, apathy, reduction in nerve impulse transmission), or even death. There are no known 
toxicity symptoms of excess thiamin.  
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2. Evidence 
 
Evaluation of erythrocyte transketolase activity, an index of thiamin status (359), before 
and after spaceflight did not yield any abnormal data (31).  
The current documented spaceflight requirement for dietary intake of thiamin is 1.2 and 1.1 
mol/d for men and women, respectively, which is the same as the U.S. recommended dietary 
allowances (RDAs) for men aged 19 and older and for women (348).  
 
3. Risk 
 
It is well known that thiamin is highly susceptible to destruction by radiation (360-362) and 
processing in foods (363). It will be crucial to determine if thiamin can survive a 3-year-plus 
mission to deep space. 
 
4. Gaps 
 
The thiamin levels in the space food supply and their stability need to be determined, 
particularly because thiamin is highly susceptible to degradation from radiation exposure. 
 
 
 
 
 
 
G. Niacin 
 
1. Background 
 
The term “niacin” includes nicotinamide, nicotinic acid, and their derivatives that have the 
biological activity of nicotinamide (348). In its coenzyme forms, nicotinamide adenine 
dinucleotide (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), niacin has many 
different metabolic roles in the human body. The nicotinamide moiety accepts hydride ions in 
numerous biological redox reactions. NAD functions in respiration and as a co-dehydrogenase 
with enzymes involved in the oxidation of fuel molecules. NAD is converted to NADH, which 
transfers electrons from the Krebs cycle through the electron transport chain. NAD also acts as a 
donor of adenine dinucleotide phosphate-ribose for the posttranslational modification of proteins 
(345). The coenzyme NADP has a role in fatty acid, cholesterol, and steroid syntheses and, as a 
co-dehydrogenase, in the pentose phosphate pathway. Conversion of folate to its active forms 
also requires NADP.  
Niacin is stored in the liver as NAD. This storage NAD can be converted from tryptophan, 
nicotinic acid, or plasma nicotinamide. Limited data show that after 80-135 days of ingesting a 
low-niacin diet, subjects’ urinary excretion of N1-methylnicotinamide is at a level representing 
deficiency status (348).  
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Niacin in the amount of 3 g/d or more has been associated with toxic effects (348). 
Flushing, gastrointestinal problems, hepatotoxicity, glucose intolerance, and ophthalmic effects 
have all been associated with high doses of the vitamin. However, many of these toxic effects 
have been shown to occur only after treatment over long periods and in amounts that far exceed 
the recommended dietary allowance (RDA). 
Deficiency of niacin leads to dermatitis, glossitis, growth retardation, and ultimately 
pellagra (diarrhea, dermatitis, and dementia), or even death. Toxicity from large doses of niacin 
can cause vasodilatory effects (flushing), gastrointestinal distress, hepatotoxicity, glucose 
intolerance, and blurred vision. 
 
2. Evidence 
 
Niacin status of astronauts during and after flight has not been measured. The current 
documented spaceflight requirement for dietary intake of niacin is 16 mg niacin equivalent 
(NE)/d (97). In the U.S., the niacin requirement is 16 mg/d of NE for men aged 19 years and 
older, and 14 mg/d of NE for women aged 19 years and older (348). One niacin equivalent is 
equal to about 60 mg of the amino acid tryptophan and can be obtained from 6 g of high-quality 
protein (345). The RDA for niacin can be met from the actual niacin content of the diet or by 
conversion of tryptophan in the diet.  
 
3. Risk 
 
Very little is known about niacin metabolism during spaceflight. One concern for 
exploration missions is the stability of niacin in the food system, particularly because of reports 
showing that the niacin content of foods decreases after exposure to 6 kGy of radiation (364).  
 
 
4. Gaps 
 
Niacin content and stability in the space food supply need to be determined. 
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H. Riboflavin 
 
1. Background 
 
The most important biologically active forms of riboflavin are flavin mononucleotide and 
flavin adenine dinucleotide (FAD). These cofactors participate in a range of redox reactions in 
numerous metabolic pathways (365). Some of these pathways are niacin-dependent and -
independent dehydrogenations, reactions with sulfur-containing compounds, hydroxylations, 
oxidative decarboxylations, dioxygenations, and reduction of oxygen to hydrogen peroxide. The 
riboflavin cofactors also play a role in the formation and function of some other vitamins, 
including folate, vitamin B12, and vitamin B6 (365). 
The highest concentrations of stored riboflavin are found in the liver, kidneys, and heart 
(348), and almost all riboflavin in tissues is enzyme-bound, such as FAD covalently bound to 
succinic dehydrogenase (366). The total body stores of riboflavin are enough to meet the 
demands of the body for 2-6 weeks (348). Unbound flavins are labile and are rapidly hydrolyzed 
to release free riboflavin. Excess free riboflavin is excreted in the urine (365). 
Riboflavin deficiency affects ferritin iron mobilization and iron absorption. Other 
symptoms of riboflavin deficiency include peripheral nerve demyelination, neurological 
abnormalities, and anemia.  
 
2. Evidence 
 
Erythrocyte glutathione reductase (EGR) activation, an index of riboflavin status (359), was 
unchanged after flight compared with preflight (31). A 14-day exposure to increased atmospheric 
pressure (that is, saturation diving) did not have a statistically significant effect on EGR, but 
EGR activation during and after the dive tended (P=0.07) to be lower than before the dive (358). 
The current documented spaceflight requirement for dietary intake of riboflavin is 1.3 mg/d. In 
the U.S., the recommended dietary allowance for riboflavin for men and women aged 19 years 
and older is 1.3 and 1.1 mg/d, respectively (348).  
 
3. Risk 
 
Cataract incidence is higher in space travelers than the general population (271), and 
cataracts have also been described in riboflavin-deficient animal models (365, 367). Although no 
evidence exists that riboflavin status changes during spaceflight, the possibility that this nutrient 
could be involved in cataract formation cannot be ignored. 
Riboflavin is relatively heat-stable, but it is readily degraded by light (365, 368). It does not 
seem to be degraded by γ-radiation of foods (361, 369). 
 
4. Gaps 
 
No evidence exists that riboflavin status is altered during 4 to 6-months of spaceflight (31); 
however, riboflavin content in the space food supply needs to be investigated to ensure that 
riboflavin will not degrade during long-duration storage. Riboflavin is relatively heat-stable, but 
it is readily degraded by light (365, 368). It does not seem to be degraded by γ-irradiation of 
foods (361, 369). 
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I. Vitamin C 
 
1. Background 
 
The term “vitamin C” actually refers to two different compounds, both of which have 
activity against scurvy: ascorbic acid and dehydroascorbic acid. Vitamin C functions as an 
antioxidant because it acts as a reducing agent for most physiologically relevant reactive oxygen 
species, reactive nitrogen species, singlet oxygen, and hypochlorite. It serves as a cofactor for 
enzymes involved in the biosynthesis of collagen, carnitine, and neurotransmitters. Vitamin C 
also provides antioxidant protection by returning α-tocopherol to its biologically active state 
during lipid oxidation. The reducing agents glutathione and either reduced nicotinamide adenine 
dinucleotide (NADH) or reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
regenerate the oxidation products of ascorbate.  
It has been suggested that vitamin C requirements should be greater in individuals who are 
under excessive physical or emotional stress, given the role of ascorbate in the biosynthesis of 
steroid hormones and neurotransmitters. However, no substantial data show that vitamin C 
metabolism is altered in healthy subjects under mental or emotional stress (322). 
The total body pool of vitamin C varies with intake. Higher concentrations are found in the 
pituitary and adrenal glands, liver, spleen, heart, kidneys, lungs, pancreas, leukocytes, eye tissues 
and humors, and brain, while lower concentrations are found in the saliva, muscle, and plasma. 
Blood cell and tissue concentrations become saturated at intakes of 100-140 mg/d, and steady-
state plasma vitamin C concentrations occur with intakes of 200 mg/d. Catabolic turnover varies 
from 10-45 mg/d, and turnover is reduced with low intakes. Maximum body pools of ascorbate 
are ~2 g.  
Vitamin C deficiency most commonly presents as any of an array of symptoms commonly 
referred to as scurvy. Scurvy is seen in adults within 45-80 days of stopping vitamin C intake. 
Intake below the recommended dietary allowance (RDA) can cause a deficiency once the body 
pools fall below ~300 mg of ascorbic acid. The length of time until scurvy symptoms develop 
when intake is suboptimal depends on the size of the individual’s body pool of vitamin C before 
intake is decreased. 
Deficiency of vitamin C leads to fatigue, depressed immune function, and ultimately scurvy 
(fatigue, muscle cramps, bruised and/or bleeding gums), or even death. Toxic amounts of 
vitamin C lead to gastrointestinal distress. 
 
2. Evidence 
 
Vitamin C assessments from ISS have not been completed yet, but they will be available 
soon and may raise additional questions. A recent short-duration bed rest study documented no 
statistically significant changes in vitamin C (Figure 43), but results showed a trend toward an 
increase, which might be related to dietary intake or plasma volume shifts (356). 
 
Risk Factor of Inadequate Nutrition 
 
 68
 
 
 
Figure 43. Plasma vitamin C in 7 
subjects during 21 d of bed rest. Data 
are expressed as the percentage 
change (mean±SD) from before bed 
rest (356). The vertical dotted line 
marks the end of bed rest. 
 
 
 
 
 
 
 
 
 
 
 
The stability of vitamin C has been studied in food supplies, and it is generally unstable at a 
neutral or alkaline pH, or in high-oxygen environments (370). Vitamin C is also unstable when 
exposed to light or heat (370), as well as in irradiated foods (371, 372). Salem (372) found that γ-
irradiation of fresh onion bulbs significantly reduced their vitamin C content. This group also 
found that vitamin C content of onion bulbs had decreased about 50% after 6 months of storage. 
The destructive effects of γ-irradiation (10 kGy) on vitamin C are also evident in commercial 
spices, such as basil, black pepper, cinnamon, nutmeg, oregano, parsley, rosemary, and sage 
(373). Exposure of these spices to γ-rays for >3 months resulted in a marked increase in quinone 
radicals. 
The current documented spaceflight requirement for dietary intake of vitamin C is 90 mg/d. 
In the U.S., the RDAs for vitamin C for men and women aged 19 years and older are 90 and 75 
mg/d, respectively. They are set by assuming a coefficient of variation of 10% because 
information about the standard deviation is unavailable. The RDA is defined as equal to the 
estimated average requirement (EAR) plus twice the coefficient of variation to cover the needs of 
at least 98% of the population (322). Because of the increased level of stress predicted for 
orbiting crews, the requirement for vitamin C in space crews was initially defined as 100 mg/d 
for men and women (4, 5), at a time when the U.S. RDA was 60 mg/d. 
 
3. Risk 
 
One concern for spaceflight is the possibility that vitamin C could be degraded in foods 
during extended-duration missions when space foods are exposed to large amounts of radiation 
and undergo long-term storage (up to 5 y).  
Free-radical formation is increased in space because greater amounts of radiation are 
present than on Earth. Because of this and increases in other oxidative stressors, antioxidants 
such as vitamin C are in greater demand by the body to act as buffers and minimize the oxidative 
damage. Studies have shown that supplementation with vitamin C and other antioxidants can 
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modify human tissue radiosensitivity and protect DNA against damage (374, 375). Just as 
important to consider, however, is the possibility that vitamin C could induce DNA damage. Cai 
and colleagues (375) found that vitamin C can act as an antioxidant to prevent DNA damage 
caused by ionizing radiation, but in the presence of copper, it can also act as a reducing agent to 
induce DNA damage. Because vitamin C can reduce redox-active metals, such as iron and 
copper, this “antioxidant” can increase the pro-oxidant chemistry of these metals (376). Thus, 
vitamin C can serve as both a pro-oxidant and an antioxidant. 
 
4. Gaps 
 
Vitamin C content and stability in the space food supply need to be determined. Evaluation 
of the impact of vitamin C supplementation during exposure to oxygen or high-linear energy 
transfer radiation should be investigated before recommendations can be made for supplement 
use during flight. 
 
 
 
 
 
 
 
 
 
J. Vitamin B6 
 
1. Background 
 
Vitamin B6 comprises a group of three compounds and their 5′-phosphates (P): pyridoxal 
(PL) and PLP, pyridoxine (PN) and PNP, and pyridoxamine (PM) and PMP. These vitamers of 
B6 serve as coenzymes in many transamination reactions by forming a Schiff’s base with the -
amino group of lysine and the carbonyl group of PLP (348, 377). They can also function in 
decarboxylation reactions, such as the formation of γ-aminobutyric acid from glutamate and 
serotonin from 5-hydroxytryptophan, and they function in trans- and desulfhydration, where 
cysteine is synthesized from methionine and pyruvate is generated from cysteine. The vitamers 
also function in cleavage reactions, racemization of D- and L-amino acids, synthesis of multiple 
compounds, glycogen catabolism (where vitamin B6 is required for the activity of glycogen 
phosphorylase), and steroid hormone action (where the vitamers decrease the actions of steroids) 
(345).  
About 80% of vitamin B6 is stored in muscle tissue and 10% is stored in the liver, with the 
rest being stored in the blood plasma pool. Data from studies have shown that total body stores 
are about 1,000 mol or 167 mg (348). Overall body half-lives of the vitamers of vitamin B6 are 
about 25 days (348, 378).  
Deficiency of vitamin B6 leads to dermatitis, microcytic anemia, convulsions, altered 
mental status, hyperhomocysteinemia, or even death. Toxic levels of vitamin B6 lead to sensory 
neuropathy or even death. 
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2. Evidence 
 
No change occurred in the activation of red blood cell transaminase of astronauts on 4- to 6-
month spaceflights (31). Weightlessness has been shown to reduce the cross-sectional area of 
muscle fibers and is associated with a change from type I to type II muscle fibers (379). As 
vitamin B6 is stored mainly in muscle tissue (380), a decrease in muscle cross-sectional area 
could reduce the amount of the vitamin that is stored. Increased excretion of 4-pyridoxic acid 
during bed rest, a finding observed in short- (356) and long-duration bed rest studies (381), likely 
reflects this loss of muscle stores of vitamin B6.  
There is no evidence that vitamin B6 status changes during long-duration spaceflight; 
however, we have shown that crewmembers who have experienced vision-related issues have 
higher blood concentrations of cystathionine and 2-methylcitric acid than crewmembers who did 
not experience such issues (349). Although increased levels of these metabolites do not point to a 
vitamin B6 deficiency, they do suggest there may be a perturbation in the 1-carbon metabolism 
pathway, which is dependent on folate, vitamin B12, and vitamin B6.  
The current documented spaceflight requirement for dietary intake of vitamin B6 is 1.7 
mg/d. In the U.S., the vitamin B6 requirement for all adults over age 19 years is 1.3 mg/d (348).  
 
3. Risk 
 
Given the changes observed in vitamin B6 metabolism during bed rest, vitamin B6 status 
during and after long-duration spaceflight warrants further attention. A deficiency in vitamin B6 
causes a decrease in the synthesis of serotonin and catecholamines, which has been shown to be 
associated with depression (382). Excess vitamin B6 can lead to neuropathy (383-385). 
 
4. Gaps 
 
Given the changes observed in vitamin B6 metabolism during bed rest and with muscle loss, 
further attention is warranted. Vitamin B6 levels and stability in the space food supply need to be 
determined, along with an assessment of stability in an elevated radiation field.  
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K. Vitamin B12 
 
1. Background 
 
Vitamin B12 functions in many enzymatic reactions, and deficiencies result in anemia, as 
well as neurological disorders. Vitamin B12 works as a cofactor for 3 different enzymatic 
reactions: (1) the conversion of homocysteine to methionine, (2) the conversion of L-
methylmalonyl-coenzyme A (CoA) to succinyl-CoA, and (3) the isomerization of L-leucine and 
β-leucine. Vitamin B12 deficiency may cause the accumulation of folate in the serum because of 
a reduction in B12-dependent methyltransferase, also known as the methyl-folate trap (386). 
Vitamin B12 also functions in the synthesis of choline, which can be converted to the 
neurotransmitter acetylcholine. 
Unlike other water-soluble vitamins, vitamin B12 can be stored in the body for years. It is 
stored predominantly in the liver, but smaller amounts can be found in the muscles, kidneys, 
bones, heart, brain, and spleen. About 2 to 5 mg of vitamin B12 is stored in the body (348). The 
size of B12 stores remains relatively stable, partly because urinary and fecal excretion decrease in 
direct relationship to decreases in the body pools. The half-life of vitamin B12 in humans is 350 
to 400 days (348).  
No evidence of toxicity has been found with vitamin B12 supplementation in amounts 
greater than the recommended dietary allowance (348), and no adverse effects are reported to be 
caused by an excess of vitamin B12. If a person went for many years without adequate intake 
and/or supplementation, body stores could be depleted. Other factors that could contribute to a 
vitamin B12 deficiency include a decrease in gastric acidity, the presence of atrophic gastritis, and 
uncontrolled growth of bacteria accompanied by malabsorption of food-bound B12 (387). 
Deficiency of vitamin B12 leads to pernicious anemia and demyelination of the central nervous 
system, and can lead to death (388).  
 
2. Evidence 
 
Methylmalonic acid (MMA) is generally unchanged during spaceflight, suggesting that 
vitamin B12 deficiency is not a significant issue during flight. However, blood concentrations of 
MMA were shown to be higher in crewmembers who experienced vision-related issues after 
flight than in those who did not have such issues (349), and this difference was evident before, 
during, and after spaceflight. Several studies support the notion that perturbations in the vitamin 
B12 metabolic pathway can cause ophthalmic health issues such as optic neuropathy and age-
related macular degeneration (389-391). 
Of ISS astronauts evaluated, the occurrence of off-nominal vitamin B12 values has been 
13% of preflight, 13% of in-flight, and 34 % of postflight assessments. That is, these percentages 
of astronauts studied have had at least one MMA data point outside normal limits during the 
specified flight phase (Figure 44). 
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Figure 44. Plasma methylmalonic acid 
data collected on ISS astronauts. Each 
point represents an individual test point, 
and the horizontal bars represent mean ± 
SD. Dashed lines represent normal ranges 
(Smith and Zwart, unpublished 
observations). 
 
 
 
 
 
 
The current documented spaceflight requirement for dietary intake of vitamin B12 is 2.4 
g/d. This is the defined required amount of vitamin B12 in the U.S. for both men and women 
aged 19 years and older (348).  
 
3. Risk 
 
Alterations in vitamin B12 metabolism or requirements during long-duration flights could 
have critical health implications for the crew, and warrant further investigation, especially with 
respect to vision-related issues. 
 
4. Gaps 
 
Ongoing evaluation of one-carbon-metabolism pathways, vitamins, and polymorphisms are 
required for better understanding of the role of vitamin B12 in astronaut vision issues. As artistic 
depiction of this is presented in Figure 102. Given the incidence of elevated MMA findings, and 
of crewmembers referred to their flight surgeons for evaluation of vitamin B12 status, this role of 
vitamin B12 warrants further study. Vitamin B12 levels and stability in the space food supply 
should be determined. 
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L. Biotin 
 
1. Background 
 
Biotin is a required cofactor for pyruvate carboxylase, acetyl-CoA carboxylase isoforms 1 
and 2, propionyl-CoA carboxylase, and β-methylcrotonyl-CoA carboxylase (392). The 5 biotin-
dependent enzymes are involved in carbohydrate, fatty acid, and amino acid metabolism (392), 
and the primary role of biotin is to transfer CO2 units from one compound to another. Biotin 
exists in a free state or bound to proteins. About 81% of biotin in the human body is free biotin 
in serum, and 10% is free in tissues (393). 
Low-biotin diets administered to 10 healthy subjects who also consumed large amounts of 
avidin (an egg-white protein that binds biotin very tightly) showed signs of decreased biotin 
status by the third day (394). Urinary excretion of biotin and its metabolites decreased 
significantly and urinary excretion of 3-hydroxyisovaleric acid increased significantly after 3 
days; however, these decreases were not out of the normal range until days 7 and 17, 
respectively. Serum biotin did not decrease significantly, and it was suggested that serum biotin 
is not an early and sensitive indicator of marginal biotin deficiency (395). Animal studies 
indicate that a biotin deficiency, marked by urinary biotin excretion, generally occurs about 2-3 
weeks after beginning consumption of a biotin-free diet (396, 397). 
Despite the observation that frank signs of deficiency are rare, there is growing appreciation 
of genetic, physiologic, and pharmacologic conditions that marginally impair biotin status (398-
400). This suggests that the lack of physiologic manifestations of biotin deficiency may not be a 
reliable measure to gauge biotin status. Marginal changes in biotin status have been shown to 
affect a range of metabolic factors, from carboxylase activity to the expression of non-biotin-
dependent enzymes such as glucokinase, ornithine transcarbamylase, and phosphoenolpyruvate 
carboxykinase (401-403).  
Frank biotin deficiencies are associated with neurological and dermatological 
manifestations, which are likely caused by the loss of function of biotin-dependent enzymes. 
Seizures, hearing loss, optic atrophy, dermatitis, and aciduria (associated with elevated blood 
concentrations of organic acids) are common symptoms of a frank biotin deficiency. There is no 
evidence of toxicity of biotin at high intake levels. 
 
2. Evidence 
 
Biotin status has never been measured during or after long-duration spaceflight, but it is 
unlikely there are any frank biotin deficiencies, which would present as neurological and 
dermatological manifestations.    
The current documented requirement for dietary intake of biotin during spaceflight is 30 
g/d. In the U.S., the dietary reference intake for biotin has been based only on adequate intake 
(AI) data (348). To date, no recommended dietary allowance has been reported for biotin due to 
lack of data and a general consensus that colonic bacteria synthesize biotin that contributes to the 
daily supply. Because microbial synthesis of biotin takes place in the lower part of the intestine, 
where nutrient absorption is limited, controversy exists regarding how much of the biotin 
produced by colonic bacteria is available for host metabolism. The AI for adults is extrapolated 
from the AI for healthy infants consuming breast milk and has been determined to be 30 g/d for 
men and women >19 years. 
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3. Risk 
 
Virtually nothing is known about biotin as it relates to spaceflight. Alterations in 
metabolism or requirements during long-duration flights, or the occurrence of drug/nutrient 
interactions, could have significant health implications for crews. 
 
4. Gaps 
 
Biotin levels in the space food system need to be determined. The biotin status of astronauts 
during and after flight, as well as the fact that gastrointestinal changes during spaceflight may 
lead to changes in the microbial synthesis of biotin, warrant further study. Furthermore, the 
interaction of biotin with some pharmacological agents (such as phenobarbital) included in the 
medical kit supplied to astronauts during spaceflight has been shown to yield biotin deficiencies 
in other populations (399). 
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M. Pantothenic Acid 
 
1. Background 
 
The primary function of pantothenic acid lies in its role as a precursor of coenzyme A 
(CoA) and as a component of acyl carrier protein (ACP). Pantothenic acid, in the form of CoA 
and ACP, is required for numerous lipid, carbohydrate, and protein metabolic reactions. CoA is 
necessary for acetyl and acyl transfer reactions associated with catabolism, and it acts as a 
precursor to ACP. ACP is a coenzyme in the fatty acid synthase complex. 
Free pantothenic acid is found in various parts of the body: 10-15 mol/L in the liver, ~100 
mol/L in the heart, 1-5 mol/L in plasma, 50-100 mol/L as CoA, and 10 mol/L as ACP. 
About 70-90% of CoA is found in the mitochondria. Any excess pantothenic acid is excreted in 
urine (404). 
Because pantothenic acid is widely distributed in foods, deficiencies have been reported 
only in cases where semisynthetic diets or antagonists to the vitamin were used. Individuals 
became deficient after 63 days on a diet virtually devoid of the vitamin (405). 
Because pantothenic acid is required in numerous metabolic reactions, deficiency of the 
vitamin can cause neurological, immunological, hematological, reproductive, and gastrointestinal 
dysfunctions. Specific symptoms include dermatitis, growth retardation, numbness and burning 
of hands and feet, impaired antibody production, headache, fatigue, insomnia, increased 
sensitivity to insulin, and intestinal disturbances. Pantothenic acid deficiency is rare because of 
its presence in a wide variety of foods of both plant and animal origin. Deficiency of the vitamin 
is frequently associated with multi-nutrient deficiencies, making it difficult to detect specific 
symptoms of pantothenic acid deficiency. There is no conclusive evidence that adverse effects 
occur from high intakes of pantothenic acid.  
 
2. Evidence 
 
No data regarding pantothenic acid intake or status during or after spaceflight are currently 
available. The current documented requirement for dietary intake of pantothenic acid during 
spaceflight is 30 mg/d (97). In the U.S., the dietary reference intake for pantothenic acid has been 
based only on adequate intake (AI) data (348). No recommended dietary allowance has been 
reported for pantothenic acid. The AI for adults is based on mean intakes and is 5 mg/d for men 
and women >19 years. No upper limit has been reported for pantothenic acid, but doses of the 
vitamin as high as 10-20 g/d have been well tolerated, with occasional diarrhea reported (404).  
 
3. Risk 
 
The stability of pantothenic acid under conditions of long-term spaceflight (such as 
extended storage time and exposure to high-linear energy transfer radiation) will have to be 
determined to minimize the risk for pantothenic acid deficiency symptoms. 
 
4. Gaps 
 
Pantothenic acid levels in the space food system should be determined, as well as their 
stability under conditions of long-term spaceflight conditions.   
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N. Calcium 
 
1. Background 
 
Calcium is critical for maintaining the body’s structural and mechanical functions, and it 
constitutes 37% to 40% of the bone mineral hydroxyapatite in the body (406). In addition to its 
obvious role in the musculoskeletal system, calcium has a critical role in modulation of the 
function of important proteins and regulation of metabolic processes. Calcium binding is 
responsible for the activation of a wide range of proteins, including those involved in cell 
motility, blood coagulation, muscle contraction, neural transmission, glandular secretion, and 
cell division (407, 408). Circulating calcium levels are under tight control and are maintained 
within a narrow range (409).  
Bone acts as the body’s reservoir for calcium. Total skeletal calcium is on average 1100-
1500 g, and inadequate calcium intake has significant impact on adult bone (410). About 1% of 
the body’s calcium stores resides in the intracellular structures, cell membranes, and extracellular 
fluids (408). 
Calcium depletion is not uncommon in many subgroups of the population. During acute 
starvation, urinary calcium remains constant; the largest amounts of calcium loss occur in feces, 
with much of the mineral loss apparently coming from bone (197). Gamble et al (198) examined 
blood mineral concentrations in children during acute starvation and showed that calcium levels 
did not change after 4 days of fasting. Studies in dogs and cats indicate that significant changes 
occur only when more than 35% of body mass is lost (411). Blood calcium levels after chronic 
semi-starvation are variable, but most studies indicate that plasma or serum calcium levels 
decrease (197). Controlled calcium balance studies during semi-starvation provide more variable 
results, with individual calcium balances ranging from positive to negative (197). 
Calcium absorption may be decreased in a variety of disease states, including Crohn’s 
disease, diabetes, chronic renal failure, and malabsorption syndromes (408). Although the daily 
calcium intake requirement increases with age, many of the elderly and other population groups 
have inadequate intakes. Assessment of calcium deficiency by clinical laboratory analyses is 
difficult because circulating calcium is tightly regulated over a wide range of intakes (408). 
Imaging techniques (such as dual-energy x-ray absorptiometry and quantitative computed 
tomography) that enable determination of bone mineral content may provide a good indicator of 
long-term calcium nutritional status. 
Deficiency of calcium leads to reduced bone mass and osteoporosis. An excess of calcium 
leads to kidney stones, hypercalcemia, and ultimately renal insufficiency or even death. Intakes 
up to 2500 mg/d are considered safe under normal conditions (408). 
 
2. Evidence 
 
As a result of skeletal unloading during flight (314, 412-421), bone mineral is lost, leading 
to increased urinary excretion of calcium (94, 413, 415). Bone loss is a significant health concern 
for long-duration spaceflight (422-424). It is estimated that the rate of bone mineral loss during 
spaceflight is about 0.5-1% per month (417, 425, 426). The bone loss and increased risk of renal 
stone formation during and after flight (181, 182) are significant.  
The Skylab studies showed that during spaceflight, bone mineral was not uniformly lost 
from all parts of the skeleton. Loss of bone tissue was most profound in weight-bearing bones 
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such as the os calcis. Of the 3 men aboard the 59-day Skylab 3 mission, 1 lost a significant 
amount of os calcis bone mineral (–7.4%) but the other 2 did not (+2.3% and +1.4 %). Calcium 
excretion in the urine was 200% of the preflight value for the man who lost os calcis mineral and 
50% of the preflight values for the other 2 men (413).  
While blood calcium concentrations are tightly maintained (Figure 45, Figure 46), negative 
calcium balance was observed during the Skylab (39, 94, 413, 415, 427, 428) and Mir (30, 63) 
missions. During the 84-day Skylab 4 mission, the calcium balance was –200 mg/d (94, 429), but 
no significant calcium losses occurred during the 28-day Skylab 2 mission (413, 425). Increased 
urinary and fecal calcium excretion accounts for most of the deficit in calcium (30, 39, 63, 94, 
181, 413, 415, 428). During the Skylab 4 mission, calcium losses correlated roughly with 
mineral losses in the os calcis (430) and increases in the excretion of hydroxyproline. 
 
 
 
 
Figure 45. Plasma calcium of Skylab 
crewmembers (N=9) before and after flight 
(39). 
 
 
 
 
 
 
 
 
 
 
Figure 46. Serum calcium of Shuttle crewmembers (N=2-6) 
during and after flight, expressed as percentage change from 
preflight values (208). 
 
 
 
 
 
 
 
 
Figure 47. Plasma parathyroid hormone (PTH) 
concentrations of Skylab crewmembers (N=9) 
before and after flight (39). 
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Bone resorption increases during spaceflight, as shown by the concentrations of bone 
markers (431-433) and by the results of calcium tracer kinetic studies (30, 63). Urinary 
hydroxyproline was elevated 33% after 84 days of flight (94, 434). Urinary collagen crosslinks, 
also markers of bone resorption, were elevated >100% during spaceflight compared with 
preflight levels (63, 431). Calcium tracer kinetic data indicated that bone resorption increased 
about 50% during flight (63). 
Bone formation either remains unchanged or decreases during spaceflight (30, 63, 425). As 
indicated by serum concentrations of bone-specific alkaline phosphatase and osteocalcin, bone 
formation was unchanged during Mir flights but increased 2-3 months after landing (30, 63). 
Trends toward decreased levels of bone formation markers were noted in two Mir studies with 
one subject each (432, 433). Studies, using calcium tracer techniques, of bone formation in three 
Mir crewmembers (30, 63) were equivocal (formation unchanged or decreased). Together, 
increased resorption and decreased or unchanged formation yield an overall negative calcium 
balance (30, 63). 
 
 
 
Figure 48. Plasma total alkaline phosphatase of 
Skylab crewmembers (N=9) before and after 
flight (39). 
 
 
 
 
 
 
 
 
A number of related factors likely contribute to the loss of bone mineral during 
weightlessness. Decreased calcium absorption has been observed among Mir astronauts (30, 63), 
which likely resulted from the decreased concentration of circulating 1,25-dihydroxyvitamin D 
that was also observed in these crewmembers (30, 63). While it is important to maintain calcium 
intake during flight, the lower absorption during flight suggests that this is not a viable 
countermeasure for weightlessness-induced bone loss, a fact proven in bed rest studies (435).  
Spaceflight analog studies (such as bed rest) with humans have shown qualitative effects on 
bone and calcium homeostasis similar to those shown in flight studies (424), with quantitative 
effects generally being of smaller magnitude. Effects include loss of bone mass (436-438), 
decreased calcium absorption (439), increased urinary calcium and biochemical markers of 
resorption (415, 439-446), increased risk of renal stone formation (443, 444), and decreased 
serum concentrations of parathyroid hormone (PTH) (296, 441) and 1,25-dihydroxyvitamin D 
(296, 439, 441, 447). 
Histomorphometry (438, 448) and measurement of biochemical markers of bone 
metabolism have shown that bone resorption increases during bed rest. Hydroxyproline excretion 
in bed rest subjects (439) is elevated. Collagen crosslink excretion during bed rest (431, 439) is 
elevated about 50% above control levels, compared with the greater than 100% increase during 
flight (63, 431). Excess dietary calcium will not protect against bone loss (449). 
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Histomorphometry data from bone biopsies also show that bone formation decreases during 
bed rest (438, 441, 448), but the concentrations of biochemical markers (296, 437, 439) indicate 
that formation is unchanged. This difference likely reflects the difference between site-specific 
(biopsy) and systemic (biochemical markers) indices of bone formation. After ambulation 
following bed rest, bone formation is generally increased (437, 439). 
Bone loss and altered calcium metabolism occur in paralyzed individuals (as reviewed by 
(450)), and there are a number of similarities between these changes and those associated with 
spaceflight (451-454). The loss of bone that occurs after spinal cord injury seems to stabilize 
after about 25 weeks (455). Studies of bone metabolism have not been possible during space 
missions of this duration, and the limited postflight bone assessment does not allow 
determination of the rate of loss. 
If the rate of bone calcium loss is constant throughout a flight (a reasonable assumption 
judging by collagen crosslink excretion data (30, 63, 431)), about 250 mg of bone calcium is lost 
per day (30, 63, 94, 456). The nature and degree of bone mineral loss over time varies between 
subjects (417-420, 424, 457).  
Long-term follow-up data on bone recovery are far from complete (420, 458). However, if 
the rate of postflight recovery estimated from biochemical data is also assumed to be constant 
(reasonable according to ground-based (436) and flight (30, 63) data), the rate of recovery is 
about +100 mg/d (30, 63). By these estimates, on flights up to about 6 months, it takes 2-3 times 
the mission duration to recover the lost bone. For longer flights, however, the usefulness of these 
assumptions is questionable, as spaceflight data are not available. Although more data clearly are 
required to validate this hypothesis, it nevertheless has significant implications as mission 
durations increase.  
The current documented spaceflight requirement for dietary intake of calcium during flight 
is 1200-2000 mg/d. In the U.S., the recommended dietary allowance is defined as 1000 mg for 
men and women age 19-50 years, and increases to 1200 mg/d for women 51 years and older and 
men 71 years and older (279).  
 
3. Risk 
 
The ability to understand and counteract weightlessness-induced bone mineral loss will be 
critical for crew health and safety during and after extended-duration space station and 
exploration missions (459-462). Changes in the endocrine regulation of bone metabolism seem 
to reflect adaptation to the weightless environment. Decreases in calcium absorption and plasma 
levels of PTH and 1, 25-dihydroxyvitamin D are expected physiological responses to increased 
resorption of bone that may occur as the body adapts to an environment in which bones bear less 
weight. This evidence, and the lack of improvement provided by earlier dietary countermeasures, 
indicate that supplementation of the diet with nutrients such as calcium and vitamin D will not 
correct this problem (435). Adequate nutrition will, however, be a required component in the 
success of whatever countermeasures are identified and implemented (199, 460). 
For planetary missions, the ability of a partial terrestrial g force (such as the 0.38g on Mars) 
to reduce bone loss, or even begin recovery, is unknown. Although no data on partial-g responses 
are available, the general consensus among investigators is that forces less than 0.5g are likely to 
be of little value. 
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4. Gaps 
 
The effect of near-weightlessness on the human skeletal system is one of the greatest 
concerns in safely extending space missions (422, 463). Adequate intake of dietary calcium will 
be critical for maintaining skeletal health. Both dietary protein (amount and type) and dietary 
sodium affect calcium metabolism. In addition, the use of pharmacological countermeasures may 
have implications for calcium homeostasis. Specifically, the bisphosphonates exert their effects 
by inhibiting osteoclast-mediated bone resorption, lowering serum calcium in subjects who are 
normocalcemic or hypercalcemic (464). It is recommended that subjects receiving 
bisphosphonates have adequate vitamin D status before therapy and that their calcium status be 
monitored (465-467).  
Although it is unlikely that diet is solely responsible for the bone mineral loss associated 
with spaceflight, even modest protective effects from a balanced diet would benefit crew health. 
Using diet modification as a countermeasure has several advantages, including no additional 
costs and no additional time required by astronauts during flight. The ratio of acid and base 
precursors in the diet could be an important predictor of the extent of bone loss during 
spaceflight and could be determined from the menu choices before flight. Maintaining a diet 
balanced in acid and base precursors would involve food choices and could be done with the help 
of a dietitian planning the menus. Furthermore, until in-flight resources for research are 
available, a pre- and postflight investigation of the relationship between diet and bone 
metabolism could provide a basis for defining optimal nutritional recommendations during 
recovery after spaceflight. (Small Assessment Team nutrition gap 5 is “Can one test track net 
bone Ca+ changes?”) 
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O. Phosphorus 
 
1. Background 
 
Phosphorus is an important component of cell membranes and bone. Phosphate accounts 
for about 60% of bone mineral (406), and most (80%) of the body’s extracellular phosphorus is 
present in the bone as hydroxyapatite (468). Phosphorus is also a critical element of most 
enzymes, cellular messengers, and carbohydrate fuels.  
Deficiency of phosphorus leads to hypophosphatemia, which causes cellular dysfunction 
and can lead to anorexia, muscle weakness, bone pain, and ultimately rickets, or even death. 
Osteomalacia, a defect in bone mineralization, often occurs as a result of long-term phosphorus 
deficiencies. Inadequate intake of phosphorus can cause the release of calcium from bone, 
cardiomyopathy, and a reduction in chemotactic, phagocytic, and bactericidal properties of 
granulocytes (468). An excess of phosphorus leads to hyperphosphatemia, ectopic calcification 
of the kidney, or even death. Excessive phosphorus intake has been shown to affect calcium 
absorption by increasing excretion of endogenous calcium in the feces (469).  
Human studies show that phosphorus can be depleted by daily antacid treatment with either 
magnesium-aluminum hydroxide (60 mL, 4 times per day) or aluminum hydroxide (30 mL, 4 
times per day) (470). Serum calcium of these subjects was elevated within 12 days of treatment, 
and by day 20, the phosphorus balance was negative (470). Animal studies have demonstrated 
that the removal of phosphate from the diet rapidly induces hypercalcemia, hypercalciuria, and 
hypophosphaturia. Rats fed a low-phosphate diet showed signs of deficiency after 11 days (471). 
 
2. Evidence 
 
Plasma phosphate was determined in Skylab crewmembers before, during, and after flight 
(Figure 49).  
 
 
 
 
Figure 49. Plasma phosphate of Skylab 
crewmembers before, during, and after flight 
(2). 
 
 
 
 
 
 
 
 
Long-duration ISS spaceflight data show that urinary phosphorus concentrations are about 
45% less after landing than before launch (Figure 50) (31). 
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Figure 50. Urinary phosphorus of ISS crewmembers (N=11) 
before and after long-duration spaceflight. Adapted from (31).  
 
 
 
 
 
 
 
 
In the U.S., the recommended dietary allowance for phosphorus (410) is 700 mg/d for men 
and women 19 years of age and older. The current documented spaceflight requirement for 
dietary intake of phosphorus during flight is 700 mg/d, and phosphorus intake should not exceed 
1.5 times the calcium intake (97).  
 
 
3. Risk 
 
Adequate phosphorus intake before and during flight will be critical for preserving bone 
quality and quantity. In addition, a dietary calcium:phosphorus ratio greater than 1.5 is known to 
decrease calcium absorption, which could impair skeletal integrity. Serum phosphorus rises with 
increasing phosphorus intake, and if hyperphosphatemia occurs, it can result in calcification of 
the kidney. For this reason, ensuring optimal phosphorus intake during flight becomes very 
important (425). Because phosphorus deficiency can cause muscle weakness and osteomalacia, 
maintaining adequate status of phosphorus during flight will be critical for preventing impaired 
performance on landing, which could limit crew capability for getting out of the spacecraft in an 
emergency. 
 
4. Gaps 
 
Nominal determinations of phosphorus content of the space food system are required, as 
well as further investigation of the mechanism and implications of decreased phosphorus 
excretion after long-duration spaceflight. Small Assessment Team nutrition gap 7 is “What are 
the potassium, magnesium, and phosphorus changes in relation to cardiovascular issues and bone 
loss?” 
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P. Magnesium 
 
1. Background 
 
Magnesium is the fourth most abundant cation in the body, and within the cell its 
abundance is second only to that of potassium (472). It is required as a cofactor for over 300 
enzyme systems and serves as a substrate for phosphate transfer reactions in all cells. More than 
half of the body’s magnesium is contained in bone, about 30% in muscle, and the remainder 
mostly in soft tissue (473).  
Few studies have addressed experimental magnesium depletion in humans. Consuming a 
diet containing 10 mg/d for 110 days led to a steady decline in plasma magnesium to levels 10-
30% of control values, and urinary magnesium levels were negligible (< 1 mEq/d) within 7 days 
(473). Abnormal neuromuscular signs occurred in 5 of 7 subjects after 25-110 days of 
magnesium deficiency (473). Deficiency of magnesium leads to neuromuscular 
hyperexcitability, seizures, cardiac complications, or even death (410). Adequate intake of 
magnesium is necessary to prevent hypocalcemia, resistance to vitamin D, and resistance to 
parathyroid hormone. 
No evidence has been reported of adverse effects associated with toxicity from naturally 
occurring sources of magnesium, but large doses may cause gastrointestinal distress. Excessive 
intake from supplements has been shown to impair calcium absorption (473). 
  
2. Evidence 
 
Apollo serum and urinary magnesium levels are shown in Figure 51 (104), and in-flight and 
postflight Shuttle data are shown in Figure 52. 
Figure 51. Serum (N=32) and urinary (N=23) magnesium levels in Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). 
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Figure 52. Serum magnesium levels of Shuttle 
crewmembers (N=2-6) during and after flight, 
expressed as a percentage change from preflight 
(208). 
 
 
 
 
 
 
 
Crewmembers on Skylab flights had lower plasma magnesium levels at landing (Figure 
53).  
 
 
 
Figure 53. Plasma magnesium levels of 
Skylab crewmembers (N=9) before and 
0, 1, 3-4, and 14 days after flight (2). 
 
 
 
 
 
 
 
 
 
Several studies show that 
magnesium metabolism may be altered during and after long-duration spaceflight (31, 39, 474). 
After crewmembers had spent 4 to 6 months in space, their urinary magnesium was about 45% 
less than it was before flight (Figure 54) (31). The causes and implications of this are being 
evaluated in ongoing ground-based and flight studies. 
 
 
 
 
 
 
 
 
 
 
FD2 FD4 FD6 FD7 R+0 R+3 R+10
-10
-5
0
5
10
Se
ru
m
 m
ag
ne
si
um
(%
 f
ro
m
 p
re
-fl
ig
ht
)
Skylab
Pr
efl
igh
t
R+
0
R+
1
R+
3/4
R+
14
1.8
1.9
2.0
2.1
2.2
2.3
Pl
as
m
a 
m
ag
ne
si
um
 (m
g 
%
)
Risk Factor of Inadequate Nutrition 
 
 85
 
 
 
 
Figure 54. Serum (left panel) and urinary (right panel) magnesium before and after 4- to 6-month 
spaceflights on the International Space Station. Each line represents one crewmember. The “Pre Mean” 
point on each line is the average of data collected about 6 months and 6 weeks before launch. R+0 = 
Recovery plus zero days, i.e., landing day. These samples are typically collected 2-8 hours after landing. 
From (1, 31). 
 
A Russian report on the impact of spaceflight on the magnesium content of bones 
documented 32% lower concentrations in the compact layer of the femoral epiphysis and 
diaphysis, vertebral body, and sternum compared with non-flight controls (475). These changes 
were reported as appearing “with a high degree of certainty.” No changes were observed in the 
calcaneus. (Note: this study reported on the autopsy results following the tragic end of the 24-day 
Salyut 1 mission, compared with controls.) 
The current documented requirement for dietary intake of magnesium during spaceflight is 
420 and 320 mg/d for men and women, respectively (97). In the U.S., the recommended dietary 
allowance (RDA) for magnesium (410) is 400 mg/d for men aged 19-30 years and 420 mg/d for 
men aged 31-70 y. The RDA is 310 mg/d for women aged 19-30 years and 320 mg/d for those 
aged 31-70 y. 
 
3. Risk 
 
Adequate magnesium intake before and during flight will be critical to reducing the 
potential for altered magnesium status and to help preserve bone quality and quantity. 
Maintaining adequate magnesium status during flight will be critical for maintaining 
musculoskeletal structure and function and, thus, for preventing impaired performance on 
landing, which may limit crew capability of getting out of the spacecraft in an emergency. 
 
4. Gaps 
 
Nominal determinations of magnesium content of the space food system are required. The 
significant decrease in urinary magnesium excretion after 4- to 6-month spaceflights (31) also 
warrants further investigation.  
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Q. Iron  
 
1. Background 
 
Iron is an essential element involved in oxygen transport, oxidative phosphorylation in 
carbohydrate and lipid metabolism, and electron transport in cytochromes and cytochrome 
oxidase (476, 477). Adequate iron is crucial for meeting the needs of organs and tissues, but 
excess iron is detrimental to cells and can cause oxidative damage. The body achieves iron 
balance through regulation of absorption by enterocytes in the intestine and regulation of iron 
export from cells. Once iron is absorbed into the enterocyte, it can be bound to ferritin and 
stored. Serum ferritin has been shown to be a sensitive indicator of iron stores (478). Ferritin is 
exponentially correlated with storage iron, as determined by quantitative phlebotomy in patients 
with iron overload (479).  
Iron deficiency is the most common nutritional deficiency worldwide, but iron toxicity is 
also worthy of concern. Deficiency of iron leads to anemia, fatigue, reduced work capacity, 
impaired behavior and intellectual performance, cognitive deficits and memory loss, heart 
palpitations, impaired thermoregulation, and decreased immune function (480-482). Toxic 
amounts of iron may lead to tissue damage or cancer. High iron intakes have also been related to 
gastrointestinal distress. The toxic potential of iron derives from its ability to exist in 2 oxidative 
states (ferrous and ferric forms). Iron serves as a catalyst in redox reactions; however, when 
these reactions are not properly modulated by antioxidants or iron-binding proteins, cellular 
damage can occur (483). Adaptation of iron metabolism in humans typically allows the 
maintenance of normal body iron concentrations in spite of disparate physiological requirements 
and dietary supply (484). Body iron, about 4 g in the adult human, is determined by 
physiological iron demands, dietary supply, and adaptation (476, 484, 485). Dietary iron is a 
function of both content and bioavailability of total food iron; bioavailability is lower in non-
heme than in heme iron sources. Dietary factors that inhibit iron absorption include tea, coffee, 
bran, calcium, phosphate, egg yolk, polyphenols, and certain forms of dietary fiber (476). 
Conversely, meat, fish, poultry, and ascorbic acid will enhance the bioavailability of non-heme 
iron. 
Iron is known to be involved in immune system functionspecifically, adaptive and innate 
immune responseand both iron overload and iron deficiency affect immune function. As 
reviewed by Dao and Meydani, iron overload can affect susceptibility to infection (486). On the 
other hand, iron deficiency affects the function of certain immune cells, including neutrophils 
and natural killer cells, and production of cytokines (486). As with any nutrient, supplementation 
must be used with caution, as some have found that in areas of the world where infection rates 
are high, such as malaria-endemic regions, iron supplementation can actually increase the risk of 
infection, suggesting that the supplemented iron provides an environment for pathogens to thrive 
(487). Others have shown that iron deficiency can help protect against some types of infections 
(488).  
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2. Evidence 
 
Evidence from short- (weeks) and long-duration (months) space missions shows that red 
blood cell (RBC) mass decreases during flight because of neocytolysis (489, 490). An early 
hypothesis for the cause of decreased RBC mass was that RBC synthesis in space was 
understimulated relative to synthesis on the ground (491). Decreased release of mature RBCs 
into the circulation is associated with a decrease in circulating erythropoietin concentrations. 
Serum erythropoietin decreases in the first few days of spaceflight, but it returns to preflight 
levels later and iron turnover is unchanged during flight (490, 492), indicating that synthesis of 
RBCs and hemoglobin is unchanged. A consequence of the decreased RBC mass is the 
subsequent transfer of the iron from newly synthesized cells into storage proteins and processes. 
Evidence of this includes increased circulating concentrations of serum ferritin, an index of iron 
storage, after short- and long-duration spaceflights (31, 474, 493). In addition to these 
physiologic changes that can affect tissue iron stores, dietary iron content is very high in the 
International Space Station (ISS) food system, largely because many of the commercial food 
items in the ISS menu are fortified with iron (2). The mean iron content of the standard ISS 
menu is 20 ± 6 mg/d, and individual crewmembers have had intakes in excess of 47 mg/d for 
some weeks during long-duration missions. For reference, the defined spaceflight requirement 
for iron is 8-10 mg/d for both men and women (2, 97), and the current U.S. Dietary Reference 
Intake (DRI) for men is 8 mg/d and the DRI for women is 10 mg/d (277). The tolerable upper 
intake limit for iron as defined by the Institute of Medicine is 45 mg/d (277). 
Indices of iron metabolism and erythropoiesis return toward normal relatively quickly 
(days) after landing, although the replenishment of RBC mass may take several weeks. The 
repletion of RBCs usually occurs after the disproportionate return of plasma volume, so that a 
dilutional “anemia” often occurs after flight (494). For example, a 3% to 5% decrease in 
hematocrit between landing (R+0 d) and R+3 days is common after both short- and long-
duration flights (494). 
Although the in-flight decrease in RBC mass is substantial (Figure 55), the efficient 
postflight recovery suggests that the change represents an adaptation to weightlessness. After the 
first weeks of flight, RBC mass and body fluid volumes reach new plateaus (lower than on 
Earth), as shown by data from long-duration flights (43, 495-497). The triggering mechanism for 
these changes is unknown. One hypothesis is that the body senses a decreased requirement for 
blood volume and adapts accordingly. This may be related to changes in fluid (circulatory) 
dynamics and reduced gravitational strain on the circulatory system during flight, which may 
result in easier delivery of oxygen to tissues, or to the decreased plasma volume and increased 
concentration of RBCs in the first few days of spaceflight. The decrease in RBC mass has no 
documented functional consequences. 
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Figure 55. Red blood cell mass (mL/kg body mass) after 
spaceflight. Each point represents one crewmember. Data are 
expressed as the percentage change from preflight values. 
From (493). 
 
 
 
 
 
In-flight data show that iron stores increase 
early during a mission (within 15 d) and then return to preflight concentrations by the end of a 6-
month mission (498). In a recent study with 23 crewmembers of missions 50 to 247 days in 
duration, ferritin increased about 220% in women and 70% in men by flight day 15 (498). At 
several time points, the transferrin index exceeded 1 µmol iron/µmol transferrin, which provides 
evidence that iron overload occurred (499). Other acute-phase proteins (C-reactive protein and 
ceruloplasmin) were not changed during flight, indicating that the ferritin response was likely not 
just an inflammatory response. In this study the amount of increase in ferritin (area under the 
curve) was associated with the change in bone mineral density after flight, which was supported 
by the association between ferritin and other markers of iron status and markers of bone 
resorption. The greater the increase in ferritin during flight (or the longer it was elevated; either 
case would result in a greater area under the curve), the greater the decrease in bone mineral 
density in the hip, trochanter, hip neck, and pelvis after long-duration spaceflight (498). The 
change in ferritin over the course of a 6-month mission is presented below (Figure 56), and is 
very similar to the change in urinary 8-hydroxy-2ʹ-deoxyguanosine (8OHdG, a marker for 
oxidative damage) during spaceflight). These data are important to show that mean ferritin 
concentrations during flight that were not outside the normal clinical range were associated with 
evidence of oxidative damage and bone resorption, and this is supported by other studies in 
healthy ground-based populations (500-502). 
 
 
Figure 56. The percentage change from 
preflight in serum ferritin (red circles, solid 
line) and urinary 8OHdG (blue squares, 
dashed line) before, during, and after long-
duration spaceflight (N=23). “Pre” was 
determined from the mean of preflight data 
points (3 for ferritin, 4 for 8OHdG), and 
percentage change was calculated from that 
average. Adapted from (498). 
 
 
 
Bed rest studies have not proven to be consistently reliable models for the hematological 
changes of spaceflight. Early bed rest studies showed a decrease in RBC mass during bed rest, 
but erythropoietin was unchanged and hematocrit increased (503), suggesting that the 
mechanisms that bring about hematological changes during bed rest are different from those that 
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act during flight. If the reduced RBC mass during flight is caused by the reduced gravitational 
load on the circulatory system, it is reasonable to assume that bed rest alone would not alleviate 
these forces, but would only reposition them. More recent studies have shown small changes in 
iron status measurements, the most consistent being a drop in hematocrit and hemoglobin after 
reambulation (356, 357), suggesting an impact of plasma volume replacement, with a smaller 
role of hematopoiesis. 
Another model is provided in studies involving changes in altitude, where the descent from 
high to low altitude induces changes similar to those observed for spaceflight (decreased red cell 
mass, increased iron storage) (504). Exogenous erythropoietin prevented the changes (504), 
suggesting that it is involved in the regulating mechanism, as it may be in the initial change in 
spaceflight. 
The NASA Extreme Environment Mission Operations (NEEMO) undersea environment 
provides an excellent spaceflight analog for changes in iron status, specifically with respect to 
the environment in the NEEMO habitat (358). Probably because of the increased air (including 
oxygen) pressure in the habitat, and greater oxygen availability, body iron stores are elevated 
during the NEEMO 10- to 14-day saturation dives (31, 493). As discussed above, excess iron can 
act as an oxidant and cause tissue damage (505, 506). In several NEEMO missions, we found 
that total body iron was related to markers of oxidative damage (Figure 57) (507). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. Relationship between iron stores and oxidative damage in three NEEMO missions, where crewmembers 
were exposed to saturation dive conditions for 10-12 days. The panel on the left presents data from 12 crewmembers 
on the NEEMO 12 and 13 missions (507), and the panel on the right presents data from 6 crewmembers on the 
NEEMO 5 mission (358). The regression line in both graphs is significant (P<0.05). Adapted from (2, 507). 
 
Serum ferritin is routinely increased during NEEMO dives, and evidence for oxidative 
damage and stress is also observed (358). On a recent NEEMO mission, RBC folate was 
decreased during the dive, and plasma folate status was inversely correlated with serum ferritin 
(355). Decreased superoxide dismutase activity and peripheral blood mononuclear cell 
poly(ADP-ribose) were also evident during the dive, indicating that a DNA repair response 
occurred (355). Exposure to higher oxygen pressures also increases crewmembers’ risk for 
oxidative damage to DNA, proteins, and lipids (508-511). 
The current documented spaceflight requirement for dietary intake of iron is 8-10 mg/d for 
men and women. In the U.S., the recommended dietary allowance (RDA) is 8 mg/d for men aged 
19-70 years and 18 mg/d for women aged 19–50 y, dropping to 8 mg/d in women over 50. 
Historical spaceflight iron requirements for missions of 30-120 days were to be less than 10 
0 500 1000 1500 2000
0
5
10
15
20
SOD (U/g hgb)
To
ta
l b
od
y 
iro
n 
(m
g/
kg
)
0 500 1000 1500 2000
0
5
10
15
20
SOD (U/g hgb)
To
ta
l b
od
y 
ir
on
 (m
g/
kg
)
Risk Factor of Inadequate Nutrition 
 
 90
mg/d (4, 5), matching the RDA at the time. Regardless of whether the requirement was less than 
8 mg/d or 10 mg/d, the food system was unable to support this requirement, and intakes have 
often been much higher (intakes as high as 20-25 mg iron/d have been observed). This high 
intake is worthy of concern because of the potential for elevated tissue iron to cause deleterious 
effects. 
 
 
3. Risk 
 
The implications of moderately increased iron stores in the body include exacerbated bone 
loss, oxidative stress, cardiovascular disease, and cataracts or other ophthalmic issues. For 
example, ground studies show that increased body iron stores (assessed by measuring serum 
ferritin) were related to the rate of change in regional bone loss over a 3-year period in healthy 
subjects (512). This finding supports what we have observed during spaceflight (498). Other 
risks with iron overload are retinal degeneration and cataract risk (513). We have seen that, in rat 
studies of iron loading plus radiation exposure, increased oxidative damage occurs in the retina 
as well as systemically and in the liver (514). Furthermore, the formation of free radicals 
subsequent to elevation of iron stores has also been linked on Earth to cardiovascular disease and 
cancer. Although aspects of some of the evidence supporting this thesis contradict each other 
(515, 516), a correlation between coronary heart disease and iron status has been described in a 
number of recent studies (517-519), and an association between increased incidence of 
myocardial infarction and increased iron stores (as measured by serum ferritin) has been 
observed (519, 520). In a prospective Finnish study, increased risk of all cancer types combined 
and colorectal cancer in particular was associated with high iron stores (521). The relationship 
between iron, lipids, and cancer has also been documented in the Framingham study (522). A 
relationship has also been indicated between excessive iron stores and ascorbic acid deficiency; 
when reductions in ascorbic acid occur, vitamin A and selenium tend to exacerbate iron-induced 
peroxidation processes (523). These data suggest that the alterations in erythropoiesis and iron 
metabolism that occur in microgravity could cause significant changes affecting crew health. 
 
4. Gaps 
 
Better characterization of iron metabolism during spaceflight with respect to other systems 
is warranted because of the high levels of dietary iron, the increase in iron stores early during 
flight, and the potential for iron to act as an oxidizing agent during spaceflight, complicated by 
increased radiation levels. It is known that bacterial virulence increases upon exposure to 
microgravity (524), and ground studies also show that increased iron status can increase risk for 
infection (525). Investigating the increase in iron status during flight with respect to changes in 
immune function will be an important next step in understanding the implications of elevated 
iron status during flight. Furthermore, iron absorption has yet to be determined during flight. 
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R. Copper 
 
1. Background 
 
Copper is an essential cofactor for enzymes involved in energy production, metabolism of 
oxygen and iron, maturation of the extracellular matrix and neuropeptides, and neuroendocrine 
signaling (526). Deficiencies in copper have implications for bone health, the nervous system, 
immune function, the cardiovascular system, and lipid metabolism (526). The involvement of 
copper in bone health is specifically related to lysyl oxidase function and collagen synthesis 
(267, 526). 
Copper is not usually stored in tissues, but liver, brain, and kidney typically contain the 
largest amounts per unit tissue mass (526). Total body copper is about 50 to 120 mg (0.79-1.9 
mmol) (527). Copper transport and regulation involve the blood protein ceruloplasmin. 
Frank copper deficiency is rare in human populations consuming a normal diet; however, 
copper deficiencies have been noted in infants fed milk formulas, infants recovering from 
malnutrition and fed cow’s milk, and patients receiving total parenteral nutrition for a prolonged 
period (528). Six patients fed (through the gastrointestinal tract) a diet containing 15 µg 
copper/100 kcal for 12 to 66 months (529) developed a copper deficiency. 
When copper deficiency occurs it leads to normocytic, hypochromic anemia; decreased 
production of leukocytes and neutrophils; and defects in connective tissue (specifically in 
collagen synthesis) that can lead to vascular and skeletal problems and central nervous system 
dysfunction, or even death (528). Heartbeat irregularities have also been reported in cases of 
copper deficiency (530). Deficiency symptoms, including macrocytic anemia, bone 
abnormalities, and decreased neutrophil production, have been reported in subjects with serum 
copper concentrations ranging from 0.9 to 7.2 µmol/L (529). Toxic concentrations of copper lead 
to oxidative damage, gastrointestinal distress, liver damage, or even death (526).   
 
 
2. Evidence 
 
Serum copper (Figure 58) and ceruloplasmin (Figure 59) of ISS crews have been 
determined as part of the medical requirement to assess nutritional status in long-duration 
crewmembers, and no significant changes were noted after flight (31). In-flight determinations of 
copper status have not yet been reported. 
 
 
Figure 58. Serum copper before and after 4- to 6-month 
missions on the International Space Station. Each line 
represents one crewmember. The “Pre Mean” point for 
each line is the average of data collected about 6 months 
and 6 weeks before launch. R+0 = Recovery plus zero days, 
i.e., landing day. These samples are typically collected 2-8 
hours after landing. From (1, 31). 
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Figure 59. Serum ceruloplasmin before and after 4- to 6-
month missions on the International Space Station. Each 
line represents one crewmember. The “Pre Mean” point 
on each line is the average of data collected about 6 
months and 6 weeks before launch. R+0 = Recovery plus 
zero days, i.e., landing day. These samples are typically 
collected 2-8 hours after landing. From (1, 31). 
 
 
 
One Russian report on the effect of spaceflight on copper content of bones (475) 
documented “non-uniform changes” in copper content of bone from different regions after flight 
relative to nonflight controls. Copper content of the femoral epiphysis was 81% to 159% greater, 
while the amounts of copper in the vertebral body and sternum were 36% and 58% less, 
respectively. (This study reported on the autopsy results after the tragic end of the 24-day Salyut-
1 mission, relative to controls.) 
During a 17-week bed rest study, copper balance was unchanged, but after reambulation it 
increased (531). During and after 3 weeks of bed rest, serum copper and ceruloplasmin were 
unchanged (356). After 90 days of bed rest, serum copper was slightly elevated, but the change 
was statistically significant (357). In 60- and 90-day bed rest studies, ceruloplasmin was 
unchanged (357). 
The current documented spaceflight requirement for dietary intake of copper is 0.5-9 mg/d 
(97). In the U.S., the recommended dietary allowance for copper in men and women aged 19-70 
years is 0.9 mg/d (277).  
 
 
3. Risk 
 
Changes in copper status could contribute to the effects of spaceflight on bone, red blood 
cells (RBCs), and iron status. The changes in bone during spaceflight, described in this volume, 
could be exacerbated by copper deficiency and impaired collagen synthesis. Anemia of 
spaceflight is manifested as a reduction in circulating RBC mass with elevations in serum ferritin 
and iron concentrations (43, 490). Since copper is required for iron mobilization and absorption, 
alterations in copper status may affect iron and RBC changes during flight.  
Appropriate amounts of certain nutrients, copper in particular (532), are vital for 
maintaining normal immune function. The immune system seems to be altered during spaceflight 
(102, 533-536), and this may have direct or indirect (when alterations are induced by stress or 
radiation) implications for nutrition and nutritional status as possible causes or effects (534, 537). 
 
4. Gaps 
No information about copper absorption and metabolism during spaceflight is available, 
but, given the available ground data, obtaining such information is not a high priority at this 
point. Ensuring adequate copper content of the diet and verifying that the flight data on copper 
status follow ground trends are important monitoring steps. 
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S. Manganese 
 
1. Background 
 
Manganese can function as an enzyme activator and as part of metalloenzymes. It becomes 
involved in activating enzyme-catalyzed reactions by causing conformational changes in the 
enzyme that it binds to. Manganese can also bind directly to the substrate.  
All transferases, including kinases, hydrolases, oxido-reductases, ligases, and lyases, can be 
activated by manganese. However, in the presence of a manganese deficiency, these enzymes 
can be activated by other divalent cations. Activating these enzymes gives manganese a role in 
the formation of components of connective tissue, urea formation, arginase activity, 
gluconeogenesis, the prevention of lipid peroxidation by superoxide radicals in the mitochondria, 
and the conversion of pyruvate to oxaloacetate in the tricarboxylic acid cycle. Studies are 
currently being conducted to look at the role that manganese may play in second-messenger 
pathways in tissues and the regulation of calcium-dependent processes (345). 
Only trace amounts of manganese are found in animal tissues. Humans store about 10-20 
mg of the nutrient. Although it is found in most organs and tissues, the highest concentrations are 
located in bone and in the liver, pancreas, and kidneys (345). 
Signs of a manganese deficiency in humans have not been firmly established, partly 
because other cations can perform the same role. In one study, when adult men were fed a 
purified diet with only 0.11 mg manganese/d for 39 days, all of them developed a finely scaling 
rash, along with decreased serum cholesterol, increased serum calcium and phosphorus, and 
increased alkaline phosphatase (538).  
Manganese is one of the least toxic trace minerals when it is taken orally. At excessively 
high intakes of manganese, absorption decreases and excretion increases to protect against 
toxicity. Toxic levels of manganese lead to neuropathy.  
Manganese and iron compete for binding sites. At low iron intakes, manganese is absorbed 
at a greater rate than at higher iron intakes, such that higher iron intake inhibits manganese 
absorption. Likewise, higher manganese intake can inhibit iron absorption. 
 
2. Evidence 
 
One Russian report on the impact of spaceflight on manganese content of bones (475) 
documented generally increased regional bone manganese content (26-187%) after flight relative 
to controls. (Note: this study reported on the autopsy results following the tragic end of the 24-
day Salyut 1 mission, compared with controls.) 
The current documented spaceflight requirement for dietary intake of manganese is 2.3 and 
1.8 mg/d for men and women, respectively, the same as the adequate intake of manganese for 
men and women aged 19 years and older (277). 
 
3. Risk 
 
Considering manganese’s function in preventing lipid peroxidation and the increase in lipid 
peroxidation that occurs during spaceflight, ensuring adequate manganese intake on long 
spaceflights is vital to preventing and/or minimizing oxidative stress. 
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4. Gaps 
 
Existing knowledge of manganese metabolism seems adequate; other than the nominal 
determinations of manganese content of the space food system, no other specific research is 
required.  
 
 
T. Fluoride 
 
1. Background 
 
Fluoride in bone exists in a rapidly exchangeable pool and a slowly exchangeable pool. In 
the rapidly exchangeable pool, fluoride is in the hydration shell on bone crystallites, where it is 
exchanged isoionically or heterionically with other ions nearby (410). The slowly exchangeable 
pool is mobilized during the process of bone remodeling. Fluoride has also been shown to 
influence the function of osteoblasts, enabling new bone to be made. An increase in fluoride 
absorption increases the amount absorbed by hard tissue, but urinary excretion also increases.  
Ninety-nine percent of fluoride is stored in mineralized tissues, predominantly in bone. 
Because specific signs of fluoride deficiency have not been fully elucidated for higher animals 
and humans, it is not possible to estimate a relative time to depletion. 
Fluoride deficiency increases the development of dental caries and may reduce the integrity 
of skeletal tissue (345). Supplementation of fluoride (5 or 10 mg/d) in ambulatory subjects was 
shown to have no impact on calcium homeostasis, but it resulted in a positive fluoride balance 
(539). 
Toxicity with fluoride supplementation is rare but can occur with fluoride intakes greater 
than 10 mg/d for at least 10 years (410). Toxic levels of fluoride lead to enamel and skeletal 
fluorosis and osteosclerosis. High doses (>40 mg/d) also result in side effects, including bone 
pain and gastric irritation (540, 541).  
 
2. Evidence 
 
No information about the effect of spaceflight on fluoride status of astronauts is available.  
 
In the 1970s, fluoride was evaluated as a countermeasure for bone loss associated with 
osteoporosis and simulated spaceflight (bed rest). Although fluoride balance was positive when 
subjects were supplemented with 10 mg/d, there was no impact on calcium homeostasis, and 
both the fluoride-treated and untreated groups lost calcium during bed rest (542). 
The current documented spaceflight requirement for dietary intake of fluoride is 4 and 3 
mg/d for men and women, respectively, which is the same as the adequate intake of fluoride for 
men and women aged 19 years and older (277).  
 
3. Risk 
 
Considering the loss of bone mass associated with weightlessness, adequate fluoride is 
necessary to ensure that the bone apatite remains intact.  
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4. Gaps 
 
Existing knowledge of fluoride metabolism seems adequate; other than the nominal 
determinations of fluoride content of the space food system, no other specific research is 
required. 
 
 
 
U. Zinc 
 
1. Background 
 
Zinc is a component of many enzymes, which depend on it for their catalytic activity. RNA 
polymerases, alcohol dehydrogenase, carbonic anhydrase, and alkaline phosphatase are all zinc 
metalloenzymes. Zinc provides structural integrity to these enzymes by binding to amino acids, 
and it may participate directly in the reaction at the catalytic site (345). 
Tissue and cell growth, cell replication, bone formation, skin integrity, cell-mediated 
immunity, and generalized host defense are all functions of zinc. In tissue growth, it is involved 
directly with the regulation of protein synthesis. Zinc helps to regulate transcription by binding 
to promoter sequences of specific genes. Cell membranes require zinc for protein-to-protein 
interactions and membrane proteins’ conformation. Zinc may also affect the activity of enzymes 
attached to plasma membranes. Zinc stabilizes membrane structure by maintaining phospholipids 
and thiol groups in their necessary reduced state. It also prevents oxidation of the membrane by 
occupying sites that might otherwise be occupied by pro-oxidant metals and protects against 
oxidation by its role in the synthesis of the protein metallothionein. Zinc is an integral part of the 
hormone insulin and plays a role in carbohydrate metabolism.  
About 1.5-2.5 g of zinc is stored in the human body (277). It is found intracellularly in all 
organs, tissues, and body fluids but mostly in bone, liver, kidneys, muscle, and skin (345). Over 
85% of zinc is found in skeletal muscle and bone (345, 543). Even when dietary zinc is 
suboptimal, the zinc stored in muscle, brain, lung, and heart is not released. The apatite of bones 
releases zinc slowly, and this release does not greatly affect the zinc supply (277). The greatest 
losses of zinc occur through the intestine. In men, the average daily loss of zinc from sources 
other than the intestine remains relatively constant at 1.27 mg/d, even when individuals consume 
an inadequate amount of the nutrient. For women, calculation of this value has been based on the 
differences between men and women in average surface area and menstruation and is 1.0 mg/d 
(277).  
Because the stores of zinc in the body are small, inadequate intake can quickly lead to 
exhaustion of the zinc supply. When this happens, plasma enzymes containing zinc and 
metallothionein are catabolized to provide the necessary zinc (277), which action yields a 
decrease in enzyme activity (345). Zinc deficiency can also cause decreased glucose tolerance by 
decreasing the insulin response. Basal metabolic rate has been shown to be decreased in 
individuals who were receiving a zinc-deficient diet (544). Deficiency of zinc leads to arrested 
growth and development and decreased immune function.  
There is currently no evidence of adverse effects associated with toxicity from naturally 
occurring sources of zinc. However, supplemental intake may cause suppression of the immune 
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response, decreased high-density lipoprotein (HDL) cholesterol, reduced copper status, or even 
death. Acute toxicity has been shown to produce a metallic taste, nausea, vomiting, epigastric 
pain, abdominal cramps, and bloody diarrhea. Long-term toxicity can cause copper deficiency 
because zinc and copper compete for absorption by the intestine (345). 
 
2. Evidence 
 
 
 
 
 
 
 
 
 
 
Figure 60. Serum and urinary zinc status from 11 ISS crewmembers before and after flight (2, 31).  
 
The change in the zinc status of astronauts, as assessed by serum zinc and urinary zinc 
excretion, did not change after long-duration spaceflight (Figure 60, (31)).  
The release of zinc from bones (due to demineralization) has been noted in bed rest studies 
(531, 545), and a similar increase in excretion of zinc was noted in Wistar rats flown during 
COSMOS 1129 (a 20-day spaceflight) (546).  
The current documented spaceflight requirement for dietary intake of zinc is 11 mg/d (97), 
the same as the U.S. adequate intake amount for men (adequate intake is 8 mg/d for women) 
(277).  
 
3. Risk 
 
Many compounds exist in food that can complex with zinc and decrease its absorption. 
Phytates, oxalates, polyphenols, fibers, and other nutrients, including vitamins, can all inhibit 
zinc absorption. In view of zinc’s role in metabolism, it may be necessary to provide additional 
zinc either in the diet or as a supplement on long-duration exploration missions.  
Increases in urinary zinc with increased muscle catabolism have been noted in cases of 
starvation or trauma (277). The importance of this phenomenon for spaceflight has not been 
evaluated (nor has the release of other heavy metals [such as lead] from bone during flight, 
although this has been modeled and proposed as a concern (547, 548)). 
 
4. Gaps 
 
Existing knowledge of zinc metabolism seems adequate; other than the nominal 
determinations of zinc content of the space food system, no other specific research is required. 
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V. Selenium 
 
1. Background 
 
Selenium has been shown to play a role in the maintenance or induction of cytochrome 
P450, pancreatic function, DNA repair, enzyme activation, immune system function, and 
detoxification of heavy metals. Selenium is also a cofactor for glutathione peroxidase (GPX). 
GPX plays a role in the reduction of organic peroxides and hydrogen peroxide. Selenium has 
also been shown to be necessary for iodine metabolism.  
Total body selenium stores are in the amount of about 15 mg (345). There are two selenium 
pools in the body: the selenium in selenomethionine and the selenium in GPX. Selenium 
absorption can be increased by vitamins A, C, and E and reduced glutathione, and it can be 
decreased by chelation and precipitation of the mineral by heavy metals, such as mercury, and 
phytates.  
Deficiency of selenium leads to decreased selenoenzyme activity, which may lead to 
biochemical changes that predispose to illness or even death. Selenium deficiency has been 
associated with Keshan disease, characterized by cardiomyopathy and heart tissue necrosis, and 
with Kashin-Beck’s disease, characterized by osteoarthropathy of the joints and epiphyseal-plate 
cartilages of the legs and arms (345). In rats, symptoms of acute selenium deficiency have been 
shown to appear as early as 20 days after withholding selenium. The deficiency was shown as a 
reduction in GPX activity, but no change in blood enzymes was seen (322). 
Selenium status has been related to cancer risk (Figure 61) (549), leading to much 
speculation about the ability of selenium supplementation to prevent cancer. 
 
 
 
 
 
Figure 61. Toenail selenium content and 
relative risk of prostate cancer (adapted from 
(549)). 
 
 
 
 
 
 
Toxicity of selenium is called selenosis. Nausea, vomiting, fatigue, hair and nail brittleness 
and loss, changes in nail beds, interference in sulfur metabolism, and inhibition of protein 
synthesis have all been demonstrated to result from selenium toxicity.  
 
2. Evidence 
 
The Clinical Nutritional Assessment profile (550) has documented a significant (10%) 
reduction in serum selenium concentrations after flight (31); however, whether this is related to 
intake or metabolism is not known.  
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The current documented requirement for dietary intake of selenium during spaceflight is 
55-400 g/d. In the U.S., the recommended dietary allowance for men and women, aged 19 
years and older, is 55 g/d (322).  
 
3. Risk 
 
Deficiency of selenium can lead to impaired immune function, illness, or even death. An 
excess of selenium can lead to nausea, vomiting, fatigue, or inhibition of protein synthesis, but it 
is probably not likely to occur except when selenium is consumed in large amounts in dietary 
supplements. Despite the relationship of selenium to cancer risk and antioxidant status, care must 
be taken to avoid toxicity. 
 
4. Gaps 
 
Selenium levels in the space food system need to be determined. The potential role for 
selenium in protecting against oxidative stress during spaceflight should be further investigated. 
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W. Iodine 
 
1. Background 
 
Iodine performs its main function in its ionic form, iodide, as part of the thyroid hormones 
T3 and T4. About 15-20 mg of iodide is stored in the human body (345). The thyroid gland traps 
the iodide, and it is here that 70-80% of the total body iodide is stored. The rest is stored in the 
salivary and gastric glands, with some iodide residing in the mammary glands, ovaries, placenta, 
and skin.  
Iodine deficiency causes iodine deficiency disorders, which include mental retardation, 
hypothyroidism, goiter (enlargement of the thyroid gland), cretinism, and other growth and 
development abnormalities, or even death. During a 4-week study in which rats were subjected 
to varying degrees of iodine deficiency, the most severely depleted rats showed an increase in 
thyroid mass after 4 days (551). 
No toxic side effects have been reported when 2.0 mg of iodine per day was ingested (345). 
However, with prolonged intake greater than 18 mg/d, the risk of goiter increases, as does the 
risk of thyroid cancer (277, 410, 552). Other symptoms of iodine toxicity when intake is on the 
order of several grams per day include gastrointestinal distress, thyroiditis, goiter, sensitivity 
reactions, thyroid papillary cancer, or even death (410). 
 
 
 
 
2. Evidence 
 
Iodine intake on Shuttle missions was often very high, in light of the use of iodine as a 
bactericidal agent in the water system (553), and some related changes occurred in thyroid status 
of crewmembers (554-556). As a result, in the late 1990s, a system to remove iodine from water 
was deployed on most missions. ISS water does not use iodine, and as a result, pre- and 
postflight urinary iodine levels are similar (Figure 62). 
 
 
 
 
Figure 62. Urinary iodine excretion of ISS crewmembers before and 
after long-duration spaceflight (31). 
 
 
 
 
The current documented spaceflight requirement for the dietary intake of iodine during 
flight is 150 µg/d (97), the same as the U.S. recommended dietary allowance for iodine for men 
and women aged 19 years and older (277).  
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Although providing adequate amounts of dietary iodine during spaceflight is not a critical 
issue, there is much discussion regarding the effects of the iodine used in spacecraft water 
systems (where iodine is often used as a bactericide) (555). In earlier space programs, including 
the Space Shuttle, NASA used iodine concentrations of 2 mg/L in drinking water (553). A report 
from the Food and Nutrition Board of the National Academy of Sciences states that a daily 
iodine intake in adults ranging from 50-2000 g/d has no adverse effects (557). Depending on 
water intake, iodine intake could easily exceed 2 mg/d. 
 
4. Gaps 
 
Existing knowledge of iodine metabolism seems adequate. It would be prudent to know 
precise iodine intake levels of crewmembers (from the diet and drinking water) so that potential 
hazards associated with iodine excess can be avoided.  
 
 
 
 
 
X. Chromium 
 
1. Background 
 
Chromium is thought to complex with nicotinic acid and amino acids to form glucose 
tolerance factor, which initiates the disulfide bridging between insulin and its receptor (345). 
This allows the insulin hormone to be more effective and, therefore, increases cellular glucose 
uptake and intracellular carbohydrate and lipid metabolism. Chromium may also play a role in 
pancreatic insulin secretion, internalization of insulin through decreasing membrane fluidity, and 
regulation of the insulin receptor. It may also increase the sensitivity of tissues to insulin by 
activating insulin receptor kinase.  
The human body can store 4 to 6 mg of chromium. Tissues with the greatest amounts of 
chromium are the liver, kidney, muscle, spleen, heart, pancreas, and bone. It is possible that 
chromium is stored along with ferric iron because of its transport by transferrin, which can bind 
chromium as well as iron. 
Deficiency of chromium leads to impaired glucose tolerance, or even death. Chromium 
deficiency may result in insulin resistance, which is characterized by hyperinsulinemia. This has 
been shown to be a risk factor for coronary heart disease. Several months of suboptimal 
chromium intake will lead to deficiency symptoms such as hyperglycemia and glycosuria (558). 
One study showed that 9 weeks on a low-chromium diet (5 g/1000 kcal) was long enough to 
yield changes in glucose tolerance (559). Severe trauma and stress may increase the need for 
chromium. Stress causes the release of stress hormones, including cortisol and glucagon. These 
hormones alter glucose metabolism and, in effect, chromium metabolism.  
Toxic levels of chromium lead to chronic renal failure, hepatic dysfunction, 
rhabdomyolysis (a disease of skeletal muscle), or even death. Cr6+ is more toxic than Cr3+ when 
ingested orally. Liver damage, skin ulcerations, dermatitis, and respiratory disease may all result 
from a chromium intake greater than 1,000 μg/d (345). 
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2. Evidence 
 
Little or nothing is known about chromium in space travelers. Chromium deficiency may 
result in insulin resistance, which has also been observed after spaceflight and bed rest (108-
110). Whether the insulin resistance associated with spaceflight is related to chromium is 
unknown. The current documented spaceflight requirement for dietary intake of chromium is 35 
g/d. 
In the U.S., adequate intake of chromium is defined as 35 g/d for men aged 19-50 years 
and as 30 g/d for men aged 50 years and older. Adequate intake is defined as 25 g/d for 
women aged 19-50 years and as 20 g/d for those 50 years and older (277).  
 
3. Risk 
 
Although it may be plausible that changes in glucose metabolism during spaceflight are 
partly related to chromium, given that nothing is known about chromium during spaceflight, 
there are no concerns about chromium at this point. 
 
 
4. Gaps 
 
Existing knowledge of chromium metabolism seems adequate; other than the nominal 
determinations of chromium content of the space food system, no other specific research is 
required.  
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VII. N3.3: We need to determine changes in nutritional status due to spaceflight. 
 
This gap highlights the need for an evaluation of nutrition and related markers in crews 
during long-duration spaceflight.  While one could argue that the data presented throughout this 
document represent those results, we describe in this section highlights from a project designed 
specifically to collect these data. 
 
A. Background 
The medical requirement to evaluate nutritional status (Clinical Nutritional Assessment, 
MedB8.1) has been implemented with two Mir and all International Space Station (ISS) U.S. 
crewmembers to date (31), along with most USOS crews (i.e., CSA, ESA, and JAXA 
crewmembers as well). In 2006, a project was initiated and sought to expand the nominal 
medical testing in 3 ways: 1) include in-flight blood and urine collection, 2) expand nominal 
testing to include additional normative markers, and 3) add an R+30 session to allow evaluation 
of postflight nutrition and implications for rehabilitation. This expansion project was known as 
the Nutritional Status Assessment protocol, and given that it was defined as a Supplemental 
Medical Objective (SMO), was designated as SMO 016E. 
Before 2006, it was not possible to assess nutritional status during flight because blood and 
urine could not be collected or returned during ISS missions. The findings of altered nutritional 
status for several nutrients after landing are worthy of concern, and we require the ability to 
monitor the status of these nutrients during flight to determine if there is a specific impetus or 
timeframe for these decrements. In addition to allowing us to monitor crew nutritional status 
during flight, in-flight sample collection allows better assessment of countermeasure 
effectiveness.  
The SMO 016E protocol is also designed to expand the original Clinical Nutritional 
Assessment medical requirement (MR016L, later MedB8.1) to include additional normative 
markers for assessing crew health and countermeasure effectiveness. Additional markers of bone 
metabolism are measured to better monitor bone health and countermeasure efficacy. New 
markers of oxidative damage are measured to better assess the type of oxidative insults that 
occur during spaceflight. The array of nutrient assessment variables has been expanded to 
include better markers of vitamin status. Additionally, stress hormones and hormones that affect 
bone and muscle metabolism are measured. These additional assessments permit better health 
monitoring, and allow more accurate recommendations to be made for crew rehabilitation. Many 
of these variables have been included to follow the recommendations of an extramural panel that 
met in 2005 to define nutritional standards and requirements for spaceflight (97).  
The original protocol was extended to include an additional postflight blood and urine 
collection (R+30). Several nutritional assessment variables are altered at landing, but it is not 
known if the changes are still apparent after 30 days, or whether the decrements in status on 
landing day require intervention for status to return to preflight levels.  
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B. Highlights from Nutrition SMO 
 
1. Vision  
 
About 20% of astronauts on long-duration International Space Station (ISS) missions have 
developed measurable ophthalmic changes after flight (560). The Nutrition SMO 016E has 
provided biochemical evidence that the folate-dependent one-carbon metabolic pathway may be 
altered in those individuals. Serum concentrations of homocysteine, cystathionine, 2-methylcitric 
acid, and methylmalonic acid were significantly (P<0.001) higher (25-45%) in astronauts with 
ophthalmic changes than in those without such changes (Figure 63). These differences existed 
before, during, and after flight. Serum folate tended to be lower (P=0.06) in individuals with 
ophthalmic changes.  
 
 
 
 
 
Figure 63. Serum 2-
methylcitric acid (2-
MCA), methylmalonic 
acid (MMA), 
homocysteine, and 
cystathionine before, 
during, and after long-
duration spaceflight in 
crewmembers who have 
experienced ophthalmic 
changes during flight 
and those who have not. 
Figure adapted from 
Zwart et al (349). 
 
 
 
 
 
 
 
 
Preflight serum concentrations of cystathionine and 2-methylcitric acid, and mean in-flight 
serum folate, were significantly (P<0.05) correlated with changes in refraction (postflight 
relative to preflight, see Figure 64). At first, investigators thought the ophthalmic changes were 
caused by fluid shifts and increased intracranial pressure brought on by microgravity, but data 
from the Nutrition SMO 016E provided evidence for an alternative hypothesis: that individuals 
with this altered metabolic pathway may be predisposed to anatomic and/or physiologic changes 
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that render them susceptible to ophthalmologic damage during spaceflight. These data have been 
published (349), and a follow-on project is underway to clarify this finding. 
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Figure 64. The absolute refractive change in the right eye after flight relative to before flight was 
significantly associated with mean preflight homocysteine, cystathionine, and 2-methylcitric acid, 
and with mean in-flight serum folate. A Somers’ D measure of association was used for analysis. 
Raw data are presented in the graphs. One crewmember with visual or intracranial pressure issues 
did not experience refractive changes after flight, and that crewmember had the highest preflight 
homocysteine and the highest in-flight serum folate, and was the only crewmember with visual or 
intracranial pressure issues to have reported taking multivitamin supplements during the 6-month 
mission. This individual also had the highest grade of disc edema of all crewmembers to date. 
The data from that subject are included in the graphs above (N=20 in all graphs above). Data 
from Zwart et al (349). 
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2. Monitoring Effects of Exercise on Bone and Body Composition  
 
The first ISS crews used an interim resistive exercise device (iRED). The iRED had a 
maximum load equivalent of 135 kg (1337 N force), an elastic force curve at the higher load 
ranges, and an eccentric force that was 60% to 80% of the concentric force. Early reports from 
ISS (419, 561) indicated that the iRED provided no greater bone protection than devices used in 
previous space programs (such as Mir) in which only aerobic and muscular endurance exercises 
were available. Studies of bone loss countermeasures on these early ISS missions were 
additionally confounded by the fact that the iRED was subject to several technical problems and 
was not usable for long periods (6, 41, 58). Although some improvements were made in the 
iRED, they did not overcome its inherent limitations of load quality and quantity. In late 2008, 
the Advanced Resistive Exercise Device (ARED) was launched to ISS. A more robust device, it 
has much greater resistance capability (562). It allows greater absolute loads (2675 N, 600 lb), 
provides a constant load throughout the range of motion, is quickly reconfigured to engage 
flywheels and provide variable force simulating the inertia associated with gravitational loading, 
and has an improved eccentric:concentric ratio of about 90%. In addition the ARED allows 
performance of a much greater variety of exercises. Given the site specificity of bone loss during 
spaceflight to weight-bearing bones (417), a highly periodized exercise program with a variety of 
lower-body exercises was designed to target mechanical loads to the skeletal sites displaying the 
greatest declines in bone mass.  
With data from the Nutrition SMO and shared bone densitometry (DXA) data from 
operational testing, we have documented (41) that astronauts who have access to sufficient 
resistance exercise, coupled with adequate energy intake and vitamin D status, can return from 
spaceflight missions of 4 to 6 months with measured bone mass and bone mineral densities 
seemingly no different from baseline measures—for most skeletal regions (Figure 65). Although 
further work is needed to refine these factors (by developing optimal exercise prescriptions and 
optimal nutrition), the results provide the first evidence that nutrition and exercise may be able to 
mitigate bone loss and reduce risk for spaceflight-induced osteoporosis (41, 58). 
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Figure 65. Bone mineral density and 
body composition (expressed as % 
change per month) in crewmembers on 
the Russian space station Mir, and on 
ISS flights with exercise on the iRED 
or ARED. Figure from (41). 
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3. Men and Women in Space: Effects of Exercise on Bone and Stone Risk  
 
Sex differences in bone loss have never been carefully studied as a primary research question 
(563). When the paper comparing iRED and ARED exercise devices was published in 2012, the 
number of ISS subjects small, in part because many crewmembers participated in other 
countermeasure studies and were not included in that initial analysis. In 2014, an updated look at 
these data was published, with additional subjects included. This study confirmed the initial 
findings with a much larger set of data. In 42 astronauts (33 male, 9 female), the bone mineral 
density response to flight was the same for men and women (58), and those with access to the 
ARED did not have the typical decrease in bone mineral density that was observed in early ISS 
crewmembers with access to the iRED (Figure 66) (41). Biochemical markers of bone formation 
and resorption responded similarly in men and women. These recent data are encouraging, and 
represent the first in-flight evidence in the history of human spaceflight that diet and exercise can 
maintain bone mineral density on long-duration missions. 
 
 
 
Figure 66. Bone mineral density (BMD) loss 
after flight in men (N=33, open bars) and 
women (N=9, solid bars) who used either the 
iRED or ARED exercise device. Data are 
expressed as percentage change per month of 
flight. Figure adapted from (58). 
 
 
 
The bone biochemical changes in crewmembers exercising with the ARED were very similar 
to what had been observed in bed rest studies testing resistance exercise. That is, the exercise did 
not affect bone resorption, but did increase bone formation (41). In the flight study, as published, 
a significant (P<0.001) increase in the bone formation marker bone-specific alkaline phosphatase 
occurred after landing in astronauts who had access to resistance exercise (41). In one bed rest 
study, heavy resistance exercise 6 days a week led to dramatic increases in bone formation 
markers (564). In another bed rest study with resistance exercise every other day (combined with 
a treadmill protocol), subjects had roughly half the bone formation response (81) of subjects in 
the first study (564). The exercise did not have a significant effect on serum total calcium or 
urinary calcium. When data from additional crewmembers who had exercised with the ARED 
became available, these data solidified the “trend” into statistical significance (58). The slow 
increase in bone formation over time during flight, despite exercise with the ARED, is likely 
related to the fact that the astronaut conditioning and strength trainers were initially reluctant to 
have crewmembers exercise too hard with the ARED, to minimize the risk of injury. This slow 
and steady increase in formation over time (41) is different from results of the first bed rest 
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study, in which formation markers plateaued at the first determination during bed rest (6 weeks 
of bed rest) (564). 
Although this mode of bone remodeling, with increases in biochemical markers of both 
resorption and formation, maintained bone mineral density, it may yield a bone with strength 
characteristics different from those that existed before spaceflight. Studies to assess bone 
strength after flight are underway at NASA, to better understand the results of bone remodeling. 
Studies are also underway to evaluate optimized exercise protocols and nutritional 
countermeasures. 
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4. Iron Status, Oxidative Damage, and Bone  
 
In-flight data from the Nutrition SMO indicate that iron stores increase early in flight, and 
then return to preflight concentrations by the end of a 6-month mission. In 23 (16 M / 7 F) 
crewmembers examined, ferritin increased 217% in women and 68% in men on flight day 15. 
Transferrin and transferrin receptors decreased later in flight, which results support the idea that 
mobilization of iron to storage in tissues increased. Other acute-phase proteins were not elevated 
during flight, suggesting that inflammation was not solely responsible for the observed increase 
in serum ferritin.  
Although mean ferritin concentrations during flight were not outside the normal clinical 
range, the Nutrition SMO data showed that the increase in ferritin was associated with evidence 
of oxidative damage and bone resorption, an association that is supported by other studies in 
healthy ground-based populations (500-502). The greater the increase in ferritin during flight (or 
the longer it was elevatedeither case would result in a larger area under the curve), the greater 
the decrease in bone mineral density (BMD) in the hip, trochanter, hip neck, and pelvis after 
long-duration spaceflight. Also supporting this result were the correlations between ferritin or 
transferrin index and biochemical markers of bone resorption (n-telopeptide, helical peptide) or 
urinary calcium during spaceflight. Several human and animal studies support these findings and 
show that mild iron overload (but within a normal clinical range) is associated with bone loss by 
a mechanism believed to be related to oxidative stress (512, 565). The change in ferritin over the 
course of a 6-month mission is presented below (Figure 67), and is very similar to the change in 
urinary 8OHdG (a marker for oxidative damage) during spaceflight. These findings are similar to 
those in animal studies by our group and others (566-568).  
Although we know that consuming enough calories and exercising with the ARED mitigate 
changes in BMD (41), the data pertaining to iron storage and status provide evidence that the 
change in iron status may be another important factor to consider when defining spaceflight 
dietary intake requirements. 
 
 
 
Figure 67. The percentage change in ferritin and 
urinary 8OHdG before, during, and after long-
duration spaceflight (N=23). “Pre” was determined 
from the mean of preflight data points (3 for ferritin, 
4 for 8OHdG), and percentage change was calculated 
from that average (498). 
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5. Cytokines 
 
Assessment of plasma cytokines has been demonstrated to have clinical utility as a biomarker 
for various specific immunologic diseases or other disruptions in physiological homeostasis. 
Elevated levels of IL-6, IL-7, IL-10, and IFNγ have been detected in the plasma of HIV-infected 
patients and correlate well with prognosis (569). Plasma levels of cytokines have also been found 
to correlate with disease presence or prognosis in rheumatoid arthritis (570), myelofibrosis (571), 
Sjögren syndrome (572), chronic obstructive pulmonary disease (573), and pelvic inflammatory 
disease (574).  
It has been suggested that persistent immune dysregulation may increase specific clinical 
risks for astronaut crewmembers participating in exploration-class deep space missions (575). 
Given the paucity of cytokine data from samples obtained during long-duration spaceflight, we 
planned to obtain such data as part of the Nutrition SMO project. This was a cross-Discipline 
effort, in conjunction with the Immune Discipline, and was meant to be complementary to their 
studies of immune function and cytokine analysis in samples collected during relatively stressful 
periods of the mission. The Nutrition SMO samples were generally not collected during phases 
with vehicles arriving, docked, or departing, and thus samples collected for the immune function 
studies could provide additional information.  
Findings indicated that a pattern of persistent physiological adaptations occurs during 
spaceflight that includes shifts in immune and hormonal regulation (Figure 68). Whether these 
adaptations increase crew risk for adverse medical events during spaceflight has yet to be 
determined. The pattern of cytokine elevations observed during spaceflight is somewhat 
surprising, in that within categories there are differential increases: some inflammatory cytokines 
or chemokines are elevated, whereas others are not. This may be explained by different cytokines 
having different plasma half-lives, different kinetics or magnitude of expression versus binding 
of cytokines by target cells, or the location and nature of the pro-inflammatory stimuli that may 
affect crewmembers during spaceflight. Further investigations will be required to precisely 
define the mechanistic causes of in-flight immune dysregulation. It is clear, however, that 
dysregulation of immunity during spaceflight includes the previously described alterations in 
cellular distribution and function (576), and newly characterized immunoregulatory alterations 
(Figure 68). Even if immunoregulatory changes are subclinical during orbital flight, clinical risk 
to crewmembers could be elevated for deep space missions. As studies continue to characterize 
in-flight immune alterations, the development of countermeasures to enable exploration missions 
to be conducted safely may be warranted (577). 
 
 
Figure 68. Characterization of cytokine 
changes during (and after) flight, based on 
data from (577). Arrows indicate changes 
observed during flight (except for IL-6, 
where increases were noted at landing). 
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6. Body Mass 
 
Body mass is one of the most basic overall measures of health, as noted every time one visits 
a physician’s office on Earth. Determination of “weight” in weightlessness, however, presents 
some unique challenges, as described in a recent report (60). On ISS are two devices for 
measuring body mass: a Body Mass Measuring Device (BMMD), which uses spring oscillation, 
and a Space Linear Acceleration Mass Measuring Device (SLAMMD), which uses the physics of 
the equation: force = mass  acceleration.  
Maintaining body mass is a critical element of health, in space or on Earth. In 2014, we 
published an analysis of the body mass data from ISS, including a comparison of data collected 
from the two mass measuring devices (60). Crewmembers lost 2% to 5% of their body mass in 
the first month of flight, and subsequently maintained the lower body mass during flight (Figure 
69) (60). Postflight measurements were lower than preflight values, supporting the notion that 
the loss in body mass during flight is real and not an artifact of the change in measurement 
device. Body mass loss can generally be explained by the subjects not consuming the number of 
calories recommended by the World Health Organization (60). The occurrence of a consistently 
lower energy intake throughout flight that was not accompanied by additional loss of body mass 
indicates that subjects were in energy balance during the mission. Early Space Shuttle data 
indicated that energy requirements are not changed on short-duration missions, but currently no 
data are available to address long-duration energy requirements. Energy requirements may be 
lower after the first ~30 days of flight, and this question is being addressed in a current ISS 
research protocol sponsored by the European Space Agency.  
 
 
 
Figure 69. In-flight body mass measured by the BMMD (black 
lines) or SLAMMD (gray dashed lines), expressed as 
percentage change from before flight (N=25). Adapted from 
(60). 
 
 
 
 
It is worth noting that loss of body mass during flight has lessened over time. Recent data 
from crewmembers who maintained body mass (assessed post flight) and performed heavy 
resistance exercise show the potential importance of being able to maintain body mass, in that 
these crewmembers came back leaner, with less fat, and had maintained bone mineral density at 
preflight levels (41, 58). This result is much better than the losses by crewmembers on Mir (29, 
63), Shuttle (22, 71), or even early ISS missions (31, 578), when many individuals lost more than 
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5% of preflight body mass, an amount worthy of concern, and in many cases lost more than 10% 
of preflight mass. In crewmembers who must meet strict medical requirements for flight 
certification, including weight limits, a loss of 10% of body mass is clinically significant. 
When SLAMMD and BMMD data for the same subjects were collected relatively close to 
each other, the results matched rather well, given the fact that for most of the data the 2 
measurements were taken about 7 days apart. The correlation (Figure 70) had a slope of almost 
1, indicating that BMMD and SLAMMD taken together produce very similar results (60). This 
analysis does not speak to the accuracy of either device, though, only saying that their 
measurements are consistently offset from each other by about 1.2 kg independent of body mass. 
Both BMMD and SLAMMD are less precise than the standard scale, but given the much more 
complex design of BMMD and SLAMMD, this decrease in precision might be expected and 
unavoidable. The decrease in precision of the BMMD and SLAMMD, compared to their 
precision reported in the literature (579, 580), could be due to human factors such as body 
position on these devices, reaction and movement during tests, or varying centers of mass, all of 
which can decrease the precision of the measurement.  
 
 
 
Figure 70. Comparison of in-flight body mass data 
from the SLAMMD and BMMD. For the linear 
relationship (dashed line), the Pearson r= 0.9829. 
The solid black line is a line of unity for 
comparison. Adapted from (60). 
 
 
 
The next steps to take to evaluate the SLAMMD and BMMD would be to properly assess 
accuracy by measuring a known reference mass on both devices during spaceflight. Until this 
test is completed, it is difficult to determine which instrument is accurately measuring the 
crewmembers’ true in-flight mass. Further studies would also need to be done to clarify the time 
course of the change in body mass within the first 30 days of flight.  
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7. Vitamin D  
 
Before the Nutrition SMO was implemented, it was well documented that vitamin D status 
(25-hydroxyvitamin D) decreased after long-duration spaceflight (30, 31, 39, 63). The absence of 
ultraviolet light during spaceflight diminishes vitamin D stores in the body, as observed during 
the 84-day Skylab mission (39) and more recent Mir missions (30, 63) and International Space 
Station (ISS) Expeditions (31). Reported supplement use was not related to 25-hydroxyvitamin 
D status. Despite the reported use of vitamin D supplements by some of the astronauts (average 
supplement use was 3.0  2.8 per week), the mean serum concentration of 25-hydroxyvitamin D 
for the ISS crewmembers in this study was about 25% less after landing than before launch.  
At about the time that the Nutrition SMO 016E was implemented, vitamin D supplement 
recommendations to crews increased from 400 IU/d to 800 IU/d. The in-flight 25-
hydroxyvitamin D data provide evidence that 800 IU/d is enough to maintain vitamin D status 
during long-duration spaceflight (Figure 71).  
 
 
Figure 71. Pre- and postflight data from MedB8.1 
show that vitamin D status decreased after long-
duration spaceflight, despite vitamin D 
supplementation with 400 IU/d. In-flight data from 
SMO 016E showed that 800 IU/d was enough 
vitamin D to maintain status during long-duration 
spaceflight. Red lines depict Institute of Medicine-
defined lower acceptable limits (with respect to 
bone health), and upper advised limit (279). The 
green line at 80 nmol/L reflects what many 
perceive as an optimal level with respect to 
parathyroid hormone suppression and non-bone 
health outcomes. Figure adapted from (31, 41). 
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8. Fish and Bone  
Data from ISS have documented a relationship between fish intake and bone loss in astronauts 
(that is, those who ate more fish lost less bone; Figure 72) (147). Related findings have also been 
shown in two sets of ground-based spaceflight simulation studies evaluating the role of omega-3 
fatty acids, the fatty acid found in fish (147). In a bed rest study, the rate of bone breakdown was 
related to omega-3 fatty acid intake (again, more omega-3, less bone breakdown). In a series of 
cell culture studies, cells that break down bone were less active when omega-3 fatty acids were 
added (147). Although more detailed studies are required during spaceflight and using controlled 
dietary sources of omega-3 fatty acids from the space food system or supplements, these results 
have broad implications for all Americans, especially in light of the incidence of osteoporosis 
and other bone diseases, which affect millions of people. 
 
Figure 72. Data from long-duration spaceflight showing that consumption of more servings of fish per week was 
related to less bone resorption after flight, as indicated by resorption marker urinary n-telopeptide (NTX) on the left, 
and greater bone density, as indicated by whole-body bone mineral density (BMD) on the right). Data are adapted 
from Zwart et al, 2010 (147). 
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9. Urine Processor Assembly  
The ability to reclaim water from urine will be a pivotal factor in implementing exploration-
class missions. When the prototype Urine Processor Assembly (UPA) on ISS clogged due to an 
unknown precipitate in 2009, the Nutrition SMO urine volume and calcium excretion data from 
24-h pools and single voids were closely examined (191). Urine 24-h volume was about 17% 
lower during flight than before flight, and urinary calcium concentration was 50% greater during 
flight than before flight. The increased urinary calcium concentration during flight was identified 
as a primary reason for UPA failure. New recommendations for percentage of water to be 
recovered were made as a result of those findings. In 2012, when the data were reevaluated with 
Nutrition SMO data from an additional 10 subjects, it was clear that crewmembers in recent 
years are drinking more fluid than crewmembers in the past, and as a result urinary calcium 
concentration is lower (Figure 73). 
 
 
Figure 73. Urinary calcium concentration before and during flight, 
by year of collection. Each symbol represents a 24-h urine 
collection (N=23, up to five 24-h collections/subject), mean ± SD. 
The horizontal green dashed line represents a calcium concentration 
of 28.3 mg/dl, the expected calcium precipitation point for UPA 
water recovery at 70% (new set point), and the red dashed line 
represents calcium concentrations of 14.2 mg/dl, the expected 
calcium precipitation point for UPA water recovery at 85% (the 
original set point). 
 
 
 Suggestions for ways to mitigate high calcium concentrations included exclusion of the first 
morning void because that void is typically more concentrated than other voids throughout the 
day. Another suggestion was administration of low doses of bisphosphonates to crewmembers to 
reduce calcium excretion. A plot of in-flight single-void calcium data from the Nutrition SMO 
showed that neither of the suggested countermeasures looked promising (Figure 74).  
 
Figure 74. Concentration of calcium in urine voids relative to 
the time of day when they were collected. Filled circles 
represent crewmembers who were taking bisphosphonates 
during their mission. These data were evaluated to see if 
operational decisions (such as excluding the first morning void 
or prescribing bisphosphonates) could decrease the risk of 
calcium precipitating in the UPA. SV = single void (as 
opposed to 24-h pool data). 
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From a plot of in-flight urine calcium concentration (from 24-h pools) versus in-flight mean 
fluid intake estimated from the food frequency questionnaire, with one exception, all voids were 
below 23.7 mg/dl, the cutoff point for a 75% water recovery from the Recycle Filter Tank 
Assembly when fluid consumption was greater than 32 mL fluid/kg body weight (Figure 75). 
For the 23 crewmembers in this analysis, that would average to 2.5 L/d fluid consumption (from 
food and beverages).  
In September 2012, on the basis of these data, the ISS Program Control Board decided to 
increase water recovery from 70% to 74-75%. This will save an estimated 80 L of water per 
year, and 6-7 h of crew time (because of fewer tank changes). This recovery rate will also delay 
reaching the minimum reserve quantity of water (i.e., the point where water will need to be 
launched) by several months. The cost savings as a result of Nutrition SMO data will be 
tremendous. 
 
 
Figure 75. In-flight urinary calcium concentration versus 
in-flight mean fluid intake (estimated from the food 
frequency questionnaire). The green dashed lines represent 
the calcium concentration required to maintain 70% or 
75% water recovery from the UPA system. 70% represents 
the conservative lower recovery rate adopted after system 
failure in 2009, and 75% the adjustment after revisiting 
these data in 2012. Figure from (191). 
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10. Renal Stone Incidence  
 
The renal stone risk profile is determined from measured urinary oxalate, uric acid, citrate, 
and sulfate, and calculated supersaturation of calcium oxalate, brushite, sodium urate, uric acid, 
and struvite. Generally, the risk of renal stone formation is elevated during spaceflight (181). As 
with any spaceflight effect, some crewmembers are more affected than others. The graph below 
(Figure 76) is an important illustration of this. Some crewmembers had very high elevations in 
brushite or calcium oxalate supersaturation during spaceflight, while others had very low levels 
of supersaturation. Lifestyle, environmental, and dietary factors all greatly affect renal stone risk. 
Crewmembers who have an increased risk before spaceflight and then are exposed to 
microgravity with concomitant bone loss, hypercalciuria, increased urinary sodium, and 
decreased urinary output may have a further increased risk of renal stone formation during 
spaceflight.  
 
 Medical Operations has asked to review pre- and in-flight renal stone data profiles from 
crewmembers who have experienced renal stones after flight. By looking at in-flight data profiles 
for these crewmembers, we can better identify the most important measures that can predict 
future renal stone incidence, and better determine which lifestyle or dietary factors are most 
important for lowering risk.  
 
 
 
 
 
 
 
 
 
Figure 76. Estimated risk of brushite and calcium oxalate supersaturation from the Renal Stone 
Risk Profile. Each symbol represents an individual 24-h urine collection, and the solid black line 
represents the group mean. The red dashed line at 2 is the point above which the risk of 
supersaturation is greater than in the general population. 
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11. Testosterone  
 
 Testosterone, given its role in bone and muscle maintenance, is often considered either a 
potential mechanism for the musculoskeletal losses associated with spaceflight, or a potential 
countermeasure (581, 582). These considerations are based on very limited flight data from 
humans and animal models that suggest that testosterone levels are reduced during spaceflight, 
and on results from ground-based studies simulating spaceflight. Data from the Nutrition SMO 
016E show that testosterone and related hormones are unchanged by real (Figure 77) or 
simulated weightlessness, apart from transient effects after flight. Nevertheless, as we 
contemplate space exploration beyond low Earth orbit, endocrine data will be critical for 
understanding human adaptation in this unique environment, and potentially for helping to 
counteract the negative effects of spaceflight on the human body. These data have been 
published (583). 
 
 
 
 
Figure 77. Total testosterone concentrations before, 
during, and after flight. Although circulating 
concentrations decreased significantly after flight (at 
R+0), no other time point differed significantly from 
the preflight mean. N=15. Data adapted from Smith et 
al (583). 
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12. Vitamin K  
 
Phylloquinone, undercarboxylated osteocalcin, and urinary -carboxyglutamic acid (GLA) 
are all measures of vitamin K status. Vitamin K is an enzyme cofactor for the production of GLA 
residues in specific proteins (GLA-proteins). GLA-proteins are involved in a number of 
regulatory functions, including bone mineralization. Osteocalcin is a GLA-protein that is 
synthesized in osteoblasts and is thought to have a role in the regulation of bone mineralization. 
Undercarboxylated osteocalcin provides a good measure of vitamin K functional status, 
especially with respect to bone.  
Monitoring vitamin K status during flight for the Nutrition SMO has documented a lack of 
evidence that vitamin K status is decreased during spaceflight, a finding earlier reported from a 
single case study on Mir (339, 340). Nutrition SMO data from the first 15 participating 
crewmembers showed no major changes in phylloquinone, urinary GLA, or undercarboxylated 
osteocalcin (Figure 78) (341). This was an important finding, to document that a vitamin K 
countermeasure to mitigate a vitamin K deficiency during spaceflight is not needed and therefore 
likely would not have an effect on bone.  
 
Figure 78. Effect of long-duration 
spaceflight on vitamin K status of 
15 ISS crewmembers. 
Undercarboxylated osteocalcin 
(left) and urinary -carboxyglutamic 
acid (GLA, right) are shown here. 
No significant changes resulted 
from spaceflight (341). 
 
 
 
 
 
 
13. Summary 
 The findings to date from the Nutrition SMO have shed light on a number of metabolic issues 
that are important for human long-duration spaceflight, and as more data are collected we will 
continue to review, present, and publish the findings. Given the comprehensive nature of the 
Nutritional Status Assessment protocol, there are likely many lessons to be learned, beyond those 
already identified. These data will be a valuable resource for years to come. 
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VIII. N4: Does mission architecture and/or available countermeasures impact nutritional 
status of crewmembers during spaceflight? 
 
 Many aspects of space missions impinge on nutrition.  These include the more obvious 
aspects, such as mission duration and the vehicle itself, but they also include other factors.  
Spacewalks, or extravehicular activities (EVAs) can have an impact on nutrition, from exposure 
to high oxygen environments to the fact that one cannot consume food during an EVA. The type 
of food system itself can also affect nutrition.  Countermeasures for one physiological system 
can often have a negative effect on another.  For one clear example, the exercise equipment and 
protocols will alter energy and nutrient requirements.  Drug-nutrient interactions are a major 
concern, along with the common suggestion that nutritional supplements be provided to 
“eliminate” any concerns about nutrition.  Many of these factors are described in this section, 
and others can be described only after future exploration missions have been defined. 
 
A. Extravehicular Activity 
 
1. Overview 
Extravehicular activity (EVA) is a unique situation from a nutritional perspective because the 
EVA suit does not easily allow food consumption. On early Shuttle missions, a 165-kcal fruit bar 
was custom-made to fit in the EVA suit, but it was typically not consumed and is no longer 
included. As a result of the requirements of EVA preparation and EVA itself, crewmembers can 
go without food for up to 8-10 hours. Recommendations for EVA nutrition were designed to help 
maximize crew performance and efficiency. When nutrition for EVA was reviewed in 1991, the 
recommendation for EVA crewmembers was that they should consume an additional 500 kcal on 
days of EVA (4). This recommendation was designed to account for the metabolic cost of EVA 
(~200 kcal/h). 
In 2000, another review of this situation was requested by NASA’s Flight Medicine Division. 
The resulting recommendation was to provide food items for consumption during EVA 
preparation (as close as possible to the donning of helmets). The food items should contain 300-
500 kcal, with about 70-100 g of carbohydrate and a high content of soluble fiber. Candidate 
items are reviewed to ensure that in the attempt to meet the basic criteria, other undesirable 
nutrients or additives are not included and that crew preferences are accounted for. It was also 
recommended that crewmembers reconsider use of the in-suit food bar or that alternatives be 
sought. 
Fluid intake during EVA is also a concern. Crewmembers lose 6-8 ounces of fluid/h (177-
237 mL) during an EVA. The current EVA suit contains a 24- or 32-ounce drink bag (710 or 946 
mL). Only water is used (early EVAs included flavored beverages, but a problem during a lunar 
EVA resulted in a programmatic decision to include only water). Provision of in-suit fluid is an 
important factor in suit design. For the current suit, use of the 32-ounce drink bag is 
recommended. The development of a larger, disposable drink bag is highly encouraged. The 
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disposable drink bag should be designed so that a flavored drink (such as the current Shuttle food 
system beverages) could be used to increase palatability and intake, assuming that the technical 
concerns can be eliminated. 
Although the issue of nutritional support during EVA was reviewed only briefly at the 2005 
Standards and Operating Bands meeting, no recommendations were made to change the 2000 
guidelines. As suits are developed for exploration mission transit and planetary EVAs, following 
the suggestions above would alleviate problems deemed too complicated to solve with the suit 
used on the Shuttle and ISS. 
Along with food and fluid issues associated with EVA, the hyperoxic environment also has 
the potential to cause additional damage to the body. The prebreathe protocol for U.S. astronauts 
typically includes a 2.5-h prebreathe of >95% to 100% oxygen (584) to reduce the risk for 
decompression sickness. After the 2.5-h prebreathe period, astronauts are typically exposed to 
hypobaric 100% oxygen for 6-8 h during EVA. Studies from saturation dives show that oxidative 
damage occurs under similar conditions (358). Judging by the results of numerous ground-based 
studies with hyperoxia, including data from a NASA Extreme Environment Mission Operations 
14-day saturation dive (358), the potential exists for nutritional countermeasures to mitigate 
some of the oxidative damage (585-587). 
 
2. Gaps  
 Because proposed plans for lunar EVAs will be similar in duration (8-10 h) but more 
frequent (2-3 times per week) than current ISS EVA schedules, there is a clear need for 
development of nutritional support during EVAs. A nutrition support system will need to fit the 
lunar suit design. Definition of the optimal nutrition support system will need to be based on the 
results of ground studies designed to optimize performance, minimize fatigue, and minimize 
oxidative damage due to a high partial pressure of oxygen in the suit.  
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B. Supplements 
 
1. Overview 
Along with the issue of nutrient requirements for space travelers and the use of nutrients as 
countermeasures to the negative effects of spaceflight, the issue of supplements arises. 
Supplements may allow individual nutrients to be obtained when the diet cannot meet the body’s 
needs. However, foods but not supplements provide non-nutritive substances and psychological 
benefits, and supplements may have side effects, interact with medications, and be treated 
differently by the body when they are removed from the matrix of nutrients in a whole food. The 
only supplement NASA recommends for astronaut use during spaceflight is vitamin D. 
2. Supplements versus Whole Foods 
The issue of supplement use often arises with discussion of nutrient requirements for space 
travelers and the use of nutrients as countermeasures to the negative effects of spaceflight, 
especially oxidative damage and radiation-induced cancer risk. The benefits of supplements are 
such that individual nutrients can be obtained when the diet cannot meet the body’s needs. 
Drawbacks to supplements include their lack of beneficial non-nutritive substances, potential for 
side effects, interactions with medications, and different treatment by the body when they are 
removed from the matrix of nutrients in a whole food. 
It is generally agreed that nutrients should be provided to astronauts in standard foods instead 
of supplements (4, 5, 43, 97, 588). Natural foods provide valuable non-nutritive substances, such 
as fiber, carotenoids, and flavonoids, as well as a sense of palatability and psychological well-
being that will be important during long missions. The need for more detailed information about 
the “psychophysiology of hunger and eating” was noted decades ago during the early space 
programs (13), but this topic has yet to be studied in detail. It is clear from astronauts’ 
experiences on the Mir that when humans are in an isolated environment far from home, food 
becomes a psychological factor that can be a source of support or a source of frustration. 
Isolated nutrients may not provide the same protective effect on bone as they would in the 
matrix of the whole food. Omega-3 fatty acids have different effects on vasodilation, depending 
on whether they are supplied as a supplement or in a whole food (589, 590). More than 100 
phytochemicals in tomatoes likely contribute to the chemoprotective effect of tomato puree in 
addition to the lycopene known to protect against certain types of cancers. Tomato puree has 
much stronger dose-dependent, antimutagenic effects and lowers biomarkers of oxidative stress 
much more than pure lycopene alone (591, 592).  
Besides the fact that supplements lack the synergistic effects of nutrients in whole foods, 
there are numerous examples of negative side effects associated with supplement use. Symptoms 
can range from gastrointestinal effects, dizziness, or decreased white blood cell count (from 
ipriflavone, which is synthesized from the soy isoflavone, daidzein) to increased cancer risk (β-
carotene in the CARET study) or increased risk of stroke (268, 593-595).  
When many nutrients are provided as oral supplements, they are not metabolized by the body 
as they are when in foods (596). Changes in bioavailability and metabolism of nutrients can 
increase the risk of malnutrition.  
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Provision of nutrients through supplements also ignores the fact that in some cases, for 
example the omega 3:omega 6 ratio, the negative effects of other foods cannot be overcome 
simply by provision of supplements. Although this phenomenon is more difficult to document, it 
is likely the reason that epidemiological data continue to show benefits of dietary patterns over 
supplements. 
NASA currently does not recommend that astronauts take general nutritional supplements 
during flight, for several reasons. Experience to date indicates that crewmembers do not consume 
the recommended amount of energy intake, and accordingly, intake of many individual nutrients 
is therefore also inadequate. Unfortunately, the concept of a vitamin and mineral supplement to 
remedy this is unwarranted, as the primary problem—inadequate intake of food/energy—will not 
be resolved by a supplement. This situation may even be worsened if crewmembers believe that 
taking the supplement reduces the need for adequate food consumption, and thus eat even less.  
Vitamin or mineral supplements should be used only when the nutrient content of the 
nominal food system does not meet the requirements for a given nutrient, or when data show that 
the efficacy of single (or multiple) nutrient supplementation is advantageous. To date, 1 
supplement has met this standard, and that is vitamin D. Vitamin D supplements have been 
provided to all U.S. crewmembers on ISS. Early crews received 400 IU vitamin D3 per day (31), 
but recently this was raised to 800 IU per day of supplementation (97); this level allows 
maintenance of serum 25-hydroxyvitamin D around 75 nmol/L (41). 
Before a supplement is recommended, a clear deficit of that nutrient in the space food system 
must be identified, as was the case with vitamin D. Stability of nutrients in the form of 
supplements would also need to be addressed; shelf lives for exploration travel must be 
particularly long. Supplements, if they are recommended, would need to be tested in ground 
models for their efficacy in maintaining nutrient status, their stability over a long duration (3-5 
y), and their potential interaction with pharmaceuticals. Most importantly, supplements will need 
rigorous testing to demonstrate that the level used is not toxic to body systems, and will need 
close monitoring during flight to ensure that their interactions with the spaceflight environment 
do not prevent them from being effective or safe. For example, ground-based studies have shown 
that high doses of antioxidants, when provided in situations where oxidant stressors are present 
(such as cigarette smoking), can actually have a detrimental effect (597). Recent studies have 
also found that supplementation with certain antioxidants such as vitamin E and vitamin A can 
increase risks of cancer and all-cause mortality (598, 599). 
 
3. Gaps 
 Before a supplement is recommended, a clear deficit of that nutrient in the space food system 
must be identified, as was the case with vitamin D. Stability of nutrients in the form of 
supplements would also need to be addressed, especially considering the long proposed shelf-
lives of food items for exploration-class missions. Supplements, if they are recommended, would 
need to be tested in ground models to test their efficacy in maintaining nutrient status, their 
stability over a long duration (3-5 y), and their potential interaction with pharmaceuticals, as well 
as to identify their side effects on all body systems.  
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C. Nutrient-Drug Interactions 
 
1. Overview 
 
While a specific gap has not been identified regarding nutrient-drug interactions, this is 
clearly an area requiring additional study. An understanding of interactions between 
pharmacotherapeutic agents and nutrients is necessary to implement safe and effective medical 
care and clinical intervention operations for astronauts on long-duration missions. The most 
common studies of interactions between pharmacological agents and nutrients concern their 
effects on a nutrient or drug’s absorption, distribution, biotransformation, and excretion.  
Normally, drugs must undergo biotransformation to allow their activation or excretion. For 
the activity of a drug to be terminated by excretion, the compound must be made water-soluble 
by biotransformation. For most drugs, this process yields a water-soluble compound that is less 
active than the original compound. Biotransformation occurs in 2 phases. Phase I is an oxidation 
or hydrolysis reaction to expose, add, or cleave a functional group. Cytochrome P450 enzymes 
are involved in this process. Humans have 12 families of cytochrome P450 enzymes, but CYP1, 
CYP2, and CYP3 are the forms most commonly used in drug metabolism (600). Cytochrome 
P450 enzymes are unique in their ability to use a wide range of substrates (601). Phase II 
biotransformation involves the conjugation of the parent compound to a polar group (acetate, 
glucuronides, sulfates, amino acids, glutathione), which inactivates most drugs. 
Biotransformation of drugs is influenced by several factors that could be affected by spaceflight 
and the space food system: dietary factors, nutrient metabolism, monoamine oxidase inhibitors, 
and antacids and proton pump inhibitors. 
 
2. Dietary Factors 
Dietary factors (either excess or deficiency) can influence both phases of drug 
biotransformation. In phase I, 3 factors are required: a sufficient energy source (because of the 
high energy demands of this system), a protein source for enzyme synthesis, and iron for 
cytochrome formation (602). Phase II requires glucose, sulfur-containing amino acids, and 
glutathione (602).  
The effects of nutrients on drug metabolism have been well studied in animal models; 
however, relatively few dietary factors have been studied in humans (602, 603). Results from 
animal studies must be carefully weighed because of some differences between the cytochrome 
P450 enzymes of animals and humans.  
One of the most well-documented food-drug interactions is between grapefruit juice and a 
number of medications (604, 605). Flavonoid compounds such as naringin, naringenin, limonin, 
and obacunone, which are present in grapefruit juice, act as substrates for particular intestinal 
cytochrome P450 enzymes (CYP3A4 and CYP1A2). Within hours of ingestion, grapefruit juice 
decreases CYP3A4 protein expression for up to 24 hours (606, 607). The decrease in CYP3A4 is 
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associated with a decreased capability for drug metabolism, and therefore increased drug 
bioavailability.  
Other foods, nutrients, or supplements known to affect phase I and II biotransformations and 
cytochrome P450 enzymes include protein, carbohydrates, lipids, certain vitamins, minerals, 
char-broiled foods, red wine, monosodium glutamate and aspartate, and herbs such as St. John’s 
wort (602, 603, 608-611). Generally, high-protein diets increase drug metabolism, and low-
protein diets decrease drug metabolism. For instance, antipyrine and theophylline are 
metabolized more rapidly when subjects are on a high-protein diet (603). Other macronutrients, 
including carbohydrates, can affect phase I and phase II biotransformation reactions when 
intakes are very high or low. Theophylline (for asthma) is particularly sensitive to dietary 
protein:carbohydrate ratios; increasing the ratio can decrease effectiveness of the drug, and 
decreasing the ratio may lead to toxic effects of the drug (612). Fatty acids in the diet can also 
affect cytochrome P450 enzymes because they can be metabolized by these enzymes. 
Specifically, CYP2E1 is responsible for lipid peroxidation, and activity of this enzyme is 
enhanced in the presence of highly polyunsaturated fatty acids such as fish oils.  
 
3. Metabolism of Nutrients 
Some nutrients are metabolized by cytochrome P450 enzymes; therefore, drugs or other 
nutrients that alter the activity of these enzymes can alter nutrient metabolism. Vitamin D and 
vitamin A are 2 examples of nutrients whose metabolism involves cytochrome P450 enzymes. 
Exposure of 7-dehydrocholesterol to sunlight converts this substrate to previtamin D3. 
Previtamin D3 undergoes an isomerization to form vitamin D3, a biologically inactive compound. 
CYP27A is a mitochondrial mixed-function oxidase that is responsible for hydroxylating vitamin 
D3 to form 25-hydroxyvitamin D3 (613). CYP3A4 has been found to be a 25-hydroxylase as well 
(614). CYP27B converts 25-hydroxyvitamin D3 to 1,25-dihydroxyvitamin D3. CYP24 is a 24-
hydroxylase that hydroxylates the vitamin D side chain and ultimately terminates hormonal 
activity of the vitamin. Inhibition of CYP24 has recently been targeted in the development of 
novel anti-cancer drugs. Because 1,25-dihydroxyvitamin D3 exerts antiproliferative and 
differentiating effects on many cell types including cancer, preventing its inactivation by 
inhibiting CYP24 activity may prove to be beneficial in treating cancer (615). Certain drugs are 
known to activate CYP24 activity, including rifampin, isoniazid, and phenobarbital (616, 617). 
Several studies show a relationship between the use of these drugs and osteomalacia (618, 619), 
which is caused by a deficiency of vitamin D. The discovery of the involvement of CYP3A4 in 
the metabolism of vitamin D may explain the effects on vitamin D metabolism of numerous 
drugs, including inducers or inhibitors of this enzyme (for example, grapefruit juice, 
erythromycin, omeprazole, carbamazepine, and dexamethasone), or implicate them in 
unexplained effects on vitamin D metabolism. 
Vitamin A metabolism involves the actions of CYP1A2 and CYP4A4 in the conversion of 
retinol to retinoic acid (620, 621). Inducers of CYP1A2 (cigarette smoke, cruciferous vegetables, 
broiled beef, rifampin) may affect vitamin A metabolism.  
 
Risk Factor of Inadequate Nutrition 
 
 126
4. Monoamine Oxidase Inhibitors 
First-generation monoamine oxidase inhibitors include agents such as antidepressants 
(phenelzine, tranylcypromine, pargyline, and selegiline), chemotherapeutic drugs (procarbazine), 
antiprotozoal drugs (furazolidone), and analgesics (meperidine). Monoamine oxidase is 
responsible for metabolizing dietary phenylethylamines, including tyramine, in the 
gastrointestinal tract and in the liver. Inhibitors of monoamine oxidase prevent the breakdown of 
these compounds, and therefore the compounds are taken up in the brain. In the brain, tyramine 
displaces norepinephrine from storage vesicles, which results in release of a flood of 
norepinephrine at synapses. Acute hypertension and the potential for stroke or myocardial 
infarction could result from this process (602). Fermented foods and protein-rich foods that have 
begun to spoil are rich in phenylethylamines (602).  
 
5. Antacids and Proton Pump Inhibitors 
By altering the pH of the stomach, chronic antacid or proton pump medications can 
negatively affect the bioavailability of several nutrients, including phosphate, thiamin, folate, 
vitamin B12, vitamin C, iron, and vitamin A (602, 622, 623). Antacids can precipitate folic acid at 
a pH greater than 4.0, thus rendering it insoluble and not available for absorption (624). A high 
pH also affects thiamin bioavailability because the vitamin is not stable at high pH (602). 
Similarly, at a neutral pH, the antioxidant action of vitamin C on dietary nitrites is hindered. 
Normally, dietary nitrite is quickly reduced to nitric oxide by ascorbic acid in the acidic gastric 
juice and it is then absorbed by the mucosa. However, at neutral pH, the nitrite does not react 
with ascorbic acid and instead accumulates in the stomach, which can increase the likelihood that 
potentially carcinogenic N-nitroso compounds will be formed (623). These changes are observed 
mostly in subjects who are infected by Helicobacter pylori and are taking proton-pump inhibitors 
(623).  
Vitamin B12 and vitamin A are also malabsorbed at higher pH because an acidic environment 
is essential for their release from dietary proteins. Because large stores of vitamin B12 exist in the 
body, malabsorption of this vitamin is unlikely to lead to deficiency unless a subject has been 
taking proton pump inhibitors chronically for at least 2 years (622). This would be particularly 
harmful if vitamin B12 stores were low before therapy began. 
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6. Summary of Pharmacology and Drug-Nutrient Interactions  
Currently no data are available that pertain to specific drug-nutrient interactions during 
spaceflight. The main concerns for a long-duration mission involve use of pharmacological 
agents that are taken chronically. Side effects will be especially harmful if the status of all 
nutrients is not adequate at the beginning of a long-duration mission. Addressing these concerns 
of drug-nutrient interactions will be especially crucial for crewmembers who embark on 
exploration-class missions lasting several years. 
 
7. Gaps 
 
Currently, no data are available regarding specific drug-nutrient interactions during spaceflight. 
The main concerns for a long-duration mission involve the use of pharmacological agents that 
are taken chronically. Side effects will be especially harmful if the status of all nutrients is not 
adequate at the beginning of a long-duration mission. Addressing these concerns of drug-nutrient 
interactions will be especially crucial for crewmembers who embark on exploration-class 
missions lasting several years. 
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IX. N6: What impact does the spaceflight environment have on oxidative damage? N15: 
We need to identify the most important nutritional factors for oxidative damage 
during spaceflight. 
 
 
A. Overview 
 
The space environment exposes astronauts to numerous sources of oxidative stress. Some 
of these sources are extravehicular activity (EVA) and EVA prebreathe protocols, exercise, diet, 
and radiation (498, 501, 625-627). After spaceflight, anabolic processes and substrate 
competition between muscle rebuilding and host defense mechanisms stress the antioxidant 
defense system and may contribute to postflight increases in oxidative damage (326).  
 
B. Hypoxic Conditions  
As exploration missions come closer to reality, we will need to better understand risks 
associated with the type of EVAs that are currently planned for those types of missions. Current 
mission designs could involve as many as 30,000 hours of EVA exploration time, which is far 
more than the 20 total hours spent conducting EVAs during the entire Apollo Program (628, 
629). Future vehicles or exploration habitats will likely operate at 8.0 to 8.2 psia and 32% to 34% 
oxygen with the balance nitrogen (629). EVAs at 4.3 psia would require some amount of oxygen 
prebreathing. As a comparison, ISS has operated at an Earth equivalent of 14.7 psia and 21% 
oxygen. The terrestrial altitude equivalent of 8 psia and 32% oxygen is about 6,000 to 8,000 feet 
(1829 to 2438 m), and would represent a hypobaric hypoxic scenario. Concerns associated with 
prolonged hypobaric hypoxic conditions include potential increased risk of vision impairment 
issues, acute mountain sickness, sensorimotor impairment, alterations in cardiovascular and 
immune function, and anorexia.  
 
C. Extravehicular Activity 
Extravehicular activity, or spacewalking, is a unique situation from a nutritional 
perspective, because the EVA suit does not easily allow food consumption. On early Shuttle 
missions, a 165-kcal fruit bar was custom-made to fit in the EVA suit, but it was typically not 
consumed, and is no longer included. Crewmembers can go without food for as long as 8 to 10 
hours while they are preparing for and performing EVA. Nutritional recommendations for EVA 
were designed to help maximize crew performance and efficiency. When nutrition for EVA was 
reviewed in 1991, the recommendation for EVA crewmembers was that they should consume an 
additional 500 kcal on days of EVA (4). This was designed to account for the metabolic cost of 
EVA (~200 kcal/h). 
In 2000, another review of this situation was requested by NASA’s Flight Medicine 
Division. The resulting recommendation was to provide food items for consumption during EVA 
preparation (as close as possible to the donning of helmets). The food items should contain 300 
to 500 kcal, with about 70 to 100 g of carbohydrate and a high content of soluble fiber. 
Candidate items are reviewed to ensure that in the attempt to meet the basic criteria, undesirable 
nutrients or additives are not included, and that crew preferences are accounted for. It was also 
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recommended that crewmembers reconsider use of the in-suit food bar, or that alternatives be 
sought.  
Fluid intake during EVA is also a topic of concern. Crewmembers lose 6 to 8 ounces 
(177 to 237 mL) of fluid per hour during an EVA. The current EVA suit contains a 24- or 32-
ounce (710 or 946 mL) drink bag. Only water is used (early EVAs included flavored beverages, 
but a problem during a lunar EVA resulted in a programmatic decision to include only water). 
Provision of in-suit fluid is an important factor in suit design. For the current suit, use of the 32-
ounce drink bag is recommended. The development of a larger, disposable drink bag is highly 
encouraged. The disposable drink bag should be designed so that a flavored drink (such as the 
current Shuttle food system beverages) could be used to increase palatability and intake, 
assuming that the technical concerns can be eliminated. 
Because missions to explore a non-Earth surface (planetary or asteroid) will likely 
include EVAs similar in duration to current ISS EVAs (8 to 10 h) but more frequent (2-3 times 
per week, instead of 2-4 times/6 months), a clear need exists for development of nutritional 
support during EVAs. A nutrition support system will need to fit the lunar suit design. The 
definition of the optimal nutrition support system will need to be based on the results of ground 
studies designed to optimize performance, minimize fatigue, and minimize oxidative damage 
from a high partial pressure of oxygen in the suit.  
 
D. Reactive Oxygen Species and Exercise 
Exercise-induced fatigue and muscle atrophy are mediated in part by reactive oxygen 
species (ROS). Electron spin resonance spectroscopy technology confirmed findings from the 
1950s suggesting that short-lived reactive intermediate molecules like ROS are present in 
skeletal muscle after exercise (630). Since then, numerous studies have supported a role of ROS 
in skeletal muscle fatigue (630-632). Mitochondria are the major source of ROS in muscle cells, 
where a fine balance of ROS exists between maximizing force and minimizing fatigue (625). 
Antioxidant-mediated depletion of ROS from unfatigued muscle yields decreased production of 
skeletal muscle force (633). On the other hand, excess ROS can be detrimental in terms of 
fatigue. ROS can denature proteins directly associated with the sarcoplasmic reticulum Ca2+ 
release mechanism (634), thus compromising tension development. Also, rat studies show that 
xanthine oxidase-induced ROS yields increased diaphragm fatigue, and that the elevated ROS 
during intense exercise is implicated in the onset of muscle fatigue (635). Furthermore, 
decreased antioxidant status lowers exercise capacity and increases onset of fatigue in human 
and animal studies (630, 632). 
Astronauts perform extensive upper-body exercise during EVA, and one of the limiting 
factors in completing EVA tasks is forearm and hand muscle fatigue due to extensive tool 
operation. The fatigue often requires crewmembers to stop and rest, thereby prolonging the 
duration of EVA, and limits the number of tasks performed during each EVA. To date, there is 
little evidence showing that antioxidant supplementation has a benefit for improving muscle 
performance and inhibiting fatigue. Given the nature of the requirement for homeostasis of redox 
systems, there is a potential for antioxidant overload to decrease muscle force potential instead of 
having a protective effect.  
 
E. Radiation Exposure 
Astronauts are exposed to highly ionizing radiation, in addition to secondary radiations 
resulting from interactions with shielding materials or the human body. Biological effects of 
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radiation include damage to DNA from a direct hit from an ion track, oxidative damage from 
generated reactive oxygen species (ROS), and oxidative damage induced by a bystander effect 
(123, 636, 637). A bystander effect occurs when cells damaged by radiation particles secrete 
cytokines or other proteins that can generate ROS in cells that are not destroyed (638).  
 
F. Oxidative Damage Markers During Spaceflight and in Ground Analogs 
Evidence for oxidative stress resulting from spaceflight exposure exists in multiple 
tissues, including ophthalmic tissue (273, 639); in urinary and blood biomarkers of damage to 
DNA, lipids, and protein (31, 327, 498, 640); and in gene expression (641, 642). Plasma 
malondialdehyde (MDA), 8-iso-prostaglandin F2α (PGF2), and urinary 8-hydroxy-2-
deoxyguanosine (8OHdG) have been measured during and after flight as indicators of lipid 
peroxidation (MDA and PGF2α) and DNA damage (8OHdG) (29, 327). A significant elevation 
of urinary 8OHdG has been noted after long-duration missions (Mir and ISS) (31). These data 
are supported by results from the ground-based analog NEEMO, in which crewmembers 
underwent 10- to 14-day saturation dives (358, 507). Urinary PGF2α was significantly decreased 
during flight but was elevated about 2.5-fold after flight (327), and plasma MDA was increased 
both during and after flight (327). In a Russian 120-day bed rest study, increased concentrations 
of markers of lipid peroxidation were found in subjects, and this increase was mitigated with 
vitamin E (643). 
The apparent increases in oxidative damage observed during and after flight could be 
caused by a number of factors, including altered DNA repair mechanisms, decreased antioxidant 
defense systems, or simply increased oxidative stress. Microgravity does not affect the repair of 
double-strand chromosome breaks (644, 645), but evidence exists that downregulation of 
antioxidant defense systems occurs during spaceflight (646). Along with increases in markers of 
oxidative damage and decreases in antioxidant defense systems, a decrease in total antioxidant 
capacity also occurs. 
 
 
 
G. Fruits and Vegetables 
 
 A recent effort has been made to allow for healthier foods to be flown for ISS crewmembers.  
One major goal of this effort is to provide more fruits and vegetables, which have documented 
effects on overall health, on specific systems, and on oxidative damage itself.  While teasing out 
specific effects, most believe the antioxidant properties of fruits and vegetables are integral to 
their success in disease mitigation, although individual nutrient supplement trials generally fail to 
help enlighten this phenomenon. Diets high in fruits and vegetables have been documented to 
reduce oxidative damage (647). Dietary effects on microbiome, specifically fruits and 
vegetables, have also been identified (648-650).  This has not been studied during flight, and 
hopefully this new effort will help fill this gap, and inform our understanding of both food and 
nutrition related issues. 
 
 
H. Antioxidants and Related Nutrients: Selenium, Vitamin E, Vitamin C 
Selenium has been shown to play a role in the maintenance or induction of cytochrome 
P450, pancreatic function, DNA repair, enzyme activation, immune system function, and 
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detoxification of heavy metals (651). Selenium is also a cofactor for glutathione peroxidase, 
which plays a role in the reduction of organic peroxides and hydrogen peroxide. Selenium has 
also been shown to be necessary for iodine metabolism.  
Postflight reductions in serum selenium of more than 10% have been observed after ISS 
flights (31). Whether this is related to intake or metabolism is not known.  
Deficiency of selenium can lead to impaired immune function, illness (Keshan disease 
and Kashin-Beck’s disease), or even death. Excess selenium can lead to problems affecting 
gastrointestinal, neurological, cardiopulmonary, and renal systems (651). Toxicity is not likely to 
occur except when selenium is consumed in large amounts in dietary supplements, but care must 
be taken to avoid toxicity despite the relationship of selenium to cancer risk and antioxidant 
status.  
Vitamin E is a lipid-soluble, chain-breaking antioxidant found in body tissues, and is also 
the first line of defense against lipid peroxidation reactions. Eight naturally occurring compounds 
have vitamin E activity: 4 tocopherol derivatives (α-, γ-, δ-, and β-tocopherol) and 4 tocotrienol 
derivatives (α-, γ-, δ-, and β-tocotrienol) (321). The tocopherols that are most abundant in 
biological systems are α- and γ-tocopherol, but small amounts of δ-tocopherol and γ-tocopheryl 
quinine are also present. About 90% of the tocopherol found in human plasma is in the form of 
α-tocopherol (322). After ISS crewmembers had spent 4 to 6 months in space, their plasma γ-
tocopherol was 50% less than preflight levels (31), but no change in α-tocopherol, or vitamin E 
to lipid ratio, occurred in these subjects (Figure 79). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 79. Serum α-tocopherol (top left) and γ-tocopherol (top 
right), and total vitamin E:lipid ratio (bottom) before, during, 
and after long-duration spaceflight. All data are mean ± SD. 
(6) 
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Oxidative stress can increase in microgravity and high-radiation environments (326-328), 
and the antioxidant properties of vitamin E may help to counteract the free-radical damage 
caused by high-linear energy transfer radiation in space. Pretreatment with antioxidants may help 
decrease radiation damage during missions (329), and it may be necessary to provide enough 
vitamin E for astronauts’ blood levels of the vitamin to be higher during spaceflight than on 
Earth. However, knowledge gaps weaken the evidence for use of vitamin E as a countermeasure. 
Clinical trials have documented negative side effects of pharmacologic vitamin E 
supplementation alone or with other antioxidants; it can increase risks of cancer in humans and 
animals (598, 599, 652, 653). 
The term “vitamin C” actually refers to 2 different compounds, ascorbic acid and 
dehydroascorbic acid, both of which have activity against scurvy (654). Vitamin C functions as 
an antioxidant because it acts as a reducing agent for most physiologically relevant reactive 
oxygen species, reactive nitrogen species, singlet oxygen, and hypochlorite. It serves as a 
cofactor for enzymes involved in the biosynthesis of collagen, carnitine, and neurotransmitters 
(654). Vitamin C also provides antioxidant protection by returning α-tocopherol to its 
biologically active state during lipid oxidation. The reducing agents glutathione and either 
reduced nicotinamide adenine dinucleotide (NADH) or reduced nicotinamide adenine 
dinucleotide phosphate (NADPH) regenerate the oxidation products of ascorbate (654). 
It has been suggested that vitamin C requirements should be greater for persons who are 
under excessive physical or emotional stress, given the role of ascorbate in the biosynthesis of 
steroid hormones and neurotransmitters. However, no substantial data show that vitamin C 
metabolism is altered in healthy subjects under mental or emotional stress (322). 
As a cofactor in collagen synthesis, vitamin C has been investigated for potential effects 
on bone health. Although in the Framingham Study higher vitamin C intake was found to be 
associated with lower bone mass (655), the significance of this association was marginal when 
data were adjusted for potassium intake. This suggests that vitamin C may be a secondary factor 
related to fruit and vegetable reduction in bone loss (656-659), as described elsewhere in this 
text. Other studies have found that vitamin C intake or supplement use is related to improved 
bone health and bone mass, but this relationship depends on adequate calcium intake (660-663). 
Vitamin C has been related to cataract and cancer incidence (664-666), both of concern for space 
travelers. 
Deficiency of vitamin C leads to fatigue, depressed immune function, scurvy (fatigue, 
muscle cramps, bruised and/or bleeding gums), and eventually even death. As noted in the 
introduction, scurvy resulted in more sailor deaths during the age of sail than all other causes of 
death combined (3). Toxicity of vitamin C leads to gastrointestinal distress, and has been 
reported in subjects consuming more than 1000 mg/d (664).  
Vitamin C assessments of ISS crewmembers have been conducted, with generally no 
changes after landing relative to before launch (unpublished data). Recent long- and short-
duration bed rest studies documented no statistically significant change in vitamin C, but results 
showed a trend for an increase, which might be related to dietary intake during the study relative 
to the subjects’ nominal intake (356, 667). 
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The stability of vitamin C in food supplies has been studied, and it is generally unstable 
at a neutral or alkaline pH and in high-oxygen environments (370). Vitamin C is also unstable 
when exposed to light or heat (370), and in irradiated foods (371, 372). Salem (372) found that γ-
irradiation of fresh onion bulbs significantly reduced their vitamin C content. This group also 
found that vitamin C content of onion bulbs had decreased about 50% after 6 months of storage. 
The destructive effects of γ-irradiation (10 kGy) on vitamin C were also evident in commercial 
spices such as basil, black pepper, cinnamon, nutmeg, oregano, parsley, rosemary, and sage 
(373). Exposure of these spices to γ-rays for >3 months resulted in a marked increase in the 
concentration of quinone radicals. Evaluation of vitamin C stability in space foods showed an 
average loss of 27% after 1 year of storage (Cooper et al, unpublished data). Fortunately, the 
vitamin C content of food items and potential menus is high enough that, depending on mission 
profile, intake of vitamin C might still meet requirements. 
A major concern for spaceflight is the possibility that vitamin C could be degraded in 
foods during extended-duration missions when space foods are exposed to large amounts of 
radiation and undergo long-term storage (foods may be sent to Mars in advance of the crew, and 
left there for up to 5 y). This could be catastrophic. 
Free-radical formation is increased in space because greater amounts of radiation are 
present than on Earth. Because of this and increases in other oxidative stressors, antioxidants 
such as vitamin C are in greater demand by the body to act as buffers and minimize the oxidative 
damage. Studies have shown that supplementation with vitamin C and other antioxidants can 
modify human tissue radiosensitivity and protect DNA against damage (374, 375). Just as 
important to consider, however, is the possibility that vitamin C could induce DNA damage. Cai 
and colleagues (375) found that vitamin C can act as an antioxidant to prevent DNA damage 
caused by ionizing radiation, but in the presence of copper, it can also act as a reducing agent to 
induce DNA damage. Because vitamin C can reduce redox-active metals such as iron and 
copper, this “antioxidant” can increase the pro-oxidant chemistry of these metals (376). Thus, 
vitamin C can serve as both a pro-oxidant and an antioxidant, and the amount of it required by 
exploration crewmembers needs to be carefully addressed (as does the amount of almost all 
nutrients). 
Vitamin C content and stability in the space food supply need to be determined. 
Evaluation of the impact of vitamin C supplementation during exposure to oxygen or high-linear 
energy transfer radiation should be investigated before recommendations can be made for 
supplement use during flight. This should be evaluated in a coordinated effort to find an 
antioxidant profile for space travelers. After data have been gathered about vitamin C status 
during and after flight, and preferably after data are available pertaining to the influence of 
spaceflight-induced stress on vitamin C, an evaluation of intake requirements needs to be made. 
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X. N7.1: We need to identify the most important nutritional factors for musculoskeletal 
health. 
 
 
A. Bone and Calcium 
 
Whereas nutrition is critical for virtually all systems, the interaction of nutrition with bone is 
perhaps more extensive and complex than most of its interactions with body systems. Bone is the 
body’s reservoir of calcium, which provides structure and strength to bone, but also provides a 
ready resource to maintain blood calcium levels during periods with insufficient dietary 
provision of calcium. Several nutrients are required for the synthesis of bone, including protein 
and vitamins D, K, and C.  
Multiple risks are associated with bone loss during spaceflight. Almost as soon as 
weightlessness begins, bone resorption increases, and calcium (and other minerals) are released 
into the blood and urine. This increases kidney stone risk on short missions, and on longer 
missions, chronic bone and calcium loss can increase risks to bone health both in the near term 
(eg, risk of fractures) and in the long term (eg, risk of osteoporosis-like bone degradation). The 
International Space Station provides the opportunity for relatively large numbers of 
crewmembers to fly on missions of 4 to 6 months, with even longer missions being planned. At 
current capacity, 6 crewmembers are on board at a time: 3 Russian cosmonauts and 3 astronauts 
from the other partner agencies (Canadian, European, Japanese, and U.S. space agencies). This 
number of crewmembers has allowed the effects of spaceflight on bone physiology to be 
documented, along with the testing of countermeasures aimed at counteracting bone loss.  
Although this topic has been reviewed extensively (314, 418, 419, 421, 424, 457, 463, 668), 
we attempt to provide here an overview of bone and calcium changes that occur during 
spaceflight, and we review the research efforts made to understand bone loss, including more 
detail about specific nutrients. We provide an update on recent countermeasure studies, which 
have started to show progress toward meeting the challenge of mitigating risks associated with 
bone and calcium changes during flight.  
 
 
1. Bone Loss 
Bone is lost during spaceflight, primarily from weight-bearing bones. This was first 
documented on Skylab missions (413, 669), and later on Mir (417, 426, 433, 670) and ISS 
missions (41, 58, 561). Attempts to come up with a simple way to express the amount of loss 
usually estimate it at about 0.5% to 1% per month (417, 418, 425, 426), roughly similar to 
postmenopausal bone loss rates over a year. Bone mineral density losses at landing after 6-month 
ISS missions are estimated to be 2% to 9% for different bone sites (419), with significant site-to-
site and individual-to-individual variability. The bone loss and mineral shedding are 
accompanied by an increased risk of renal stone formation during and after flight (116, 117, 181, 
182, 671). The subject-to-subject variability seems a characteristic of spaceflight-induced bone 
loss (424), and as more data are accrued, may provide insight to find a means to mitigate this loss 
(672). 
Long-term follow-up data on bone recovery are far from complete (420, 458). However, if 
the rate of postflight recovery estimated from biochemical data is also assumed to be constant 
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(reasonable according to ground-based (436) and flight (30, 63) data), then the rate of recovery is 
about +100 mg/d (30, 63). By these estimates, on flights up to about 6 months, it takes 2 to 3 
times the mission duration to recover the lost bone. Analysis of bone recovery data from dual-
energy x-ray absorptiometry (DXA) analyses suggests that while regional differences exist, the 
half-life of bone recovery after flight is on the order of 5 to 9 months after flight (420, 672). For 
longer exploration missions, however, the usefulness of these assumptions comes into question, 
as spaceflight data are not available for these durations. Although more data clearly are required 
to validate this hypothesis of bone mineral recovery, it nevertheless has significant implications 
as mission durations increase. Beyond bone mineral density, questions of changes to, and 
recovery of, bone architecture and strength also remain unanswered. 
 
 
2. Bone Metabolism 
Bone is a metabolically active tissue, constantly undergoing turnover through breakdown 
(resorption) and formation processes. When these 2 processes are in balance, no net loss (or 
gain) of bone occurs. Alterations in either, or both, of these processes can be problematic. 
Bone resorption increases during spaceflight. This wasn’t clearly documented until the 
1990s, when markers specific to resorption were identified and analytical capability was 
commercialized. Collagen crosslinks are chemical linkages that give collagen its strength; they 
were found to be released during the resorption process and not metabolized before renal 
excretion. Many assay variants are available commercially, and are based on immunoassay 
techniques that bind to different portions of the crosslink molecules. Increased collagen crosslink 
excretion, and thus bone resorption, has been shown to be clearly increased during spaceflight 
(30, 63, 431-433, 673, 674). Earlier studies showed that plasma concentrations of a similar but 
more easily confounded marker, hydroxyproline, were elevated during short-duration Shuttle 
flights (673) and Skylab missions of longer duration (39, 94, 434). Calcium tracer kinetic studies 
also provided data indicating that bone resorption increases about 50% during flight relative to 
preflight (30, 63) levels. 
Bone formation either remains unchanged or decreases during spaceflight (30, 63, 425). As 
indicated by serum concentrations of bone-specific alkaline phosphatase (BSAP) and 
osteocalcin, bone formation was unchanged during Mir flights, but increased 2 to 3 months after 
landing (30, 63). Trends toward decreased levels of bone formation markers were noted in 2 Mir 
studies with 1 subject each (432, 433). The results of studies, using calcium tracer techniques, of 
bone formation in 3 Mir crewmembers (30, 63) were equivocal (formation was unchanged or 
decreased). Together, increased resorption and decreased or unchanged formation yield an 
overall negative calcium balance (30, 63). 
The exact triggering mechanism for these changes in bone metabolism during spaceflight has 
yet to be identified, but the physiological and endocrine responses to the changes are as 
expected. The release of calcium from bone suppresses parathyroid hormone (PTH), which 
results in lower levels of activated vitamin D (1,25-dihydroxyvitamin D), which leads to a 
reduction in calcium absorption from the gastrointestinal tract. Studies of calcium metabolism 
were conducted on Mir astronauts, and indeed, PTH, 1,25-dihydroxyvitamin D, and calcium 
absorption were all decreased (30, 63, 674). Although it remains important to maintain calcium 
intake during flight, the lower calcium absorption during flight suggests that increasing calcium 
intake is not a viable countermeasure for weightlessness-induced bone loss, a fact proven in bed 
rest studies (316, 435).  
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Spaceflight analog studies (such as bed rest) with humans have shown qualitative effects on 
bone and calcium homeostasis similar to those shown in flight studies (424, 675), with 
quantitative effects generally being of smaller magnitude. Effects include loss of bone mass 
(436-438, 676), decreased calcium absorption (439), increased urinary excretion of calcium and 
biochemical markers of resorption (81, 357, 415, 439-446, 667, 676, 677), increased risk of renal 
stone formation (115, 443, 444), and decreased serum concentrations of PTH (81, 296, 357, 441, 
667, 678) and 1,25 dihydroxyvitamin D (296, 439, 441, 447, 667). 
That bone resorption increases during bed rest has been shown by histomorphometry (438, 
448) and measurement of biochemical markers. Excretion of hydroxyproline (439, 445, 677) 
increases during bed rest, and excretion of collagen crosslinks (81, 296, 357, 431, 439, 667, 676, 
678) is elevated about 50% above control levels, compared with the increase of greater than 
100% during spaceflight (30, 63, 431).  
The concentrations of biochemical markers indicate that bone formation is unchanged during 
bed rest (81, 296, 357, 437, 439, 667, 678), but histomorphometry data from bone biopsies show 
that bone formation decreases (438, 441, 448). This difference likely reflects the difference 
between site-specific (biopsy) and systemic (biochemical markers) indices of bone formation. 
After ambulation begins following bed rest, bone formation generally increases (437, 439). 
Recent evidence indicates that with bed rest studies of longer duration (eg, 90 d), bone formation 
markers tend to increase (357, 676). In these initial publications, BSAP did not change 
significantly over time, but a retrospective analysis of data from multiple studies does show a 
change in BSAP that reaches statistical significance (421). 
Although early animal studies suggested that the primary change in bone metabolism was 
related to bone formation, the identification of markers specific to bone resorption in the late 
1980s (679, 680) and the availability of commercial immunoassays in the 1990s (681, 682) 
allowed resolution of this matter: bone resorption increases during spaceflight and bone 
formation decreases or does not change significantly, substantiating that spaceflight disrupts the 
balance between bone resorption and formation, which can lead to a net loss in bone mass. 
 
 
 
3. Bone Loss Countermeasures 
a. Exercise 
In-flight exercise was first implemented on Skylab missions, largely because this was the 
first vehicle to allow enough room for exercise. In addition to in-flight exercise, ground-based 
research has been conducted to help document the effectiveness of exercise as a countermeasure 
for muscle, bone, and cardiovascular maladaptations that occur during flight (462, 675, 683, 
684). With respect to bone specifically, treadmill and cycle exercise devices available on Mir did 
not prevent bone and calcium loss (30, 63, 417, 685, 686). This result has been attributed to the 
lack of resistance provided by these devices, and for the treadmill, the inability to generate 
sufficient ground-reaction force in weightlessness (687).  
Bed rest studies evaluated many types of exercises and devices, alone or in rare cases in 
combination, demonstrating positive effects of treadmill, flywheel, and weight stacks on 
maintenance of bone (as assessed by various means from densitometry to biochemistry) (296, 
564, 688-693). Most evidence, from the general scientific literature as well as spaceflight 
analogs, pointed to resistance exercise as the most likely means of counteracting bone loss 
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during spaceflight. Heavy resistance exercise in bed rest protected bone mineral density, but did 
so not by suppressing the bed rest-induced bone resorption, but rather by increasing bone 
formation (Figure 80). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 80. Bone resorption (as indicated by urinary n-telopeptide [NTX], left panel) and bone 
formation (as evaluated by serum bone-specific alkaline phosphatase [BSAP], right panel) during 17 
weeks of bed rest with (solid line) or without (dashed line) heavy resistance exercise. Data are 
expressed as percentage of pre-bed rest values, and are mean ± SD. The vertical line separates the bed 
rest and post bed rest periods. Data adapted from (564). 
 
 Bed rest studies combining resistance exercise (with a flywheel device) and supine treadmill 
exercise while in a lower-body negative pressure (LBNP) chamber on alternating days yielded 
results similar to those shown above , but with about half the response of BSAP (81) (Figure 81). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 81. Bone resorption (as indicated by urinary n-telopeptide, left panel) and bone formation (as 
indicated by serum bone-specific alkaline phosphatase, right panel) during 60 days of bed rest with 
(solid line) or without (dashed line) a combination of resistance exercise and supine treadmill/LBNP 
exercise. Data are expressed as percentage of pre-bed rest values, and are mean ± SD. Data adapted 
from (81). 
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Attempts to provide resistance exercise on early ISS missions were unsuccessful, with the 
interim resistance exercise device (iRED) providing no additional benefit over the Mir 
equipment (41, 561). This initial device was deployed on the inaugural ISS expedition, and time 
and other constraints did not permit development of all desired hardware requirements before 
this expedition was launched. Thus, the appropriately named interim resistance exercise device 
was to be used until a more advanced device capable of allowing heavier loads could be 
developed, tested, and launched to ISS.  
 In 2008, the Advanced Resistance Exercise Device (ARED) was launched to ISS. This 
device accommodated additional exercise protocols and had almost twice the loading capability 
of iRED (41, 562). Comparing crewmembers exercising with each device has been somewhat 
difficult, given that more recent crews have maintained their energy intake at levels >90% of 
estimated requirements, and have had better vitamin D status than earlier crews. These better 
nourished crewmembers exercising with the ARED maintained body mass during flight and 
came back leaner, with less body fat (Figure 82), and maintained bone mineral density in most 
regions and in whole-body scans (Figure 83), when assessed by DXA (41, 58).  
 
 
Figure 82. Body composition changes (left panel, lean body mass; right panel, total body fat) in 
astronauts on Mir and ISS missions. ISS crews had access to either iRED or ARED exercise devices. 
Data are expressed as percentage change per month of flight. Figure adapted from (41). 
 
 
 
 
 
Figure 83. Bone mineral density loss in astronauts on 
Mir and ISS missions. ISS crews had access to either 
iRED or ARED exercise devices. Data are expressed 
as percentage change per month of flight. Figure 
adapted from (41). 
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 The number of ISS subjects whose data had been analyzed when the comparison of exercise 
devices was published in 2012 was small, in part because many crewmembers participated in 
other countermeasure studies and were not included in this initial analysis. In the time since that 
initial comparison of crewmembers with access to the iRED or the ARED was published, 
another study has confirmed these findings with a much larger set of data. In 42 astronauts (33 
male, 9 female), the bone mineral density response to flight was the same for men and women 
(58) (Figure 84), and those with access to the ARED did not have the typical decrease in bone 
mineral density that was observed in early ISS crewmembers with access to the iRED (41). 
Biochemical markers of bone formation and resorption responded similarly in men and women. 
These recent data are encouraging, and represent the first in-flight evidence in the history of 
human spaceflight that diet and exercise can maintain bone mineral density on long-duration 
missions. 
 
 
 
Figure 84. Bone mineral density (BMD) loss 
after flight in men (N=33, open bars) and 
women (N=9, solid bars) who used either the 
iRED or ARED exercise device. Data are 
expressed as percentage change per month of 
flight. Figure adapted from (58). 
 
 
 
 
 
The bone biochemical changes in crewmembers exercising with the ARED were very similar 
to what had been observed in bed rest studies testing resistance exercise. That is, the exercise did 
not affect bone resorption, but did increase bone formation (41). In the flight study, as published, 
a significant (P < 0.001) increase occurred (41), and in bed rest, heavy resistance exercise 6 days 
a week led to dramatic increases in bone formation markers (564). In another study with 
resistance exercise every other day (combined with a treadmill protocol), subjects had roughly 
half the bone formation response (81) of subjects in the first study (564). The exercise also did 
not have a significant effect on serum total calcium or urinary calcium. When data from 
additional crewmembers became available, these solidified the “trend” into statistical 
significance (58). The slow increase in bone resorption over time during flight is likely related to 
the fact that the astronaut conditioning and strength trainers were initially reluctant to have 
crewmembers exercise too hard with the ARED, to minimize the risk of injury. This slow and 
steady increase over time (41) is different from results of the bed rest study, where formation 
markers plateaued at the first determination during bed rest (6 weeks of bed rest) (564). 
Although this mode of bone remodeling, with increases in biochemical markers of both 
resorption and formation, maintained bone mineral density, it may yield a bone with strength 
characteristics different from those that existed before spaceflight. Studies to assess bone 
strength after flight are underway at NASA, to better understand the results of bone remodeling. 
Studies are also underway to evaluate optimized exercise protocols and nutritional 
countermeasures. 
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b. Gravity 
Other physical countermeasures, including artificial gravity and vibration, have also been 
tested in ground-based (bed rest) settings. A more recent and complex study used centrifugation 
to create artificial gravity transients during a 21-day bed rest study (694). One hour per day of 1 
Gz exposure at the level of the heart and 2.5 Gz at the feet was beneficial for some systems (eg, 
cardiovascular, muscle) (694-696), but this regimen did not have any effect on bone or calcium 
metabolism (678, 697). Although greater durations, increased g forces, or combining 
centrifugations with exercise protocols have been proposed, these have not yet been extensively 
tested (694, 698). 
The assumption that it is lack of gravity that stimulates bone loss during spaceflight provided 
the impetus for proposing replacement of gravity by centrifugation (“artificial gravity”) as a 
countermeasure for multiple body systems (699, 700), particularly for bone. The statement has 
been made that it is known that unit (Earth) gravity maintains bone, whereas microgravity does 
not. A key question is, “How much gravity do we need?” (W. Paloski, personal communication). 
In early bed rest studies, 2- or 4-hour intervals of standing or walking mitigated the increase in 
urinary calcium excretion associated with bed rest (701). Some of the artificial-gravity studies 
have relied on short-radius centrifuges (702), others on rotating exercise devices (698, 703) 
intended to provide gravitational impact as well as physical exercise. Artificial gravity or 
hypergravity has been shown to positively affect bone, in human and some animal studies (704-
706). As noted above, 1 hour per day of centrifugation resulting in 1 Gz at the heart and 2.5 Gz at 
the feet was ineffective for bone (678). The optimal artificial gravity prescription for bone, 
including dose, duration, and frequency of centrifugation, remains to be clarified (707), along 
with its potential impact on nutrition and related systems (708). 
 
 
c. Vibration 
 Protocols for exposure to vibration, of both high and low frequency, have also been proposed 
and tested in spaceflight analogs. Although low-frequency protocols showed promise for 
protecting bone in both animal and ambulatory human studies (709-711), the beneficial findings 
were more limited when testing occurred during head-down-tilt bed rest (712). Higher frequency 
vibration, often referred to as resistance vibration exercise, has generally shown positive effects 
on bone and muscle during bed rest (713-716). Debate continues over the potential of this 
countermeasure protocol, amid safety concerns about neuromuscular issues with repeated 
vibration exposures. 
 
 
d. Pharmacological Agents 
Pharmacological agents, the most common being the bisphosphonates, have also been tested 
for their ability to mitigate weightlessness-induced bone loss. Many ground analog studies of 
bisphosphonates (including bed rest studies and studies of patients immobilized because of spinal 
cord injury or other reasons) have been conducted, with generally positive findings (438, 462, 
689, 690, 692, 717-724). However, ongoing discussion and debate surround the relative safety of 
these compounds for use in otherwise healthy individuals (astronauts), as opposed to the target 
population for whom the drugs were developed (patients with disorders such as osteoporosis). In 
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addition to resolving safety concerns, investigators have yet to determine the optimal drug, dose, 
and schedule of administration during spaceflight. As noted above with exercise, given that the 
bone loss of bed rest is about half that of spaceflight, there is little reason to believe that the same 
dose of drug will have the same effectiveness in both environments. Moreover, data from animal 
studies suggest that the disuse- or spaceflight-induced increase in bone resorption cannot fully, or 
chronically, be mitigated by bisphosphonates (725, 726). 
Endocrine therapies, including exogenous calcitonin administration (462, 677), have also 
been attempted, albeit unsuccessfully. In animal models, testosterone has also been suggested as 
a bone loss countermeasure (581, 727) on the basis of limited data showing a reduction in 
testosterone concentrations during flight in human, animal, and cellular models (728-734). 
Reduction of testosterone, however, has recently been shown to likely not be a concern during 
spaceflight. See section VI.B.11, “Testosterone,” for a more detailed discussion of these data. 
 
 
e. Nutritional Countermeasures 
 
One of the most obvious nutritional countermeasures—providing calcium—does not protect 
against bone loss (449). This result is likely related to the decreased calcium absorption seen 
during bed rest (439, 697) and spaceflight (30, 63, 674), likely related to reduced circulating 
parathyroid hormone and 1,25-dihydroxyvitamin D. Phosphate supplementation, used in an 
attempt to reduce calcium excretion, was also ineffective (735). Combination therapy with 
calcium and phosphorus was also unsuccessful at mitigating bone loss and hypercalciuria (677). 
Omega-3 fatty acids have been shown to protect bone, in the general population (144-146) 
and animal studies (736) as well as in spaceflight analog studies, including bed rest (Figure 85) 
and cell culture (147). While omega-3 fatty acids have not been studied in a controlled fashion 
during actual spaceflight, a positive correlation was found between fish intake and bone loss in 
astronauts (Figure 85) (147). That is, those who ate more fish lost less bone. These data provide 
additional evidence of the potential importance of fish oils as a countermeasure for muscle, bone, 
and radiation risks of spaceflight. Studies showing positive effects of omega-3 fatty acids 
typically look at intake of fish or other food sources of these nutrients (148-150). Studies of fish 
oil supplements added to typical diets often fail to document any benefit (151-153), thus 
highlighting the need for dietary modification, and not simply supplementation. 
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Figure 85. Relationship between omega-3 fatty acid consumption and bone resorption during bed rest 
(left panel), and relationship between fish consumption and percentage change in whole-body bone 
mineral density at landing in astronauts (right panel). Figures adapted from (147). 
 
Other nutrients, specifically sodium, protein, potassium, and vitamin K, have been documented 
to have effects on bone, and/or have been proposed or tested as countermeasures to bone loss 
(98). These are discussed in detail in other sections of this book. 
 
 
f. Fruits and Vegetables 
 
 Apart from nutrients, food patterns can obviously have effects on bone (and general) health.  
An ongoing effort to provide healthier foods for astronauts included the specific goal of 
increasing fruit and vegetable intake.  Population-based and even smaller controlled studies have 
shown extensive benefits for the inclusion of 5 to 6 servings of fruits and vegetables per day 
(737).  From a bone perspective, higher fruit and vegetable intake has been associated with 
increased bone mineral density (738-740) and lower risk of hip fracture in both men and women 
(741-744). Higher dietary quality (e.g., a diet rich in fruits and vegetables) has been shown to be 
associated with less bone breakdown and greater bone mineral density, and lower dietary quality 
(a diet rich in highly processed foods) with the opposite effects (745). Fruits and vegetables have 
even been posited as a potential alternative osteoporosis therapy (746), and at a minimum, as 
being beneficial for healthier bones during aging (747).  Beyond bone, higher fruit and vegetable 
intakes have been associated with prevention of chronic diseases, including cardiovascular 
disease (748-750) and cancer (748, 749), as discussed in later sections.   
 Specific nutrients found in fruits and vegetables have also been studied, in attempts to 
identify key ingredients. Fruits and vegetables rich in carotenoids and other flavonoids have been 
associated with lower hip fracture risk (751). Lycopene, found in abundance in tomato-rich 
foods, has also been associated with protection of bone (752) and reduction of fracture risk 
(753). Lycopene also has been shown to reduce oxidative damage and bone breakdown (752, 
754). This association of diet, oxidative damage, and bone on Earth is analogous to the 
association of iron, oxidative damage, and bone health in spaceflight (498) and ground-based 
analogs (514). Radiation, likely acting through oxidative damage, also has been identified as a 
risk factor for bone loss (567, 568). 
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4. Nutrients and Bone Health 
 
a. Calcium 
 Calcium metabolism is of critical importance in bone health, and many studies use calcium 
determinations as one measure of bone health; however, it has been well documented that excess 
dietary calcium will not mitigate bone loss during spaceflight (435, 755). Nonetheless, ensuring 
adequate calcium intake remains important, and the role of calcium excretion in kidney stone 
risk must be considered. Two other facets of calcium chemistry and biochemistry have been 
researched, with intriguing findings. One is related to the impact of calcium in the reclamation of 
water from urine on spacecraft, and the other relates to naturally occurring stable isotopes of 
calcium and their ability to document changes in bone metabolism. 
 
 Calcium Balance 
Negative calcium balance was observed during the Skylab (39, 94, 413, 415, 427, 428, 756) 
and Mir (30, 63) missions. During the 84-day Skylab 4 mission, calcium balance was –200 mg/d 
(94, 429, 756). Increased urinary and fecal calcium excretion accounts for most of the calcium 
deficit (30, 39, 63, 94, 181, 413, 415, 428). Estimates of bone calcium loss from multiple studies 
and techniques converge on the suggestion that about 250 mg of bone calcium is lost per day 
during flight (30, 63, 94, 456). When this rate of loss may slow down is not yet known, but it 
does not appear to be within the first 6 months of flight. For comparison, bone loss after spinal 
cord injury seems to stabilize after about 6 to 12 months (455, 757, 758), around the duration of 
many ISS missions. 
 
 
b. Vitamin K 
 The function of vitamin K was originally assumed to be strictly limited to involvement in 
blood coagulation, but an increasing amount of evidence indicates that this vitamin affects 
multiple physiological systems. Vitamin K is a cofactor in the posttranslational synthesis of γ-
carboxyglutamic acid (GLA). γ-Carboxyglutamic acid is a constituent of all vitamin K-
dependent proteins, and its role is related to increasing the affinity of the proteins for calcium 
(333). Vitamin K-dependent proteins include blood coagulation proteins and bone proteins (eg, 
osteocalcin, matrix GLA protein, protein S). On the basis of findings from Mir in the 1990s and 
from early ISS missions (described below), vitamin K had been proposed as a bone loss 
countermeasure (759). 
 Data from 11 U.S. astronauts on ISS Expeditions 1 to 8 (mission durations of 128 to 195 
days during 2000-2004) revealed that on landing day their serum phylloquinone (vitamin K1) 
was 42% lower than it was before flight, whereas urinary GLA did not change (31). In another 
study, undercarboxylated osteocalcin was elevated (a sign of vitamin K insufficiency) as early as 
the 8th day of spaceflight, and remained high during 21- and 180-day missions (339). Studies on 
the EuroMir 95 mission showed that markers of vitamin K status were decreased after 12.5 
weeks of spaceflight, and vitamin K supplementation (10 mg/d for 6 wk) reversed these effects 
(340). Vitamin K supplementation elevated GLA and decreased undercarboxylated osteocalcin, 
suggesting that vitamin K status was lower during spaceflight and was improved by 
supplementation (339, 340). Despite the changes on landing day, the monitoring of vitamin K 
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status during flight has documented no evidence that vitamin K status is decreased during 
spaceflight. In-flight data from 15 crewmembers on Expeditions 14 to 22 showed no major 
changes in phylloquinone, urinary GLA, or undercarboxylated osteocalcin (341). Phylloquinone 
data from those 15 crewmembers (341) plus an additional 11 crewmembers on Expeditions 23 
through 31 are shown below (Figure 86). Even with the additional data, vitamin K status did not 
significantly decrease during flight. This is an important finding, to document that a vitamin K 
countermeasure to mitigate a vitamin K deficiency during spaceflight is not needed and therefore 
likely would not have an effect on bone. 
 
 
Figure 86. Serum phylloquinone before launch 
(launch minus 180 d, or L-180, L-45, and L-10), 
during flight (flight days 15, 30, 60, 120, and 180), 
on landing day (R+0), and 30 days post landing 
(R+30). The dashed lines indicate the normal range 
for phylloquinone. Data are mean ±SD, N=26 (6). 
Data and N are expanded from the original 
publication of these findings (341). 
 
 
 
 
 
 
c. Phosphorus 
Phosphorus is an important component of cell membranes and bone mineral. Phosphate 
accounts for about 60% of bone mineral (406), and most (85%) of the body’s extracellular 
phosphorus is in bone (760). After ISS missions, urinary phosphorus excretion was about 45% 
lower than preflight excretion (31). 
Excretion of phosphorus during untreated bed rest was not changed (357) from ambulatory 
conditions. An earlier study of 3 subjects revealed increased urinary phosphorus and negative 
phosphorus balance (445). In bed rest studies, investigators have attempted to use combination 
therapy with calcium and phosphorus to mitigate bone loss and hypercalciuria, with trends in the 
right direction but no significant changes (677). 
High phosphorus intake, relative to calcium in particular, can have effects on many systems, 
including bone, kidney, cardiovascular, and others (761-763). Ideally, the ratio of 
calcium:phosphorus should be around 1.0, or higher. The ISS requirements match this, with a 
notation that phosphorus:calcium ratio should not exceed 1.5 (2, 5, 97), based on evidence that a 
dietary phosphorus:calcium ratio greater than 1.5 is known to decrease calcium absorption, 
which could further impair skeletal integrity. Serum phosphorus rises with increasing phosphorus 
intake, and if hyperphosphatemia occurs, it can result in calcification of the kidney. For this 
reason, ensuring optimal phosphorus intake during flight becomes very important (425). To date, 
phosphorus intakes have been higher than desired. The standard menu has a P:Ca ratio of 1.8 (2); 
the ratios of actual intakes have been slightly lower than that, but still greater than 1.5 (Figure 
87). Bed rest studies have tended to have P:Ca intake ratios closer to 1.0 (unpublished 
observations). 
Risk Factor of Inadequate Nutrition 
 
 145
 
 
 
Figure 87. Dietary phosphorus:calcium ratio in ISS 
crewmembers during flight (approximate flight 
days 15, 30, 60, 120, and 180). The dashed line 
indicates a ratio of 1.5. Data are mean ±SD, N=9.  
 
 
 
 
 
 
 
 
 
 
 
d. Magnesium 
Magnesium is the fourth most abundant cation in the body, and more than half of the body’s 
magnesium is in bone (473). Adequate intake of magnesium is necessary to prevent 
hypocalcemia, resistance to vitamin D, and resistance to parathyroid hormone. Excessive 
magnesium intake from supplements has been shown to impair calcium absorption (473).  
Decreased urinary magnesium after flight, relative to before flight, seems to be a hallmark of 
spaceflight (39, 495). Serum magnesium trends downward during and after flight, as seen with 
Skylab and Shuttle crews (2, 31, 39, 208, 474). After crewmembers had spent 4 to 6 months in 
space on ISS, their urinary magnesium was about 45% less than it was before flight (31).  
Autopsy results after the tragic end of the 24-day Salyut-1 mission documented that, relative 
to control subjects, the Salyut-1 cosmonauts had 12% to 32% lower concentrations of 
magnesium in the compact layer of the femoral epiphysis and diaphysis, vertebral body, and 
sternum (475). These changes were reported as appearing “with a high degree of certainty.” 
Magnesium balance was slightly negative during extended-duration bed rest studies conducted in 
Russia (690), with little effect of exercise or bisphosphonate. Recent studies conducted in the 
U.S. have shown a decrease in magnesium excretion in short- and long-duration bed rest (356, 
357).  
Magnesium shows promise for reducing the risk of renal stone formation (764). In ground-
based studies, potassium-magnesium citrate has proven effective in reducing bed rest-induced 
risk (115). Potassium citrate (KCit) has been successfully tested during ISS missions (765), and 
has been “transitioned to operations.” This means that KCit is part of the flight surgeon’s toolbox 
for helping crewmembers mitigate renal stone risk. That is, it is available on ISS for use based on 
flight surgeon discretion if clinically indicated. However, given that fluid intake for optimum 
hydration is a preferred countermeasure, and some residual concerns exist about side effects of 
potassium supplementation, it was decided not to routinely provide KCit to crewmembers. 
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e. Zinc (and Lead) 
 
Zinc status of astronauts, as assessed by serum zinc and urinary zinc excretion, did not 
change after long-duration spaceflight (31). Circulating zinc levels are an imperfect tool to 
evaluate zinc status, as other physiological factors may affect them (766). However, to increase 
the reliability of zinc status evaluation, more intensive and/or invasive techniques would be 
required. 
The release of zinc from bones (as a result of demineralization) has been noted in bed rest 
studies (531, 545), and a similar increase in excretion of zinc was noted in Wistar rats flown 
during COSMOS 1129 (a 20-d spaceflight) (546). This release of zinc associated with 
demineralization has raised concern that other metals, including lead, could also be released 
secondary to weightlessness-induced bone resorption (547, 548). Garcia et al developed a 
computer-based model that predicted that blood lead levels would actually decrease during 
microgravity exposure. The model predicted, for the majority of astronauts, that any increase in 
circulating lead would be more than offset by decreases in ingested or inhaled lead during the 
mission (767). Postflight data supported this model (767).  
 
 
 
f. Protein and amino acids 
 
Maintaining a proper protein intake is critical, as both low-protein and high-protein diets 
can cause harm (and, at the extreme, death). The interrelationship of protein and bone health is 
complex, and often seemingly contradictory. In certain populations (such as growing children), 
protein is essential for bone growth. However, in some cases, high protein intakes can be 
detrimental to bone (768), a fact confounded by the type of protein (and amino acids) consumed 
and by their relationship to other dietary factors (769, 770). The key to understanding the 
interrelationship of protein and bone may lie in understanding the complexities of the studies 
from which data are obtained, and understanding these complexities may require a full 
accounting of many nutrients and environmental factors (659, 746). 
A low-protein diet (below the recommended dietary allowance) for up to 4 weeks can 
decrease calcium absorption and induce hyperparathyroidism in otherwise healthy subjects (85, 
86). The impact of chronic low protein intake is not well understood; however, several studies 
suggest that low-protein diets are associated with loss of bone density (87, 88). 
On the other hand, lowering excessive protein intake can have beneficial effects. High-
protein diets lead to hypercalciuria, and increase the risk of fracture and the risk of renal stone 
formation (768, 771, 772). One 5-year study of 120 men revealed that the relative risk of stone 
formation due to a restricted protein (52 g/d) and salt (50 mEq/d) diet was half that due to a 
calcium-restricted diet (400 mg/d) (773). The reason for the decreased risk of renal stones on a 
low-protein diet is not well understood, but several potential mechanisms have been postulated. 
It is generally well accepted that high-protein diets induce hypercalciuria, and this can contribute 
to the formation of calcium oxalate or calcium phosphate stones. One hypothesis to explain 
protein-induced hypercalciuria is related to the “acid-ash” hypothesis that excessive animal 
protein intake provides excess sulfur-containing amino acids that are metabolized to sulfuric 
acid. Because bone is a large reservoir of base, bone can be broken down to provide carbonate or 
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phosphate to neutralize fixed acid loads. Furthermore, low urinary pH decreases urinary 
excretion of citrate, which is a potent inhibitor of stone formation. In addition, dietary animal 
protein represents a rich source of purines that may raise uric acid excretion, which could 
increase the risk of forming uric acid stones (671). 
 
 
 
 
 
 
Figure 88. The bone resorption 
marker n-telopeptide (NTX) was 
positively correlated with the ratio 
of animal protein to potassium 
intake (APro/K) during weeks 3 
and 4 of bed rest in sedentary 
(SED) bed rest subjects but only 
during week 1 in exercising (EX) 
bed rest subjects. The ratio of 
vegetable protein to potassium 
intake (Vpro/K) was correlated 
with urinary NTX excretion before 
bed rest but was not associated 
with NTX during bed rest (774).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protein-induced hypercalciuria may be detrimental to bone as well as to risk of renal stones. 
Some studies show that high-protein diets increase calcium absorption (775), but this is currently 
not well accepted. Several studies show that animal protein increases acid load more than 
vegetable protein because of the higher sulfur content per serving of food. Vegetable protein 
itself does not necessarily have less sulfur per gram of protein, but a larger mass of foods 
containing vegetable protein would have to be consumed to get the same amount of protein as 
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that from foods containing animal protein. It can be assumed that foods containing vegetable 
protein contain less sulfur than foods containing animal protein. In studies with controlled 
dietary intakes with varying sulfur content, diets consisting of animal protein yielded greater 
urinary calcium excretion and lower urinary pH than similar diets consisting of mainly vegetable 
protein (776). The results of another study comparing the effects of 2 sources of protein (meat 
and soy protein), with and without additional supplementation with sulfur amino acids, indicated 
that dietary meat elicited a greater positive association between protein intake and urinary 
calcium, sulfur, ammonia, and titratable acids than dietary soy (777). When the soy diet was 
supplemented with sulfur amino acids, urinary calcium and acid excretion increased. Conversely, 
the addition of dietary potassium (either as fruit or a K+ supplement) to both diets decreased 
urinary calcium and acid excretion (777). Other studies have shown that greater amounts of 
protein or higher ratios of animal protein to potassium are more detrimental when bone health is 
already compromised (such as during bed rest, and potentially during spaceflight) (774, 778).  
Dietary intake of protein and specific types of protein, as well as patterns of acid and base 
precursors, have recently been associated with the concentration of urinary markers of bone 
resorption during bed rest (98, 691, 774). In one study, the relationships between acid and base 
precursors in the diet and markers of bone and calcium metabolism in male identical twins 
during bed rest were investigated (296). With respect to dietary intake patterns, a strong positive 
correlation existed between markers of bone resorption (n-telopeptide [NTX], deoxypyridinoline, 
and pyridinoline) and the ratio of animal protein to potassium intake during the latter part of bed 
rest (Figure 88) shows the positive correlation between urinary NTX excretion and the ratio of 
animal protein to potassium intake during weeks 3 and 4 of bed rest. No relationship was found 
between the ratio of vegetable protein to potassium and markers of bone metabolism (Figure 88, 
right column). There tended to be a positive association between these variables before bed rest 
and during weeks 1 and 2 of bed rest, but the relationship was not significant, likely because of 
high variability among the population and small sample size (820). 
The results from the twins study described above, showing that the ratio of animal protein 
to potassium intake was less related to bone metabolism markers in the exercising group and 
more related to bone markers at the end of bed rest when calcium excretion was highest, support 
the argument that calcium status could have an important role in determining the effect of protein 
on bone. If calcium is being resorbed from bone, then acid load can have a more detrimental 
effect on bone, similar to what has been observed in other studies of the effect of high-protein 
diets on bone (768, 770). 
The idea that the levels of acid and base precursors in the diet can affect bone and calcium 
metabolism is supported by the results of studies testing the ability of a supplement containing 
essential amino acids and carbohydrate (45 g/d essential amino acids and 90 g/d sucrose) to 
mitigate muscle loss (778). The supplement contained 1.5 g of methionine, which is about 1.13 
times the recommended daily intake, in addition to the amount of methionine provided in the 
diet. The sulfur in methionine is converted in the body to sulfuric acid, and thus methionine is an 
acid precursor in the diet. It was evident that more methionine was broken down than was used 
by the body because urine pH decreased in the amino acid-supplemented group (Figure 89) 
(778). It was hypothesized (250) that this mild metabolic acidosis contributed to the higher 
urinary concentrations of bone resorption markers (Figure 90) and calcium excretion (Figure 91) 
in the supplemented group (778).  
 
 
Risk Factor of Inadequate Nutrition 
 
 149
 
 
 
 
 
 
Figure 89. Urine pH (mean ± SD) of amino 
acid-supplemented (AA, ■) and placebo 
(CON, ○) groups during 4 weeks of bed rest. 
*Significantly different from pre-bed rest, P < 
0.05. #Significant difference between groups, 
P < 0.05 (778). 
 
 
 
 
 
 
Figure 90. Urinary n-telopeptide (NTX) 
excretion (mean ± SD) of amino acid-
supplemented (AA, ■) and placebo (CON, ○) 
groups during 4 weeks of bed rest. *Significantly 
different from pre-bed rest, P < 0.05 (no 
significant difference between groups) (778). 
 
 
 
 
 
 
 
 
 
 
 
Figure 91. Urinary calcium excretion 
(mean ± SD) of amino acid-supplemented 
(AA, ■) and placebo (CON, ○) groups 
during 4 weeks of bed rest. #AA values 
were significantly different from pre-bed 
rest, P < 0.05 (778). 
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In a separate study, 11 volunteers were subjected to 60-90 days of 6º head-down-tilt bed 
rest (357). Net acid excretion, as determined by dietary acid and base components, was 
positively correlated with NTX during but not before bed rest (Zwart et al., unpublished data) 
(Figure 92). Net acid excretion has also been associated with calcium loss using meta-analysis 
techniques (779). 
 
 
 
Figure 92. Urinary n-telopeptide 
(NTX) excretion was positively 
correlated with net acid excretion 
(NAE) during but not before bed rest. 
NAE was estimated from the diet 
(357). 
 
 
 
 
 
 
 
 
 The current documented spaceflight requirement for protein intake is 0.8 g/kg per day, not to 
exceed 35% of the total daily energy intake (97). About 2/3 and 1/3 of the total amount of 
protein should be provided in the form of animal protein and vegetable protein, respectively. In 
the U.S., the recommended dietary allowances for those in the age range of the astronaut 
population are 56 g/d for men and 46 g/d for women (18). The acceptable distribution range for 
protein intake is 10% to 35% of the total energy intake (18). For historical reference, the 
spaceflight daily protein requirements were defined in 1991 for missions of 30 to 120 days as 
10% to 15% of the total energy intake (4), and in 1995 for missions up to 360 days as 10% to 
15% of the total energy intake (5). Actual intakes of protein typically exceed these 
recommendations, as discussed earlier. 
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5. Unique Aspects of Calcium and Spaceflight 
 
a. Urine Processing and Water Reclamation 
 
The ability to reclaim water from urine will be a pivotal factor in implementing exploration-
class missions. When the prototype Urine Processor Assembly (UPA) on ISS clogged due to an 
unknown precipitate in 2009, the available in-flight urine volume and calcium excretion data 
from 24-hour pools and single voids were closely examined (191). Urine 24-hour volume was 
about 17% lower during flight than before flight, and urinary calcium concentration was 50% 
greater during flight than before flight. The increased urinary calcium concentration during flight 
was identified as a primary reason for UPA failure, and new recommendations for percentage of 
water to be recovered were made as a result of those findings. In 2012, when the data were re-
evaluated with data from an additional 10 subjects in a Supplemental Medical Objective study of 
nutritional status assessment, it was clear that crewmembers in recent years are drinking more 
fluid than crewmembers did in the past, and as a result urinary calcium concentration is lower. 
The UPA extracts water by vacuum distillation, and as a result, the primary concern for the UPA 
is the concentration of calcium in the urine, not the amount of calcium excreted (191). 
Suggestions for ways to mitigate high calcium concentrations included exclusion of the first 
morning void from the system, based on the assumption that this is typically more concentrated 
than other voids throughout the day. Another suggestion was administration of bisphosphonates 
to all crewmembers to reduce calcium excretion. Single-void calcium data from the in-flight data 
showed that neither of the suggestions looked promising for lowering the calcium concentration 
of urine that enters the UPA (191). With respect to bisphosphonate treatment, people sometimes 
have the impression that the pharmacological block of bone resorption will reduce urinary 
calcium to near zero, but this is not the case. In fact, although urinary calcium decreased in ISS 
crewmembers treated with bisphosphonate, it had started higher in these individuals, so the daily 
excretion was about the same as for individuals who did not receive bisphosphonate (421). 
When in-flight urinary calcium concentration was examined in light of in-flight mean fluid 
intake estimated from the food frequency questionnaire, all but one 24-hour pool had calcium 
concentrations below 23.7 mg/dL (the cutoff point for a 75% water recovery) when fluid 
consumption was greater than 32 mL fluid/kg body weight. For the 23 crewmembers in that 
analysis, that would average to a fluid consumption (from food and beverages) of 2.5 L/d. In 
September 2012, a decision was made to increase water recovery from 70% to 74%, which 
allows a savings of >80 L H2O/year. 
 
b. Natural Calcium Isotope Composition of Bone 
Analytical techniques to assess bone health, bone loss, and bone metabolism continue to 
evolve with technology. Although densitometry techniques (such as DXA and quantitative 
computerized tomography) provide valuable assessment of specific bones, these techniques 
detect only relatively large changes in bone, which can take months to occur, despite the 
likelihood that biochemical changes are initiated within hours of exposure to spaceflight. 
Studying calcium metabolism requires either intensive balance studies or tracer kinetic studies, 
as calcium excretion alone is confounded by too many factors to be useful in noncontrolled 
studies. Bone formation and resorption markers provide the ability to assess changes in bone 
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biochemistry, but assessing the relative association of these 2 factors has not been possible to 
date, and thus it is difficult to assess net changes in bone mineral. 
A new technique to rapidly detect and quantitatively predict changes in whole-body bone 
mineral balance was recently validated in bed rest (780). This technique is based on natural, 
biologically induced variations in the presence of the naturally occurring stable (nonradioactive) 
calcium isotopes (40Ca, 42Ca, 43Ca, 44Ca, 46Ca, and 48Ca), which react at different rates depending 
on their mass (781). These variations exist because bone formation favors the lighter isotopes, 
and thus the blood and urine (and other “soft tissues”) tend to contain the “heavier” calcium 
isotopes. Bone resorption, however, releases whatever calcium is in bone, and that tends to be 
the lighter isotopes. Thus, when bone is being resorbed (as it is during bed rest), the urine 
contains greater amounts of the lighter calcium isotopes than it did before the increased 
resorption. When the isotope ratio technique was applied to a bed rest study, it was shown that 
the calcium isotope ratio shifted in a direction consistent with bone loss after just 7 days of bed 
rest, long before detectable changes in bone density occur. Consistent with this interpretation, the 
calcium isotope variation accompanied changes observed in n-telopeptide, whereas bone-specific 
alkaline phosphatase, a bone-formation biomarker, was unchanged (780).  
As the relationship between calcium isotopes and whole-body bone mineral balance is well 
established (782-784), this relationship can be used to quantitatively translate the changes in the 
calcium isotope ratio in urine to changes in bone mineral density using a simple model. Using 
this model it was estimated that subjects lost 0.25 ± 0.07% (1 SD) of their bone mass from day 7 
to day 30 of bed rest (780). This rate of loss extrapolates to a loss of 1.36 ± 0.38% of skeletal 
mass over 119 days, which is equivalent, within error, to bone loss rates determined by DXA 
scans in long-term (119-d) bed rest studies (676). 
Given the rapidity with which calcium isotope measurements detect change and their 
potential for use in assessing bone loss, this technique is ideally suited for spaceflight studies in 
which changes in bone formation and resorption are not only being altered by spaceflight itself 
but are being manipulated by various countermeasures. 
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B. Muscle and Protein 
 
Muscle Loss 
 
Spaceflight 
 
Exposure to microgravity reduces muscle mass, volume, and performance, especially in the 
legs, on both short (38, 785-790) and long flights (38, 785, 791-795). Muscle biopsy studies 
demonstrated postflight decreases in cross-sectional area only in type II (fast-twitch) myofibers, 
the muscle fiber type that responds to resistive exercise (796). 
As with most physiological systems, a variety of techniques are used to quantify changes in 
different aspects of muscle. These include functional muscle performance/exercise tests, muscle 
biopsies to evaluate cellular changes, magnetic resonance imaging (MRI) of muscle tissue, and 
tracer kinetic studies to evaluate changes in protein metabolism. Each technique provides a 
different perspective and unique information. The picture becomes more complex when results 
from models and analogs (including nonhuman ones) are compared with those from spaceflight. 
As a result, the topic of spaceflight effects on muscle is very complex, and defining and 
understanding the big picture is difficult, to say the least. This topic has been reviewed (786, 
797-801), and the difficulties of interpreting findings across the literature have also been noted 
(790, 797, 800). 
The amount of protein in the body or individual tissues is affected by the balance of protein 
synthesis and protein catabolism. Studies to understand changes in body protein, ideally, will 
include measurement of both of these factors in addition to turnover. Measuring these factors is 
not easy, and the results are variable (795, 802), but having the complete picture is critical. For 
example, although both decreased protein synthesis and increased protein catabolism will yield a 
net loss of muscle, the mechanisms and countermeasures for the 2 processes are quite different. 
Turnover studies with stable isotopes indicate that during short-term spaceflight, whole-
body protein turnover and protein synthesis increase, and a greater percentage increase occurs in 
protein breakdown (96, 803). The increase in synthesis is hypothesized by Stein et al (801, 804) 
to be related to physiological stress, as indicated by generally (but not consistently) increased 
urinary cortisol during flight (25, 28, 130). These findings are similar to those found in catabolic 
patientspatients undergoing metabolic breakdown. Decreased prostaglandin secretion has also 
been implicated in the loss of muscle tissue during spaceflight, secondary to decreased 
mechanical stress on muscle (130). On long-duration Mir flights, conversely, investigators noted 
decreased rates of protein synthesis (22), secondary to reduced dietary energy intake (69) (Figure 
93). 
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Figure 93. Protein synthesis and energy deficit. Adapted from 
Stein et al (69). 
 
 
 
 
 
 
 
Evaluation of plasma and urinary amino acid levels often does not provide a clear picture of 
muscle or even protein metabolism, but in some cases, these are among the limited available 
data. An increase in plasma amino acids was noted in cosmonauts after short (2-d) and long-
duration (63-d) flights (805, 806). Limited Shuttle flight data indicate a tendency for plasma 
branched-chain amino acids to be increased during flight, relative to preflight levels (807). Data 
from short-duration Shuttle flights have revealed little or no change in urinary amino acid 
profiles (36), but data from the Apollo (Figure 94) and Skylab missions showed increases in 
urinary excretion of the amino acid metabolites creatinine, sarcosine, and 3-methylhistidine 
(434), suggesting that contractile proteins of skeletal muscle are degraded in weightlessness.  
 
 
 
 
Figure 94. Urinary amino acid 
excretion by Apollo 
crewmembers (N=12) before 
and after flight (2, 104). 
 
 
 
 
 
 
 
 
1. Ground Analog Studies 
 
 Ground-based rodent studies generally show increased proteolysis along with reduced protein 
synthesis (795). This pattern is similar to that seen in studies of humans during flight, described 
above. 
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 In humans, bed rest is the most common model used for studying changes in muscle and 
protein during disuse. Some studies have also used unilateral limb suspension (ULLS) as a 
model for these changes, allowing subjects more freedom while significantly reducing the costs 
of such studies. Other human models have also been tested, including “dry immersion,” as 
reviewed by Navasiolava et al (808). Untreated bed rest and ULLS both result in loss of muscle 
mass and strength, as nicely reviewed by Narici and de Boer (797). 
 All of these models provide a means to collect data that would be difficult if not impossible 
to collect during actual spaceflight, and data can be collected from a larger group of subjects. 
However, it is important to remember that the model system may not, and likely does not, 
provide an exact replica of the physiological changes during spaceflight. 
 Differences between flight and ground studies may relate to a number of variables, 
identifying potential shortcomings of the analog studies. As mentioned earlier, muscle loss in 
space may be related to changes in turnover of protein in the whole body. Many studies 
document a decrease in protein synthesis during bed rest (696, 809-815). Evidence of increased 
protein catabolism during bed rest is limited, as reviewed by Bodine (800). There are 2 key 
confounding, and intertwined, issues (among others) with this area of research: energy intake and 
inflammation. 
 Energy consumption during spaceflight is generally not controlled, that is, astronauts are 
allowed to consume as much, or as little, as they desire. Historically, this lack of control has 
resulted in underconsumption, as described in section IV.A, “Food and Energy.” On the 
Spacelab Life Sciences missions, in-flight intakes of protein and energy were about 20% less 
than preflight intakes, and crewmembers lost about 1% to 1.5% of their body mass (96). The 
prospect of comparing the controllable ground-analog model with actual spaceflight, in which 
underconsumption can occur, presents a study design issue. Ground-based studies typically have 
prescribed and controlled dietary intakes or are designed to maintain body mass. With respect to 
intake, investigators typically either seek to maintain energy intake of the subjects during bed 
rest, or restrict calories to recreate the hypocaloric intakes of spaceflight. Other studies allow 
subjects to regulate energy intake voluntarily. It should be noted that, because energy 
expenditure decreases (about 15%) during bed rest secondary to decreased activity (24, 816), 
essentially all studies reduce energy intake during bed rest to some degree. Furthermore, because 
protein is an energy-containing nutrient, it is impossible to alter caloric intake without altering 
either protein intake or the relative contribution of protein to overall energy intake. This becomes 
critical in nutritional countermeasure studies, in which provision of additional protein and/or 
amino acids is often a focus. 
 Restricting energy consumption to match earlier findings from spaceflight concedes the point 
that astronauts may be able to maintain dietary energy intake during flight. This was observed 
during Skylab and EuroMir missions, albeit in a controlled fashion (that is, these crewmembers 
were participating in metabolic studies and were required to consume the planned menu) (817, 
818). More recently on ISS, crewmembers have been able to maintain energy intake at >90% of 
predicted requirements. Coupling this energy intake with heavy resistance and other forms of 
exercise, crewmembers maintained body mass, returned with an increased percentage of lean 
body mass, and maintained bone mineral density (41). This study is described in more detail 
elsewhere in the book, but it is mentioned here because it documents that crewmembers can 
consume adequate energy intake without their diet being strictly controlled.  
 Inadequate caloric intake results in 2 significant effects on protein and muscle. Initially, 
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breakdown of glycogen in muscle will reduce muscle volume, in large part because of the water 
content associated with stored glycogen. Second, the body will catabolize protein for energy. 
Thus, studies of hypocaloric subjects will inherently be confounded by this situation. As detailed 
below, provision of supplemental protein or amino acids is an oft-tested countermeasure for 
muscle loss, but it is plausible that provision of energy in any form will help maintain lean (and 
other) tissues in this metabolic environment. 
 Muscle loss has been observed in bed rest and other analog studies, even when energy intake 
and body mass are maintained. It has been argued that in individuals who lose muscle under 
those conditions, maintenance of body mass during bed rest leads to a chronic low-level 
inflammatory response, the second key confounding issue in ground analog studies. 
Inflammation can lead to increased fat mass along with muscle loss (819-821). This argument 
has led to attempts to reduce caloric intake to the point where fat mass is not changing (although 
body mass decreases, related to loss of muscle tissue). This is a difficult prospect at best, given 
that body composition is measured (typically by dual-energy x-ray absorptiometry) infrequently 
(such as every 2 wk), and thus any corrections lag behind, or may overshoot before the next 
determination.  
 The ideal answer for how to control body (or fat) mass during bed rest remains under debate. 
Nonetheless, as with any scientific study, it is critical to know the limitations and implications of 
every study design and, if possible, to relate studies with these limitations to other studies in the 
literature. One necessity for making the findings of such studies useful to readers of scientific 
papers is body mass data, which we suggest should be reported in every published bed rest study. 
 Inflammation is a key confounding issue in studies of muscle loss in spaceflight or ground 
analogs, and a common cause of inflammation is stress. Variability in stress levels may explain 
some of the variability in the results from studies of muscle loss, both flight and ground-based. 
An increase in stress level, as indicated by increased concentrations of cortisol in blood plasma 
and urine, is typically associated with the initial days of spaceflight. In many cases, urinary 
cortisol excretion returns to preflight levels after 5 to 9 days, although this phenomenon has yet 
to be fully characterized or generalized to all crews. Ground-based studies have the potential for 
inducing increased stress, but this is not an entirely consistent finding. Some studies have shown 
no change, or even a downward trend, in cortisol excretion during bed rest (822). As seen with 
studies of energy metabolism, administration of exogenous cortisol or thyroid hormone induces 
metabolic stress, which may produce a more accurate ground-based model of protein metabolism 
during spaceflight (26, 823-825).  
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2. Muscle Loss Countermeasures 
 
a. Mechanical 
Exercise is the most common first-pass approach to maintaining muscle mass and 
strength (786, 799, 826-828), but the exercise regimens tested as countermeasures to date have 
generally not succeeded in maintaining muscle mass or strength (or bone mass) during 
spaceflight (828). On Mir flights, crewmembers differed significantly with respect to in-flight 
exercise frequency and intensity (related to such factors as mission requirements and personal 
habits). However, losses of leg muscle volume, detected immediately after flight by magnetic 
resonance imaging, were almost 20% in all subjects (829). Similar findings (wide variations in 
exercise, lack of difference in bone loss) have also been documented for bone loss (63). 
Many types of exercise protocols have been proposed to aid in the maintenance of both 
muscle and bone during flight (564, 683, 813, 830-839), but these have yet to be fully tested on 
orbit. Given that ISS crews use multiple exercise devices, studies ideally will look at exercise 
protocols that use more than 1 device. Combined resistance and aerobic exercise protocols have 
shown promise for protecting muscle (and the cardiovascular system) in bed rest (79, 840); 
spaceflight testing is underway. 
Whole-body vibration alone or superimposed on resistive exercise is a rather new concept 
and has received much attention recently in the hope that it can provide a viable musculoskeletal 
countermeasure, particularly when strenuous exercise might increase the risk for injury, for 
instance in older people (714, 841-847). However, the efficacy, vibration dose, frequency, and 
duration of whole-body vibration exercise needs still further research. As mentioned earlier, 
mechanical stimulation is a prerequisite to avoid muscle and bone degradation. According to the 
mechanostat theory by Frost (848, 849), to keep up muscle and bone mass and strength, a certain 
individual level of mechanical stimulation has to be achieved. Lowering or increasing that level 
leads to respective degradation or increase. For whole-body vibration training, the vibration 
magnitude seems to be one of the key factors. Vibration magnitude is vibration frequency (Hz) 
times the amplitude or displacement (mm) (845). This is most likely the reason why mere whole-
body vibration training to the musculoskeletal system with a frequency of 20 Hz has not always 
been demonstrated to be effective for muscle and bone (850). Superimposing whole-body 
vibration training on resistive exercise seemed to be more effective. This was done in 2 bed rest 
studies with durations of 56 and 60 days and young, healthy male subjects (844, 847). When 
whole-body vibration training was added to resistive exercise, it was able to attenuate muscle 
and bone atrophy and lumbar spine deconditioning, and to prevent fat accumulation in vertebral 
marrow (844, 851-854).  
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b. Pharmacological 
Testosterone has also been suggested as a muscle (and/or bone) loss countermeasure, on 
the basis of data from animal models (581, 727) and data documenting a reduction in 
testosterone concentrations during flight in humans, animals, and cellular models of spaceflight 
(728-734, 855). A potential confounding factor is the drop in testosterone that has been observed 
in exercising bed rest subjects (but not controls) (856).  
The first in-flight testosterone data from human spaceflight were from 4 astronauts on 
Space Shuttle mission STS-55, which flew in 1993, and from 3 astronauts on Skylab 4, an 84-
day mission (857). On the Shuttle mission, after 4 or 5 days of flight, circulating testosterone 
levels were decreased relative to preflight levels, when measured in serum, saliva, and urine. 
Serum cortisol, cortisol biorhythms, and dehydroepiandrosterone-sulfate concentrations in these 
4 astronauts were unchanged during flight (733, 858). A significant confounding issue is that 
these crewmembers were consuming only about 60-85% of their basal metabolic energy 
requirements during the flight (9). Estimates of spaceflight energy requirements typically use an 
activity factor of 1.7 (that is, 1.7  basal metabolic rate) (2). This factor is based on data 
documenting that total energy requirements are unchanged during flight (21), or in some cases 
are even increased with heavy exercise (22), relative to before flight. Even if lower estimates of 
activity were used, the result would reveal significant energy deficit in crewmembers on the 
STS-55 mission, especially during the days of sample collections (9). Indeed, energy intake, 
which was very carefully documented on these missions, was below even basal requirements. 
Energy deficits, both short-term and long-term, are associated with lower circulating testosterone 
(free and total) (859-861). Thus, the discrepancy between the long-duration data presented here 
and the earlier reports of effects observed during the first week of flight could be explained 
simply by inadequate energy intake. 
Recent data show that testosterone and related hormones are unchanged by real or 
simulated weightlessness (Figure 95), apart from transient effects on landing day (583).  
 
 
Figure 95. Total serum testosterone concentrations 
before, during, and after flight. Although circulating 
concentrations decreased significantly after flight (at 
R+0), no other time point differed significantly from 
the preflight mean. N=15. Data are from Smith et al 
(583). 
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The Skylab data include urinary testosterone from 3 crewmembers; at 2 in-flight data 
points, excretion was increased relative to the preflight period (583, 857). Plasma data from the 3 
Skylab missions (N=9) are reported to have “showed a trend toward lower values after the 
mission” (857). Although we do not have urinary testosterone data on all crewmembers, these 
reports from the 1970s confirm the findings from ISS (583). 
Bed rest analog data from a number of studies demonstrate that bed rest has no effect on 
circulating testosterone concentrations (582, 583, 812, 856, 862). Consistent decreases in serum 
testosterone were observed after the subjects had been in the bed rest facility for 7 days (while 
they were still ambulatory) and then another decrease occurred when testosterone was measured 
5 days after re-ambulation. The pre-bed rest change is likely related to stress and decreased 
ambulation while subjects were in the bed rest facility, and the post-bed rest change was 
probably related to body fluid shifts during and after bed rest. No changes in testosterone 
occurred during bed rest (583).  
Bed rest studies have generally shown no effect of bed rest on circulating total or free 
testosterone (582, 583, 812, 856, 862) in sedentary subjects. Bed rest subjects, in most models, 
are required to consume energy at a level to maintain body mass. If energy deficits are indeed 
part of the observed decrease in testosterone during the Shuttle flights previously reported, this 
may also explain the difference between those flight data and bed rest study data, reported herein 
and elsewhere. Although we showed an intermittent decrease in total and free testosterone in bed 
rest subjects with or without an artificial gravity (ie, centrifugation) protocol (356), this study 
had combined the 2 pre-bed rest collection sessions. When these sessions were analyzed 
separately because of our results in the later bed rest study, it turned out that testosterone 
concentrations were indeed higher only at the first data collection point (BR-10) than during or 
after bed rest (583) (Figure 96).  
 
 
Figure 96. Total serum testosterone concentrations in subjects before, during, and after bed rest 
with (dashed line and open circles) or without (solid line and filled squares) an artificial gravity 
countermeasure. These data have been published (356), although the pre-bed rest data were 
combined as an average in the original manuscript. In this figure, the 2 pre-bed rest data points 
are graphed separately, as reported in (583).  
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One criticism of sedentary bed rest studies as an analog for spaceflight is that astronauts 
are not sedentary, especially on long-duration missions, when they exercise extensively. Wade et 
al reported that bed rest subjects with intensive exercise protocols had lower non-fasting 
circulating plasma testosterone concentrations than non-exercising bed rested controls (856). In 
this 4-week study they reported a small loss of (non-fasting) post-breakfast body mass (856, 
863), and reported that caloric and liquid intakes were designed to maintain body mass. Despite 
the exercise, which was described as including an expenditure of 214 or 446 kcal/d (5 times a 
week), actual intakes in the exercise groups were only 155 or 212 kcal/d greater than those of the 
no-exercise group (863). 
In an earlier 30-day study, Zorbas et al showed that serum testosterone decreased during 
bed rest only in trained subjects, whereas it did not change in untrained subjects during bed rest 
(864). Interestingly, when conditioned subjects were “hyperhydrated” by saline ingestion during 
bed rest, testosterone did not change relative to the pre-bed rest period. In a shorter, 3-day bed 
rest, no differences in plasma testosterone were observed before or after exercise, in typically 
untrained or trained individuals, either cyclists or weight trainers (865). The astronauts in the 
study reported herein were relatively fit before flight and exercised heavily during flight, using 
treadmill, cycle, and resistive exercise devices. Clearly, the interrelationship of energy balance, 
exercise, stress response, and endocrine function warrants further evaluation to better understand 
the adaptive responses to spaceflight. 
As reviewed by Tou (866), in studies of rats with sample collections after spaceflight 
serum (867) and urinary (868) testosterone were generally decreased relative to the preflight 
period (869). Unfortunately, in-flight biological samples are typically not available, given the 
difficulties with collection procedures in the microgravity environment. These postflight 
conclusions are consistent with data reported on landing day after a short-duration spaceflight 
(583). In ground-based rodent models, short-duration (7-12 d) unloading generally results in 
reduced circulating testosterone concentrations and an associated loss of bone and muscle mass 
(581, 727, 870). Unloading of longer duration (6 wk) in rats resulted in impaired 
spermatogenesis, but had no effect on circulating testosterone concentrations (871). Similarly, 
the production of testosterone by rat testes after actual spaceflight is diminished, as is response to 
stimulation by luteinizing hormone (LH) (872). Contradicting these findings, another study 
showed no change in circulating testosterone in suspended rats after suspension for 1 or 3 weeks, 
but an increase in testosterone of suspended animals after 8 weeks, despite reduced testicular 
weight (873). One critical confounding factor in the hindlimb-suspended rat model is that not all 
studies take (surgical) precautions to prevent ascension of the testicles into the abdominal cavity, 
which can significantly affect testosterone production, and study interpretation. Some, but not 
all, studies have accounted for this, and this limitation contributes to inconsistencies in the 
literature. 
Rotating cell culture vessels have also been used as an analog of weightlessness, with 
some limitations, as with all analogs. Cultured testicular fragments exposed to this environment, 
compared with static 1g cultures, have maintained cellular architecture and have increased both 
proliferation and testosterone secretion (874), but with altered testicular physiology (875), 
including impaired Leydig cell responsiveness to LH stimulation. Whether the lack of change in 
circulating testosterone observed in the studies reported herein obscured alterations in testicular 
physiology is unclear, but it seems imprudent to make that leap without additional data. 
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Exogenous testosterone administration in humans during bed rest studies has maintained 
muscle mass and protein balance, but with no effect on muscle strength (582). Administration of 
testosterone in suspended rats mitigates muscle and bone losses (581). Although the bone data in 
rats are confounded by differential effects on growing and adult rats (876), these results are of 
interest nonetheless. Testosterone administration to elderly individuals has shown that the bone 
response to testosterone depended on the initial circulating testosterone concentrations (877). 
That is, those with normal testosterone had less or no response to testosterone administration. 
Given these data, there is little rationale for providing testosterone during flight to mitigate bone 
loss. 
Hypergravity, induced by centrifugation, has been shown to result in increased urinary 
testosterone excretion in monkeys (730), as well as in rats (868, 870). In a similar study, effects 
of hypergravity were found on tissues of rats and some endocrine variables, but increased 
gravitational force had no effect on circulating testosterone (867). On the basis of these data, 
authors have suggested that the response to gravity is roughly linear, from hypergravity 
(increased), to unit gravity, to microgravity (decreased) (730, 867). Intriguing as this concept 
may be, the data presented herein do not support it. 
As is understandable, the proposed use of exogenous steroids is somewhat controversial. 
Muscle physiologists argue that despite the lack of change in endogenous steroids, exogenous 
androgens may prove a viable countermeasure nonetheless. There are reports of these treatments 
improving physical performance, muscle mass, and muscle strength in both young athletes and 
older sedentary men (878). The interaction of endocrine factors, aging (including middle age), 
the spaceflight environment, and the use of exercise to replace loading is not well understood. 
In summary, testosterone and related hormones are unchanged by real or simulated 
weightlessness, apart from transient effects after flight. Nonetheless, as we contemplate space 
exploration beyond low Earth orbit, endocrine data will be critical for understanding human 
adaptation in this unique environment, and potentially for helping to counteract the negative 
effects of spaceflight on the human body. 
 
c. Nutritional 
Use of protein and amino acid supplementation has long been studied as a potential 
means to mitigate muscle loss associated with spaceflight (79, 108, 825, 879-883), but results 
have been inconclusive at best. Oral doses of branched-chain amino acids had little effect on leg-
muscle protein kinetics in ambulatory male subjects (884), whereas feeding a bed rest group 
adequate energy with excess protein reversed nitrogen losses (814). However, feeding Skylab 
crewmen energy and protein equivalent to those given to the bed rest group did not prevent 
negative nitrogen balance and loss of leg muscle strength during flight (94, 95, 792). In another 
bed rest study, a leucine-enriched, high-protein diet failed to mitigate muscle loss, and at some 
sites exacerbated loss (881). It remains unclear whether nutritional measures beyond the 
consumption of adequate energy and protein would be beneficial in reducing muscle atrophy.  
In a 2011 review, Stein and Blanc evaluated the literature from bed rest studies (885), and 
found that the effect (or lack thereof) of amino acids on muscle depended greatly on protein 
intake and energy provision. Specifically, if nominal protein intake (in both treatment and 
control groups) was at levels greater than 1.1 to 1.2 g protein/kg body mass/d, then supplemental 
amino acids had no effect. If control subjects were provided with ≤0.8 g protein/kg body mass/d 
while the supplemented group consumed >1.0 g protein/kg body mass/d, then the supplement 
appeared to have an effect. If further research is conducted in this area, the issue of study design, 
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with particular reference to protein and energy intake of all groups, needs to be carefully 
assessed. The bottom line seems to be that if crewmembers consume enough protein and energy, 
then supplemental amino acids (or other variants of protein supplementation) provide no benefit 
(and as reviewed in the next subsection, “Nutrients and Muscle Health,” they may actually be 
detrimental). Thus, the primary countermeasure against muscle loss remains adequate energy 
intake, which will no doubt include protein, but protein supplements are not required. In fact, 
protein can have negative implications for other systems, bone in particular. 
 
3. Nutrients and Muscle Health 
 
Protein  
 
 Debate continues between nutritionists and exercise physiologists on the 
importance and benefit of protein intake, amount and type of protein intake, and even timing of 
protein intake on muscle. The risks associated with protein intake come from deficiency or 
excess. Deficiency of protein leads to muscle loss, weakness, wasting, tissue breakdown, 
inability to perform the job (including getting out of the spacecraft), and ultimately death. Low-
protein diets can have negative consequences for bone (85, 886-888). Excess protein exacerbates 
increased excretion of calcium and the risk of renal stone formation, and is detrimental to bone. 
Specific amino acids may additionally increase these risks. 
It is our contention that studies of the effect of protein intake on muscle are often too 
short-term (if not simply a single bout of exercise) to allow an understanding of long-term effects 
and adaptation, and are often not completely controlled with respect to treatment groups. Protein 
(or amino acids) provides not only a nitrogen source, but moreover an energy source. Studies 
often compare protein consumption with fasting, without evaluating whether a balanced meal 
would offer similar benefit. The summary above, of amino acid supplementation during bed rest, 
certainly gives reason for concern to studies of protein and exercise, with or without bed rest. 
Thus, fully balanced, long-term studies are required in order to conclusively define the effect of 
protein intake and its timing on muscle. Unfortunately, these studies require multiple treatment 
groups, which drives study costs to levels that are typically not available. We will not review this 
field of literature here, but we refer interested readers to the Muscle Spaceflight Evidence Book. 
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XI. N7.2: We need to identify the most important nutritional factors for cardiovascular 
health. 
 
 Cardiovascular issues are a key concern for space travelers (889-895), but the role of 
nutrition in cardiovascular adaptation has not (yet) been well characterized. In a few areas there 
is some degree of evidence (described below), but many more have yet to be examined. It is 
worth noting that multiple studies are being planned or are underway on ISS and in bed rest 
models that may help shed light on this area in the near future.  
 
A. Energy 
 Cardiovascular deconditioning and loss of plasma volume are negatively correlated with 
energy consumption during bed rest (72) and after spaceflight (Figure 97). That is, insufficient 
energy intake is associated with greater plasma volume loss and cardiovascular deconditioning. 
The spaceflight data came from the work of Dr. William Carpentier, who evaluated crewmember 
medical records from the Mercury, Gemini, and Apollo programs. These data have yet to be 
published in the scientific literature, but a book in which they are compiled is in final 
development, and these have also been included in recent nutrition reports (6). 
 Dr. Carpentier’s data from astronauts in the early U.S. space programs have been integrated 
and modeled to predict postflight heart rate response to lower body negative pressure (LBNP), 
standing, and tilt from factors including flight duration, plasma volume loss or energy intake, and 
preflight resting heart rate. The plots in Figure 97 and Figure 98 are based on Gemini and Apollo 
mission data. Combined with the data presented in Figure 99, these data clearly link energy 
intake and plasma volume loss with cardiovascular health during and after spaceflight. 
 
 
Figure 97. Relationship between energy intake 
(kcal/kg body mass/d) and plasma volume loss 
(mL/d) during Apollo missions. N=21. Data are 
courtesy of William Carpentier (6). 
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Figure 98. Postflight heart rate under 3 conditions, predicted (from factors including plasma 
volume loss) versus actual measured heart rate. These data are based on the following equations:  
LBNP: 29.00 – (0.064 x flight duration) + (1.45 x resting preflight heart rate) + (4.2553 x plasma 
volume loss, mL/h flight)  
Standing: 77.23 – (0.52 x flight duration) + (1.9098 x preflight resting heart rate) + (17.4758 x 
plasma volume loss, mL/h flight))  
Tilt: 330 – (2.53 x preflight resting heart rate) – (7.20 x plasma volume loss, mL/h flight)) – 
(0.078 x flight duration, h) 
Heart rates for LBNP and tilt were those recorded at LBNP = -50 mm Hg and at 70° tilt. For the 
stand test, crewmembers stood relaxed against a wall with their heels 6 inches away from the 
wall. Data are courtesy of William Carpentier (6). 
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Figure 99. Postflight heart rate, predicted (from factors including energy intake) versus actual 
measured heart rate. These data are based on the following equations: 
LBNP: 63.02 + (1.18 x preflight resting heart rate) + (0.48 x energy intake, kcal/d/kg) – (0.17 x flight 
duration) 
Standing: 115.87 + (1.12 x preflight resting heart rate) - (2.17 x energy intake, kcal/d/kg) – (0.17 x 
flight duration)  
Tilt: 239.48 – (0.75 x preflight resting heart rate) – (1.86 x energy intake, kcal/d/kg) – (0.052 x flight 
duration) 
 
 
 Similar findings relating energy intake and cardiovascular deficits were obtained from bed 
rest studies led by Dr Martina Heer to evaluate the effects of hypocaloric diets on many 
physiological systems (70, 821). The cardiovascular data showed that caloric restriction during 
bed rest led to decrements in cardiovascular physiology (specifically, performance on a stand 
test), exceeding the decrements that occurred during bed rest when subjects received adequate 
calories (unpublished results). 
 One piece of the spaceflight puzzle that is still missing is the effect of flight duration. That is, 
the data presented in Figure 97, Figure 98, and Figure 99 were generated from short-term flights, 
and this relationship may change on longer ISS missions. Given the inference from Figure 97 
that energy intake should be greater than 33 kcal/kg body mass to avoid plasma volume loss, we 
evaluated ISS intake data (Figure 100) and found that few crewmembers are meeting this 
threshold.  
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Figure 100. Energy intake during spaceflight on ISS missions 
(N=56). Each point represents an individual crewmember, 
and is their reported average daily energy intake over the 
course of the mission. Lines represent the mean ± 1SD (6). 
 
 
 
 
 
 
B. Magnesium 
 As mentioned in other sections, magnesium has benefits for metabolism of bone and calcium 
and for reduction of renal stone risk. In addition, magnesium has been shown to have effects on 
the cardiovascular system (896-898). Consistently decreased magnesium excretion after flight is 
a concern for many reasons (6), and warrants further investigation with respect to cardiovascular 
deconditioning during and after flight. 
 
 
C. Ongoing and Future Research 
1. Oxidative Stress 
 The role of oxidative stress and antioxidants in cardiovascular adaptation to spaceflight is 
currently being studied on ISS. Despite the facts that several oxidative stressors (eg, radiation, 
extravehicular activity, iron stores, exercise) could affect astronauts during flight, abundant 
evidence exists that oxidative stress occurs during spaceflight (reviewed later), and a wealth of 
literature exists about oxidative stress causing damage to the cardiovascular system, these three 
areas have never been evaluated. A study initiated on ISS in 2013 aims to accomplish the goal of 
evaluating oxidative damage during flight, as well as evaluating long-term effects after flight. 
 The findings from these studies may have significant implications for future missions. As 
described later in this book, oxidative stress is a multifaceted issue that affects many systems, 
and given the radiation concerns of exploration-class missions, it will draw greater attention in 
the future. 
 
2. Omega-3 Fatty Acids 
 While omega-3 fatty acids have a clear beneficial impact on cardiovascular health on Earth, 
such effects have not been evaluated during flight. Nonetheless, the initial efforts being made to 
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increase fish and omega-3 fatty acid intake in astronauts for the benefit of other systems (bone, 
muscle) will likely have positive effects here as well.  
 
3. Healthier Diets 
 Although it is easier to study individual nutrients in a controlled, experimental fashion, the 
effect of overall dietary quality is a topic that continues to gain ground, particularly as individual 
supplement studies fail to produce the “magic” supplement. Overall dietary quality, including 
fruit and vegetable intake, fish (omega-3 and vitamin D) intake, and food rich in phytochemicals 
and lower in sodium all combine to provide broad health effects (647, 748-750, 899, 900). Many 
of these converge on the cardiovascular system, along with benefits for bone, muscle, kidney, 
and other systems. 
 In 2014, NASA embarked on an effort to provide healthier food options for astronauts on ISS 
missions. As of this writing, the exact implementation of this effort is still in question, but the 
authors remain optimistic.  While decreased bone loss is expected to be a primary outcome of the 
effort, it is clear that providing healthier food will have implications for many other 
physiological systems (eg, cardiovascular, muscle, immune) and other risks of spaceflight (e.g., 
radiation and oxidative stress), not to mention potential benefits for crew performance and 
morale.  
 One specific objective of this effort was to increase fruit and vegetable intake.  Population-
based and even smaller controlled studies have shown extensive benefits from inclusion in the 
diet of 5 or 6 servings of fruits and vegetables per day (737). Higher fruit and vegetable intakes 
have been associated with prevention of chronic diseases, including cardiovascular disease (748-
750, 901) and cancer (748, 749). 
 The outcome of the effort to provide healthier foods for astronauts will provide a solid 
backdrop for the definition of food system and nutrient requirements for exploration missions, 
and may also have significant implications for understanding the role of nutrition in disease 
prevention here on Earth.  
Risk Factor of Inadequate Nutrition 
 
 168
 
XII. N7.3: We need to identify the most important nutritional factors for ophthalmic 
health. 
 
A. Overview 
 
 An initial ophthalmic concern for space travelers is cataract risk. While this risk is higher in 
astronauts (believed to be related to oxidative stress, as described earlier), benefits of dietary 
measures to prevent cataracts have been shown in the general population.  Along with a recent 
attempt to fly healthier foods for astronauts, a key goal has been increasing fruit and vegetable 
intake by astronauts. Cataract risk has been shown to be lower in vegetarians (902), 
strengthening this call for more fruits and vegetables in the space diet. Vegetarianism is not the 
answer in and of itself, as nutrient risks are associated with this as well.  With regard to bone, 
one study did not find a relationship between bone health and vegetarianism, and this was 
believed to be due to insufficient calcium intake in this group (903). Protein, iron, and vitamin 
B12 are also common concerns for those following strict vegetarian diets. 
Ophthalmic health among astronauts has gotten attention in recent years because of a newly 
identified issue for some crewmembers. In addition to a general increase in cataract risk (271, 
272, 274), some crewmembers have experienced vision-related changes after long-duration 
spaceflight. These changes include optic disc edema, globe flattening, hyperopic shifts, choroidal 
folds, and cotton wool spots (560). The etiology of the refractive and structural ophthalmic 
changes is currently not known and continues to be researched, but biochemical evidence 
indicates that the folate- and vitamin B12-dependent 1-carbon transfer pathway may be involved. 
Nutrition is known to be an important factor for ophthalmic health in general. This section will 
review the available literature on this topic and general nutrition in ophthalmic health, along with 
ongoing research to understand and counteract these effects of spaceflight.  
 
B. Ophthalmic Changes 
 
Mader and colleagues first described 7 cases among long-duration crewmembers on ISS 
who had evidence of ophthalmic changes after flight, including optic disc edema, globe 
flattening, choroidal folds, and hyperopic shifts (560). Since that first report was published, 
additional cases have been identified, with the prevalence approaching 20% to 30% of 
crewmembers. Myasnikov and Stepanova reported evidence of postflight edema of the optic 
nerve discs among Russian cosmonauts and 1 case (out of 10) with signs of intracranial 
hypertension, although they note the measurements were made before and after (not during) 
flight (904). The mechanism of the ophthalmic changes is not known, but microgravity-induced 
fluid shifts (2, 158), elevated exposure to CO2 in the spacecraft cabin, possible intraocular 
pressure or intracranial pressure changes, and local intraorbital (choroidal and optic nerve 
sheath) changes have been suggested as possible contributing factors. It is not clear why some 
crewmembers on some missions may experience these issues and others on the same mission, 
exposed to the same environment, do not. Recent biochemical evidence that the folate- and 
vitamin B12-dependent 1-carbon transfer pathway may be involved could help explain individual 
susceptibility to these ophthalmic changes. 
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C. One-Carbon Metabolism 
 
 One-carbon metabolism refers to a pathway that requires folate, vitamin B12, and vitamin 
B6, and is involved in purine and pyrimidine synthesis, amino acid metabolism, and synthesis of 
the methylating agent S-adenosylmethionine (SAM, Figure 101). Alterations in this pathway can 
lead to buildup of certain intermediates, including homocysteine. Factors such as genetic 
polymorphisms, pharmacological agents, and dietary intake and status of folate, vitamin B6, and 
vitamin B12 can influence plasma homocysteine concentration (905, 906). 
 
 Much of the homocysteine literature has focused on its association with coronary artery 
disease, stroke, and migraines (905, 907, 908), but some studies show associations of 
homocysteine with ophthalmic health issues. Ophthalmic issues such as age-related macular 
degeneration result from lipid deposits under the retinal pigment epithelium (909) and decreased 
retinal vessel functionality (910), and some theorize that age-related macular degeneration is 
similar to the development of cardiovascular disease (911). Because homocysteine is a risk factor 
for cardiovascular disease, many have looked at relationships between homocysteine, or other 
metabolites and vitamins in the 1-carbon metabolism pathway, and ophthalmic health issues such 
as age-related macular degeneration, dry eye, glaucoma, and optic neuropathy (389-391, 912). 
For instance, a meta-analysis showed that elevated plasma homocysteine was associated with an 
increased risk of primary open-angle glaucoma (913). Other meta-analyses have shown that 
increased serum homocysteine and low vitamin B12 status were independently associated with 
increased risk for age-related macular degeneration (391, 914). Daily supplementation with 
folate, vitamin B6, and vitamin B12 is associated with a 30% to 40% decreased risk for age-
related macular degeneration (915).  
 
B6 SAM HC
Y
SHMT 
MTRR 
SA
H
Methionine 
CYS 
5-MTHF 
THF 
5,10-MTHF 
MTHFR 
Serine 
Glycine 
Dietary folate 
MS 
B12 
B6 
CBS 
Acceptor (DNA, 
neurotransmitters, 
phosphatidylcholine,…) 
Methylated Acceptor 
Dietary protein  Muscle 
catabolism 
α-KBT 
PRP-CoA 
D-MM-
CoA
MMA 
2MCA 
L-MM-
SUC-CoA 
B12 
Biotin 
AA, 
FA
Risk Factor of Inadequate Nutrition 
 
 170
 
Figure 101. Overview of 1-carbon metabolism. AA, amino acids; CBS, cystathionine β-synthase; 
CYS, cystathionine; FA, fatty acids; HCY, homocysteine; αKBT, α-ketobutyrate; MCA, 
methylcitric acid; MM-CoA, methylmalonyl coenzyme A (CoA); MMA, methylmalonic acid; 
MS, methionine synthase; 5-MTHF, 5-methyltetrahydrofolate; 5,10-MTHF, 5,10-
methylenetetrahydrofolate; MTHFR, methylenetetrahydrofolate reductase; MTRR, 5-
methyltetrahydrofolate homocysteine methyltransferase reductase; PRP-CoA, propionyl CoA; 
SAH, S-adenosylhomocysteine; SAM,S-adenosylmethionine; SUC-CoA, succinyl CoA; THF, 
tetrahydrofolate 
 
 
 
 
 
 
Figure 102. Artistic depiction of the vision issues related to spaceflight, and the potential for 
genetic influences on the understanding of this problem. The depiction of a different DNA base 
pair in the 2 strands reflects genetic polymorphisms, or multiple forms, of the DNA. Inset 
imagery includes ISS, and a Hubble Space Telescope image of the Cat’s Eye Nebula, to reflect 
that these issues are relevant not only for ISS missions, but for exploration-class missions as well. 
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XIII. N7.4: We need to identify the most important nutritional factors for behavior and 
performance. 
 
Note: Alexandra Whitmire of the Behavioral Health and Performance Element of the Human 
Research Program contributed to this section, and we greatly appreciate her help. 
 
A. Overview 
 
 The Behavioral Health and Performance Element (BHP) is one of the 6 elements in the 
NASA Human Research Program.  BHP manages and implements a research portfolio to 
characterize and mitigate 3 specific risks for exploration-class missions and, in some instances, 
current Flight Medical Operations. Two of these risks—the risk of performance decrements and 
adverse health outcomes resulting from sleep loss, circadian desynchronization, and work 
overload, and the risk of adverse behavioral conditions and psychiatric disorders—are relevant to 
the question of nutrition of the crew during spaceflight. The primary outcomes of interest to BHP 
that are addressed here are fatigue, cognition, and mood and morale.  
Although it is one of the more difficult areas to quantify, the interrelationship of food and 
nutrition with crew behavior and performance is undeniable. Anecdotal evidence from long-
duration stays in extreme environments (such as Antarctica) indicates that as mission durations 
increase, food will play a stronger role in maintaining mood and morale. Non-space studies have 
reported on the relationships between dietary choices and psychological well-being, but this 
literature is relatively sparse as well, as nicely reviewed by Blanchflower et al (916). It is worth 
noting that psychological well-being is not just the absence of the negative, but also the presence 
of positive characteristics. These can include a sense of autonomy, competence and mastery, 
positive relations, and satisfaction with life and work.  From our perspective, food and nutrition 
can have either positive or negative effects on psychological well-being. Furthermore, a 
comprehensive review of the role of specific nutrients in cognition was published by Gomez-
Pinilla (917), and several examples from that review are highlighted herein. 
 
 
 
1. Energy 
 
Inadequate energy intake is associated with fatigue and other indices of behavior and 
performance. Ramadan fasting, during which food is not consumed for about 13 hours each day 
for 30 days, resulted in altered sleep patterns, perceived fatigue, and reduced exercise 
performance, along with metabolic, endocrine, and inflammatory alterations (918). These effects 
occurred despite the fact that energy intake during Ramadan was estimated to be more than 90% 
of pre-Ramadan intakes (2385 ±134 kcal/d on day 21, compared to 2596±133 kcal/d on day 0) 
(918).  
Biochemical evidence helps link energy intake with brain function. Signaling molecules 
in the brain link energy metabolism to synaptic processes, and one such molecule is brain-
derived neurotrophic factor (BDNF) (Figure 103).  It is found in the hippocampus and 
hypothalamus. BDNF has been shown to influence many aspects of energy metabolism, 
including appetite suppression, insulin sensitivity, and glucose and lipid metabolism (917).  
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Figure 103. This figure shows 
how diet and exercise can 
ultimately affect cognitive 
function through BDNF, a 
signaling molecule that can alter 
synaptic plasticity.  (Figure is 
from (917).) 
 
 
In addition to energy consumption, meal times and nutrient content can also affect 
performance, cognitive function, and mood and morale (919-921). Evidence indicates that meal 
timing in particular can affect the phase of the circadian rhythm, and changes in circadian phase 
can moderate the food and performance relationship. Experimental evidence has now emerged 
on the location of at least one food-entrainable oscillator—there may be several—and suggests 
that the oscillator “gene” may be “induced” by fasting and refeeding (922). 
 
 
 
2. Fruits and Vegetables 
 
Recent attempts to improve provision of healthier foods for ISS crews had the objective of 
in-flight consumption of 6 servings of fruits and vegetables per day. A study with this objective 
was predicated on mitigating bone loss, and this specific aim was based on results from several 
studies showing that greater fruit and vegetable intake is associated with higher bone mineral 
density (656, 738, 740, 745, 923).   
While greater fruit and vegetable intake of the general population has been advocated for 
some time now, the premise behind this advocacy has typically been linked to physical health as 
opposed to psychological well-being (916). Nonetheless, epidemiological studies have 
established a somewhat tenuous link between psychological well-being and fruit and vegetable 
intake, as reviewed by Rooney (924). Two recent large (close to 15,000 participants in each) 
surveys in the UK found positive associations between fruit and vegetable intake and well-being 
(925, 926). Others have shown that diets rich in vegetables, fruit, meat, fish, and whole grains are 
associated with lower odds for major depression or dysthymia, whereas “western” diets rich in 
sugar and processed foods were more likely to be associated with behavioral disorders (927). 
Supporting that concept are the results of animal studies that evaluated effects of “junk food” 
high in saturated fat and sugar; researchers found that after only 3 weeks on this type of diet, 
animals showed a decline in cognitive performance and reduced hippocampal levels of synaptic 
plasticity related to BDNF (928). 
Anecdotal evidence from spaceflight demonstrates the salience of food to crewmembers 
during their stay on the ISS. Stuster provides an analysis of 10 astronaut journals maintained 
during their 4- to 6-month missions in space (929). “Food” was the tenth most commonly 
“journaled” category. Within this category, references to the onboard supply of meal items 
composed the most frequently reported subcategory, and most references in this subcategory 
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were written in response to running low on supplies during a few of the increments. As noted by 
Stuster, all of the participants described disappointment over the depletion of favored food and 
drink items, and many wrote about the joy of finding an item that had been believed to be gone. 
Relevant testimonials from Stuster (929) include these: 
 
 We are getting tired of eating chicken all the time, but it will be OK. 
 The good news is that we have good food on board now. It makes such a huge 
difference in mental attitude. We should be fit and ready for the EVA. 
 We actually have a pretty wide assortment of food and it’s not bad at all. One of my 
concerns was being able to put up with the food for six months. Although it’s not 
quite home cooking, the folks in the food laboratories in Houston and in Moscow 
have done a pretty good job on the menu, providing us a wide assortment of quality 
food and drinks.  
 I really do wish for more American type breakfast food. The Russians eat a lot of 
cheese stuff, some of it quite good. I enjoy most of their food and am even trying 
new things that I didn’t care for previously. I hope it doesn’t get too “old” after 
several months! 
 I discovered extra main course rations in my bonus containers, so we enjoyed a 
dinner of ____ and were very happy. It is amazing how this seemingly small thing 
made our evening. On the ground, this food would not be considered particularly 
appetizing. However, take it away from us and it seems like the most delicious food 
in the world. 
 The food is getting somewhat old to us. On paper we have quite a variety and it is 
not too bad actually, but I think it is starting to all look and taste the same. Perhaps 
we are just tired of eating out of a can or wrapper. 
 
 
3. Specific Nutrients 
 
In several studies, investigators have evaluated interrelationships between nutrients and 
aspects of behavior and performance. These are briefly summarized in Table 1, which is adapted 
(and expanded) from Gomez-Panilla (917). 
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Table 1 Select nutrients that affect cognitive function (adapted from (917)). 
Nutrient Effects on cognitive function and psychological health Food sources 
Omega-3 fatty 
acids 
Increased intake associated with improved cognitive 
performance in healthy adults (930).  Amelioration of 
cognitive decline in the elderly (931); basis for treatment 
in patients with mood disorders (932); improvement of 
cognition in traumatic brain injury in rodents (933); 
amelioration of cognitive decay in mouse model of 
Alzheimer’s disease (934, 935). More controlled studies 
required to help resolve inconsistencies in the literature 
(936). 
Fish (salmon), 
flax seeds, krill, 
chia, kiwi fruit, 
butternuts, 
walnuts 
Curcumin Amelioration of cognitive decay in mouse model of 
Alzheimer’s disease (937); amelioration of cognitive 
decay in traumatic brain injury in rodents (938). 
Turmeric (curry 
spice) 
Flavonoids Cognitive enhancement in combination with exercise in 
rodents (939); improvement of cognitive function in the 
elderly (940). 
Cocoa, green tea, 
ginkgo tree, 
citrus fruits, 
wine (higher in 
red wine), dark 
chocolate 
Saturated fat Promotion of cognitive decline in adult rodents (928); 
aggravation of cognitive impairment after brain trauma in 
rodents (941); exacerbation of cognitive decline in aging 
humans (942). 
Butter, ghee, 
suet, lard, 
coconut oil, 
cottonseed oil, 
palm kernel oil, 
dairy products 
(cream, cheese), 
meat 
B vitamins B6 and B12 status related to increased incidence of 
depression and impaired cognition (943). Supplementation 
with vitamin B6, vitamin B12, or folate has positive effects 
on memory performance in women of various ages (944, 
945); vitamin B12 improves cognitive impairment in rats 
fed a choline-deficient diet (946). Combined B-vitamin 
(folate, B12, B6) supplementation enhances cognitive 
performance (947) and memory (944, 948). Nonetheless, 
more controlled studies required to help resolve 
inconsistencies in the literature (949). 
Various natural 
sources. Vitamin 
B12 is not 
available from 
plant products 
Vitamin D Important for preserving cognition in the elderly (950), 
although more controlled studies required to help resolve 
inconsistencies in the literature (951) (952). 
Fish liver, fatty 
fish, mushrooms, 
fortified 
products, milk, 
soy milk, cereal 
grains 
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Nutrient Effects on cognitive function and psychological health Food sources 
Vitamin E Amelioration of cognitive impairment after brain trauma 
in rodents (953); reduction of cognitive decay in the 
elderly (954). 
Asparagus, 
avocado, nuts, 
peanuts, olives, 
red palm oil, 
seeds, spinach, 
vegetable oils, 
wheat germ 
Choline Reduction of seizure-induced memory impairment in 
rodents (955); a review of the literature reveals evidence 
for a causal relationship between dietary choline and 
cognition in humans and rats (956). 
Egg yolks, soy, 
beef, chicken, 
veal, turkey 
liver, lettuce 
Combination of 
vitamins (C, E, 
carotene) 
Antioxidant vitamin intake delays cognitive decline in the 
elderly (957). 
Vitamin C: citrus 
fruits, several 
plants and 
vegetables, calf 
and beef liver. 
Vitamin E: see 
above 
Calcium, zinc, 
selenium 
High serum calcium is associated with faster cognitive 
decline in the elderly (958); reduction of zinc in diet helps 
to reduce cognitive decay in the elderly; lifelong low 
selenium level associated with lower cognitive function 
and depressive symptoms in humans (959, 960). 
Calcium: milk, 
coral. Zinc: 
oysters, a small 
amount in beans, 
nuts, almonds, 
whole grains, 
sunflower seeds. 
Selenium: nuts, 
cereals, meat, 
fish, eggs 
Copper Cognitive decline in patients with Alzheimer’s disease 
correlates with low plasma concentrations of copper (961). 
Oysters, 
beef/lamb liver, 
Brazil nuts, 
blackstrap 
molasses, cocoa, 
black pepper 
Iron Iron treatment normalizes cognitive function in young 
women (962). 
Red meat, fish, 
poultry, lentils, 
beans 
Glycemic load Consumption of a high glycemic diet is associated with 
lower cognitive performance (963). 
Sugar, processed 
grains 
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B. Summary 
 
Although a fair amount of literature is available that pertains to food and nutrient effects on 
aspects of cognition, behavioral health, and performance, virtually none of it pertains to 
spaceflight.  This is clearly an area where additional research is needed. Also, more integrative 
efforts are needed, in research on the ground and in spaceflight, to better understand the effects 
on food, hormones, stress response, sleep loss/circadian desynchrony, and exercise on 
behavioral, immunologic, cardiovascular, reproductive health, skeletal/muscle, and on 
sensorimotor responses. 
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XIV. N7.5: We need to identify the most important nutritional factors for immune health 
 
 
A. Overview 
 
Optimal function of the immune system is impaired in the presence of malnutrition (964). 
Without adequate nutrition, the immune system is clearly deprived of the components needed to 
generate an effective immune response (965, 966). Nutrients act as antioxidants and as cofactors 
(967). Historically, during spaceflight crews generally have lower dietary intake than they do 
under normal conditions on the ground (2). It is well known from ground research that a lack of 
macronutrients or selected micronutrients, like zinc, selenium, and the antioxidant vitamins, can 
have profound effects on immune function (968-971). Such a lack of nutrients also leads to 
deregulation of the balanced host response (972). Disruption of nutritional balance and dietary 
intake of astronauts and cosmonauts during spaceflight, which is often accompanied by a stress 
response, might influence their immune response (973, 974). However, detailed information on 
the effects of many micronutrients during spaceflight, especially their relationship to immune 
system function, is mandatory before specific nutritional recommendations can be made. 
We review in this section nutrients and their relationship to immune system function, even 
though some have been reviewed in detail earlier, and others will follow. 
 
 
B. Energy Intake 
As discussed earlier, some crewmembers have an insufficient energy intake, which can lead 
to more extensive free radical propagation because of diminished protein-based antioxidant 
defense mechanisms (2, 326). On the Mir station and the Life and Microgravity Science Shuttle 
mission, space travelers consumed inadequate energy intake and had significant increases in 
urinary excretion of 8-iso-prostaglandin-F2 and 8-oxo-7,8-dihydro-2 deoxyguanosine (8-OH-
dG), markers for oxidative damage (327). 
 
 
C. Protein and Amino Acids 
Stein et al suggest that spaceflight triggers a stress response similar to injury-induced stress 
(975). Protein and amino acid deficiencies can have profound effects on a variety of immune 
system functions (976, 977). With respect to specific amino acids, arginine is necessary for 
normal T-cell function and may become essential in catabolic states. In animal studies, 
supplementary dietary arginine has been shown to have useful effects on cellular immunity, 
including increased size of the thymus, enhanced lymphocyte proliferation in response to 
mitogen and alloantigen, augmented macrophage and killer cell lysis, and increased lymphocyte 
interleukin 2 production and receptor activity (978). Supplementation of arginine led to 
improved wound healing and immune responses in elderly subjects (979). Judging by these 
observations it might seem promising to supplement arginine during long-term missions; 
however, up to now no studies have been carried out to test arginine as a measure to improve 
immune response during spaceflight. 
Another amino acid beneficial for the immune system is glutamine. Glutamine is the most 
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abundant free amino acid in the body. It can inhibit activation of the NF-кB nuclear transcription 
factor and cytokine expression after sepsis (980). Some of the beneficial effects of glutamine are 
its antioxidant effects and its actions as a precursor to glutathione, an energy substrate for 
lymphocytes and neutrophils, and a stimulator of nucleotide synthesis (981, 982). Glutamine 
seems to have a significant beneficial effect on mortality, length of hospital stay, and infectious 
morbidity in critical illness (981). Positive results of glutamine supplementation have been 
shown in critically ill patients in whom supplemental glutamine reduced complications and 
mortality rates as well as stimulating actions on the immune system (983, 984). However, up to 
now supplementation of glutamine as a pharmaconutrient has not been tested in spaceflight or 
spaceflight analogs such as bed rest. 
 
 
D. Vitamin D 
As already described in previous chapters, the classical function of vitamin D is to regulate 
calcium homeostasis and thus bone formation and resorption. However, recent publications show 
that vitamin D also has other biological activities including immunomodulation. The latter seems 
to be mediated by the (nuclear) vitamin D receptor (VDR) expressed in antigen-presenting cells 
and activated T cells (985). Vitamin D and the VDR are required for the blood to have normal 
numbers of regulatory T cells. The discovery that VDR is inducible in lymphocytes suggests a 
role for 1,25(OH)2D3 in the immune system (986). Even the enzyme 25(OH)D3-1-α-hydroxylase 
is expressed by active macrophages, making them able to synthesize and secrete 1,25(OH)2D3 
(987). However, in macrophages the enzyme is mainly activated by immune signals such as 
interferon (IFN)-γ rather than by parathyroid hormone, which is the activator in the kidney (985). 
Moreover, the active vitamin D metabolite 1,25(OH)2D3 can also be modulated by alternative 
mechanisms to increase the ability of peripheral blood mononuclear cells from sensitized human 
donors to resist microbes (here mycobacteria). Martineau et al found that 1,25(OH)2D3 
suppressed both bacillus Calmette-Guérin and Mycobacterium tuberculosis in infected cell 
cultures, likely through “nonclassical” mechanisms including the induction of antimicrobial 
peptides (988, 989). Kondo et al found that vitamin D supplementation improved the sensitivity 
of the treatment response to pegylated interferon α/ribavirin therapy in chronic hepatitis C 
patients (990).  
Studies during or after spaceflight have shown numerous changes in astronauts’ immune 
status, including altered distribution of circulating leukocytes, altered production of cytokines, 
decreased activity of natural killer cells, decreased function of granulocytes, decreased activation 
of T cells, altered levels of immunoglobulins, reactivation of latent viruses, altered virus-specific 
immunity, expression of Epstein-Barr virus immediate early and late genes, and altered 
neuroendocrine responses (991). Furthermore, evidence exists that among individuals wintering 
over in the Antarctic for 6 months, who have high serum cortisol, a higher vitamin D status is 
related to a lower probability of viral shedding in saliva (312). In that study an interactive effect 
occurred between cortisol and vitamin D, and subjects with lower serum 25-hydroxyvitamin D 
and with the highest quartile of serum cortisol (22.5 µg/dL or higher) had more evidence for 
shedding of Epstein-Barr virus (EBV) in saliva than did individuals in the lowest quartile of 
cortisol (13.1 µg/dL or below, Figure 104). Thus, a low vitamin D status of astronauts during 
space missions might have an impact on their immune status. Further studies are mandatory to 
distinguish between the effects of vitamin D deficiency and mere microgravity effects. 
 
Risk Factor of Inadequate Nutrition 
 
 179
 
 
 
Figure 104. An interaction between 
serum cortisol, vitamin D status, and the 
probability of EBV shedding. Data from 
all 41 participants in the Antarctic study 
are included in the graph, and the data 
were statistically analyzed using the 
continuous data set of cortisol data. The 
data are split into the 2 subgroups here 
for presentation purposes. The graph is 
from Zwart et al (312). 
 
 
 
 
 
E. Vitamin B12 
Vitamin B12 functions in many enzymatic reactions, and deficiencies result in anemia, as well 
as neurological disorders. Vitamin B12 functions as a coenzyme in 2 metabolic forms: 
adenosylcobalamin and methylcobalamin. Vitamin B12 works as a cofactor for 3 different 
enzymatic reactions: (1) the conversion of homocysteine to methionine, (2) the conversion of L-
methylmalonyl-coenzyme A (CoA) to succinyl-CoA, and (3) the isomerization of L-leucine and 
β-leucine. Vitamin B12 deficiency may cause the accumulation of folate in the serum because of 
a reduction in B12-dependent methyltransferase, also known as the methyl-folate trap (386). 
Vitamin B12 also functions in the synthesis of choline, which can be converted to the 
neurotransmitter acetylcholine. Vitamin B12 deficiency may lead to alterations of immunological 
indicators, such as a reduction of lymphocytes and suppressed natural killer (NK) cell activity, 
both of which can be reversed by supplementation with vitamin B12 (992). In one study, for 4 
months elderly subjects (aged 70 years) received, in addition to their regular diet, a special 
nutritional formula providing, among other nutrients, 120 IU vitamin E, 3.8 mg vitamin B12, and 
400 mg folic acid. NK-cell cytotoxic activity increased in supplemented subjects, indicating 
increased innate immunity in elderly people (993). These few studies demonstrate the 
importance of a sufficient B-vitamin status to maintain an adequate immune response (994). 
 
 
 
F. Sodium 
High sodium intake is correlated with development of hypertension in sodium-sensitive 
people. We have shown in spaceflight as well as in ambulatory conditions on Earth that at an 
intake level of about 4000 mg/d, sodium is retained without being accompanied by fluid 
retention (40, 173, 995). A hypothesis that might explain how sodium can be bound in an 
osmotically inactive way has been brought forward by Titze et al (206, 996) and proposes that 
sodium can be stored on proteoglycans in interstitial sites. This uniquely bound sodium can 
induce a state of local hypertonicity in the skin interstitium. In a further study they suggest that 
the local hypertonicity is sensed by macrophages, which then activate a transcription factor 
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(tonicity enhanced binding protein), which in turn induces vascular endothelial growth factor C 
signaling (201, 202, 997). Macrophages play a key role in innate immunity, and therefore further 
studies in microgravity should distinguish between the effects of microgravity and high sodium 
intake on the immune system. 
 
 
G. Vitamin A 
In brief, vitamin A plays a well-known role in immune function and protection against 
infections (998-1001). A vitamin A deficiency impairs mucosal barriers and diminishes the 
function of neutrophils, macrophages, and natural killer cells (1002); it may affect host defenses 
directly (1003) or indirectly through its role in epithelial cell differentiation and host barrier 
function (1000)). The considerable immunity benefits of vitamin A, which would contribute to 
reducing the risk of various pathogen-mediated diseases, warrant a recommendation to 
supplement individuals who have minimal or poor vitamin A status. However, whether immunity 
benefits accrue from providing additional vitamin A to those with sufficient status is not known 
(1004).  
 
 
H. Vitamin C 
Ascorbic acid (vitamin C) is an essential component of every living cell. The concentration 
of vitamin C is very high in leukocytes, and the vitamin is used rapidly during infection to 
prevent oxidative damage. Vitamin C is a regulator of redox reactions and of metabolic 
checkpoints controlling activation and survival of immune cells (972). A deficiency in vitamin C 
status is associated with reduced immune function (1005). Vitamin C has been shown to 
stimulate the immune system by enhancing T-lymphocyte proliferation in response to infection, 
and by increasing cytokine production and synthesis of immunoglobulins (1006). However, the 
antioxidant role during spaceflight of neither vitamin A nor vitamin C has been investigated up 
to now. In analog studies such as (short- or long-duration) bed rest, no significant change in 
vitamin C could be shown (357, 667), but a trend for an increase was apparent. This might have 
been related to dietary vitamin C intake during the study relative to the intake before the study 
(357).  
 
 
I. Vitamin E 
Vitamin E is a strong antioxidant that can support monocyte/macrophage-mediated responses 
(1007). Vitamin E and selenium have synergistic functions in tissues to reduce damage to lipid 
membranes by the formation of reactive oxygen species during infections. The ability of vitamin 
E to scavenge lipid-soluble free radicals depends to some extent on the status of 2 other 
antioxidant compounds, vitamin C and glutathione, which are involved in reducing oxidized 
vitamin E back to a reusable (that is, able to be oxidized) form. Additionally, vitamin E may 
improve T-cell function by decreasing production of prostaglandin E2 by macrophages, by 
modulating the amino acid cascade initiated by lipoxygenase and/or cyclooxygenase (131). 
Furthermore, vitamin E influences lymphocyte maturation, possibly by stabilizing membranes 
and allowing enhanced binding of antigen-presenting cells to immature T cells through increased 
expression of intercellular adhesion molecule-1. 
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J. Copper 
Copper has wide-ranging functions in the body, including many considered vital for 
spaceflight (102, 533-536). This fact might have direct or indirect (when alterations are induced 
by psychological stress or radiation stress) implications for nutrition and nutritional status being 
possible causes or effects of alterations in immune system function (2). Nonetheless, to date, 
little to no information is available about copper metabolism during spaceflight. 
 
 
K. Zinc 
In addition to its many essential functions in growth and development, zinc is essential for 
the function of cells of the immune system (1008). It has an important role in promotion of 
wound healing and in maintenance of intestinal integrity. A deficiency of zinc is also associated 
with reduced concentrations of insulin-like growth factor 1 and reduced rates of protein 
synthesis. Therefore, zinc deficiency could be especially detrimental during immobility. 
However, zinc status of astronauts, as assessed by mean serum zinc and urinary zinc excretion 
(admittedly, not the best markers of zinc status), did not change after long-duration spaceflight 
(2). No data are available on the use of zinc supplementation as a countermeasure during 
spaceflight. 
 
 
L. Polyphenols 
Naturally occurring polyphenols like resveratrol, quercetin, curcumin, and catechins have 
shown antioxidant and anti-inflammatory effects (1009). These effects seem to be modulated 
through different pathways such as protein kinase-dependent pathways activated by the nuclear 
transcription factor NF-кB or by mitogens, as well as through preventing the generation of 
reactive oxygen species by iron binding (1010). Additionally, polyphenols seem to activate 
sirtuin 1 directly or indirectly and are beneficial for that reason, besides their other functions in 
regulation of oxidative stress, inflammation, and autoimmunity. Accumulating evidence has 
shown that polyphenols such as resveratrol, curcumin, catechins, and quercetins have a 
regulatory role in immune function in vitro and in vivo (537, 1011-1016). Therefore, they might 
also have beneficial effects in prevention of immune dysfunction during long-term space 
missions, particularly because body iron stores are higher during spaceflight. However, the role 
of polyphenols in sirtuin 1-mediated or iron-related regulation in immune function remains to be 
studied. No results have been obtained during spaceflight yet; however, a recently selected flight 
study will examine the effect of increasing polyphenol intake on bone health in particular. 
 
 
 
M. Iron 
As mentioned previously, the maintenance of iron homeostasis is extremely important for 
human health. During spaceflight, it is well established that iron homeostasis is altered (2, 498). 
The decreased red blood cell mass, increased serum ferritin, decreased transferrin receptors, and 
increased serum iron all provide evidence for increased iron storage during spaceflight. 
Furthermore, the space food system provides almost 3 times the recommended iron intake (2). 
Iron plays an ambiguous role in human health: not only do humans require it for survival, but 
also microorganisms (including pathogens) require iron acquisition from the environment for 
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their survival. Cells of the innate immune system have genes that regulate proteins that can 
modulate iron homeostasis at the cellular and systemic level to restrict iron availability to 
invading microorganisms. One such protein is hepcidin, a key regulator of iron homeostasis and 
a critical factor in the anemia of inflammation (1017, 1018). Hepcidin has been shown to be 
endogenously expressed by innate immune cellsmacrophages and neutrophils. It plays a role 
in making iron less available by increasing intracellular iron sequestration and decreasing 
circulating iron concentrations, and it is influenced by cytokines IL-6 and IL-1 (1019, 1020). 
Studies need to be done to determine the role of increased iron stores during spaceflight on 
immune function and reactivation of latent viruses.  
 
 
N. Polyunsaturated Fatty Acids 
Polyunsaturated fatty acids (PUFAs), such as omega-3 fatty acids, protect cells from 
oxidative damage and radiation-related risks (123, 1021), both of which are concerns for space 
travelers. The mechanism of action of omega-3 fatty acids in protecting cells is likely related to 
multiple pathways, but evidence exists that the nuclear transcription factor NF-κB is affected 
differently by omega-3 and omega-6 fatty acids (1022). This transcription factor affects 
transcription of genes involved in cell cycle regulation and inflammatory processes. NF-κB is 
activated by arachidonic acid and specifically by prostaglandin E2, but Camandola and 
colleagues have found that eicosapentaenoic acid (a PUFA) inhibits NF-κB activation (1022). 
We have reported elevated NF-κB after short-duration spaceflight (147). The effects of 
omega-3 fatty acids on inflammatory cytokines, and specifically TNFα, are well documented on 
the ground (147, 1023-1025), but warrant further studies during spaceflight. 
 
 
 
O. Food, Microbiome, and Immunity 
 
 Growing evidence documents the interrelationship of diet, the microbiome, immune system 
function, and disease (650, 1026-1030).  This is a relatively new field, and while NASA has 
initiated some experiments evaluating the microbiome in ISS crews, more work clearly is 
required.  Additional proposals have been submitted (and as of this writing are still under review) 
to evaluate the potential for developing and flying healthier foods and their ability to influence 
immune system function and other factors in health and disease. 
 
 
P. Summary 
In summary, astronauts in space are generally not optimally nourished. Dietary intake 
tailored to the astronauts’ needs may be beneficial for their immune system function. 
Furthermore, the environmental stress of spaceflight can lead to changes in immune response as 
well as in the nutritional needs of the individual astronaut. Nutrition for optimal immune 
response and other functions is required to support optimal astronaut health during long-duration 
missions. However, it is important to be aware that “one size does not fit all.” An immune 
nutrient intake profile that is appropriate for one astronaut or one condition may be of minimal 
benefit for another individual or condition, and could be harmful in other settings. Making 
evidence-based decisions in choosing the optimal diet or formula will minimize adverse effects. 
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To reach that level of individualized diet for astronauts, further research is needed to assess 
whether diet can benefit immune function during spaceflight. The use of basic clinical 
pharmacology, molecular biology, and clinical research principles in the study of nutritional 
therapy during spaceflight and analog studies will lead to answers on how to administer the right 
nutrients, in the right amounts, at the right time during astronauts’ space missions. 
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XV. N13: Can renal stone risk be decreased using nutritional countermeasures? 
 
 A renal stone risk profile is determined from measured urinary oxalate, uric acid, citrate, 
calcium, sodium, magnesium, sulfate, potassium, pH, phosphorus, and total volume, and 
calculated supersaturation of calcium oxalate, brushite (calcium phosphate), sodium urate, uric 
acid, and struvite. Generally, renal stone risk is elevated during spaceflight (181). As with any 
spaceflight effect, some crewmembers are more affected than others. The graph below (Figure 
105) is an important illustration of this. Some crewmembers had very high elevations in brushite 
or calcium oxalate supersaturation during spaceflight, whereas others had very low levels of 
supersaturation. During spaceflight, environmental and dietary factors all greatly affect renal 
stone risk. Crewmembers who have an increased risk before spaceflight and then are exposed to 
microgravity with concomitant bone loss, hypercalciuria, increased urinary sodium, and 
decreased urinary output may have a further increased risk of renal stone formation during 
spaceflight. 
 
Figure 105. Estimated 
supersaturation risk from the Renal 
Stone Risk Profile before, during, 
and after spaceflight. Each symbol 
represents a 24-h urine pool, and 
the solid black line represents the 
group mean. The red dashed line is 
the point above which the risk is 
greater than in the non-stone-
forming population (2, 6). 
 
 As of 2013, 25 renal stone events had been reported among 19 crewmembers, with the 
majority of these stone events occurring post flight (Robert Pietrzyk, personal communication). 
To minimize the risk of stone formation, potassium citrate (KCit) has been successfully tested 
during ISS missions (765), and has been “transitioned to operations.” This means that KCit is 
part of the flight surgeon’s toolbox for mitigating the renal stone risk of crewmembers and is 
available on ISS for use at flight surgeon discretion if clinically indicated. The use of KCit was 
shown to increase urinary pH, thus increasing the solubility of uric acid and thereby decreasing 
the risk of uric acid stone formation. The dosage of KCit must be carefully prescribed so as not 
to increase the risk of brushite stone development due to elevated urinary pH. However, given 
that fluid intake for maintenance of hydration is a preferred countermeasure, and some residual 
concerns exist about potassium supplementation side effects, it was decided not to routinely 
provide KCit to crewmembers.  
 Magnesium and citrate are both considered protective when it comes to the risk of forming 
calcium-containing renal stones. However, they do not minimize risk for all forms of kidney 
stones; specifically, these urinary stone inhibitors do not reduce the risk of sodium urate kidney 
stones. Thus, taking KCit or KMgCit should not be perceived as a panacea for stone risk. In fact, 
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in our data, sodium urate supersaturation is significantly correlated with urinary citrate excretion 
(Figure 106). 
 
Figure 106. Relationship between urinary citrate and 
sodium urate supersaturation. The dashed line at 2 
represents the average risk of sodium urate stone 
formation for the general population, with numbers 
above 2 being higher than average risk. Citrate, which 
typically protects against renal stone risk, is actually 
positively correlated with sodium urate supersaturation 
(Pearson r = 0.065; P < 0.016). Data are from 1399 24-h 
urine collections (2, 6).  
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XVI. Conclusion 
 
Nutrition is critical for health, both on Earth and in space. Determining the nutritional 
requirements for travelers on short-, medium-, and long-duration exploration missions is critical 
for ensuring crew health. Requirements have been defined, as described herein, but in most cases 
have never been validated.  In other cases, requirements for specific foods have not yet been 
defined (e.g., fish, fruits, vegetables, nuts), and these play as critical a role as the defined 
nutrients, if not a larger one, given all we do not know about the thousands of phytonutrients that 
exist, for example. 
The ability of nutrients and nutrition to mitigate the negative effects of space travel is far 
from being fully explored. Ground-based evidence is being amassed but is yet to be fully tested. 
In many ways, nutrition offers a suite of countermeasures that requires no more crew time than 
that already allotted for meals. While care clearly needs to be taken to avoid excessive amounts 
of any nutrient, the risks compared with those of pharmacological countermeasures are 
negligible. 
This document details the nutrition evidence collected to date that has direct or indirect 
implications for space travelers. Although much has been done to obtain this evidence, a 
significant further effort will be required to validate the requirements listed herein, to optimize 
nutrition for astronauts, and ultimately to use this nutrition tool fully to help mitigate the health 
risks of microgravity exposure. 
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XIX. Appendix A. Nutrient Requirements and Dietary Intake Data Tables 
 
Table 1. Planned (menu) and targeted nutrient intake on International Space Station missions.1 
  Menu Content2 
NASA Spaceflight 
Requirement (5) 
Energy, kcal/d 2877 ± 1673 Based on WHO (27) 
Energy, % WHO 99 ± 13  
Total carbohydrate, % of kcal 50 ± 3  50-55 
Total protein, g/d 126 ± 10  
Total protein, % of kcal 17 ± 1  12-15 
Animal protein, g/d 72 ± 7 60% 
Vegetable protein, g/d 33 ± 3 40% 
Total fat, % of kcal 31 ± 1  30-35 
Total dietary fiber, g/d 33 ± 4 10-25 
Retinol equivalents, μg/d 1420 ± 205 1000  
Vitamin D, μg/d 4.2 ± 1.0 10 
Vitamin E (total α-tocopherol 
equivalents), mg/d 
12.1 ± 1.9 20 
Vitamin K (phylloquinone), μg/d 105 ± 19 80 
Vitamin C (ascorbic acid), mg/d 191 ± 39 100 
Thiamin, mg/d 2.0 ± 0.1 1.5 
Riboflavin, mg/d 2.2 ± 0.2 2.0 
Niacin, mg/d 29.8 ± 1.9 20 mg niacin equivalents 
Pantothenic acid, mg/d 5.1 ± 0.8 5.0 
Vitamin B6, mg/d 2.3 ± 0.2 2.0 
Total folate, μg/d 434 ± 53 400 
Vitamin B12 (cobalamin), μg/d 4.6 ± 0.7 2.0 
Calcium, mg/d 1020 ± 109 1000-1200 
Phosphorus, mg/d 1856 ± 165 1000-1200 (NTE 1.5 x Ca) 
Phosphorus:calcium ratio 1.83 ±0.17 <1.5 
Magnesium, mg/d 424 ± 40 350 
Iron, mg/d 22.7 ± 4.5 10 
Copper, mg/d 3.6 ± 0.9 1.5-3.0 
Zinc, mg/d 22.1 ± 6.2 15 
Manganese, mg/d 5.7 ± 0.7 2-5 
Selenium, g/d 146 ± 16 70 
Iodine, mg/d 1.0 ± 2.8 0.15 
Sodium, mg/d 5625 ± 531 <3500 
Potassium, mg/d 3995 ± 360 3500 
Water, g/d 2155 ± 206 1 mL/kcal, > 2 liters per day 
WHO, World Health Organization. 
1Table adapted from Smith and Zwart (1).  
2Menu data are derived from either proximate analysis of space foods (macronutrients, most minerals) or 
estimations (animal protein, vegetable protein, all vitamins, selenium) from similar items in the Nutrition Data 
System for Research (NDS-R) database, versions 4.03/31, 4.05/33, 4.06/34, 5.0/35, 2005, and 2006, developed by 
the Nutrition Coordinating Center, University of Minnesota, Minneapolis, MN, USA (1031). 
3All data are the mean  SD and represent the average from menus of 19 ISS astronauts.  
  
 
 
Table 2. Nutrient intake data for several space programs are reported below. For ISS, we report the data on nutrients available from the Food Frequency 
Questionnaire analysis.  
  Apollo Skylab Shuttle ISS (E1-13) ISS (E14-25) ISS (E26-37) 
N 33 9 32 19 19 17 
Energy, kcal/d 1880 ± 415a 2897 ± 447 2090 ± 440 2313 ± 514 2317 ± 591 2444 ± 536 
Energy, % WHO 64.2 ± 13.6 99.1 ± 8.2 74.2 ± 16.0 79 ± 18 83 ± 17 84 ± 15 
Protein intake, g/d 76.1 ± 18.7 111.0 ± 18.4 78.0 ± 18.8 102 ± 25 96 ± 34 109 ± 30 
Protein intake, % of 
kcal 16.3 ± 2.1 15.7 ± 2.1 14.9 ± 2.4 18 ± 2 16 ± 2 18 ± 2 
Carbohydrate intake, 
g/d 268.9 ± 49.1 413.3 ± 59.3 304.0 ± 67.3    
Carbohydrate intake, 
% of kcal 58.1 ± 7.1 57.5 ± 9.1 58.4 ± 5.0    
Fat intake, g/d 61.4 ± 21.4 83.2 ± 13.8 64.0 ± 17.8    
Fat intake, % of kcal 28.9 ± 5.5 26.8 ± 8.6 27.2 ± 4.4    
Calcium, mg/d 774 ± 212 894 ± 142 826 ± 207 878 ± 274 944 ± 258 1074 ± 205 
Phosphorus, mg/d 1122 ± 325 1760 ± 267 1216 ± 289    
Magnesium, mg/d  310 ± 58 294 ± 74    
Iron, mg/d   15.0 ± 3.9 18 ± 5 18 ± 5 20 ± 5 
Zinc, mg/d   12.0 ± 2.9    
Sodium, mg/d 3666 ± 890 5185 ± 948 3984 ± 853 4601 ± 1239 4658 ± 1593 3823 ± 785 
Potassium, mg/d 2039 ± 673 3854 ± 567 2391 ± 565 3315 ± 513 3214 ± 863 3559 ± 784 
Water, g/d 1647 ± 188b 2829 ± 529 2223 ± 669 2012 ± 462 2142 ± 387 2320 ± 581 
Abbreviations: E, expedition numbers of ISS missions; ISS, International Space Station; WHO, World Health Organization. 
aAll data are mean ± SD. Empty cells show where data were not available. Data updated and expanded from earlier reports (2, 1032).  
bN=3 for water intake during Apollo missions. 
  
 
XX. Appendix B. List of Figures 
 
Figure 1. In-flight dietary intake of crewmembers in different space programs. Data are expressed as 
percentage of energy requirements predicted by the World Health Organization (WHO) (27). Apollo 
N=33, Skylab N=9, Shuttle N=32, Mir N=7, ISS E1-18 N=26, E19-36 N=31. E = expedition. Apollo 
and Skylab data are from Bourland et al (7). Figure from (6), adapted from earlier publications (2, 
42), with additional published data included (1, 31, 41). ..................................................................... 14	
Figure 2. Postflight body weight (BW) in Mir and ISS crewmembers (N=20). Data are expressed as the 
mean ± SD of the percentage change from preflight body weight. R+0 = landing day, and AME1 and 
AME2 = first and second annual medical exams after return from the mission, respectively. (2) ...... 15	
Figure 3. Body weight in Apollo crewmembers (Apollo 7 through 17) before (F-0) and after (R+0) flight 
(64). ...................................................................................................................................................... 16	
Figure 4. In-flight body mass measurement data from 55 ISS crewmembers. Data are expressed as 
percentage change from preflight values. Figure and data adapted from Zwart et al (60). .................. 16	
Figure 5. Body mass on landing day expressed as percentage change from preflight. Each symbol 
represents a crewmember from a mission on the Space Shuttle (green, N=25), Skylab (red, N=9), Mir 
(blue squares, N=19), ISS Expeditions 1-18 (dark purple, N=26), or Expeditions 19-36 (light purple, 
N=31). Some durations have been adjusted slightly to ensure anonymity. Data updated from initial 
publications (2, 6, 10). .......................................................................................................................... 16	
Figure 6. Relationship between energy intake (kcal/kg body mass/d) and weight loss (change in body 
mass/d, kg) during Apollo missions. N=33. Data are courtesy of William Carpentier, as originally 
presented in (6). .................................................................................................................................... 17	
Figure 7. In-flight oxidation of body fat related to in-flight energy deficit. Adapted from (22). ............... 17	
Figure 8. Body weight changes in a crossover-design bed rest study to evaluate the hypocaloric impact of 
nutrition on integrated physiology. Data are expressed as the change from the group average body 
weight before bed rest (6). .................................................................................................................... 18	
Figure 9. Leucine oxidation (an index of net protein catabolism) in a crossover-design bed rest study to 
evaluate the impact of hypocaloric nutrition on integrated physiology. There was a significant 
(P=0.04) interaction between bed rest and diet (adapted from (70)). ................................................... 18	
Figure 10. Urinary calcium in a crossover-design bed rest study to evaluate the impact of hypocaloric 
nutrition on integrated physiology.  Data are expressed as mmol Ca excreted per 24 hours before, 
during, and after bed rest. From inset legend: Up, ambulatory phase; HDT, head-down-tilt bed rest 
phase. .................................................................................................................................................... 19	
Figure 11. Lower-body negative pressure (LBNP) “survival” in a crossover-design bed rest study to 
evaluate the impact of hypocaloric nutrition on integrated physiology.  Data are expressed as the 
number of subjects who were able to tolerate different amounts (minutes) of LBNP (72). ................. 19	
Figure 12. Protein intake during spaceflight on ISS missions (N=56). Each point represents an individual 
crewmember, and is their reported average intake over the course of the mission. Dashed lines 
represent spaceflight (and ground-based) protein intake requirements of 0.8 g protein/kg body mass, 
and the range of protein intakes (1.2.-1.7 g/kg) recommended by the American Dietetic Association, 
Dietitians of Canada, and American College of Sports Medicine for high-intensity athletes (90). The 
blue lines represent the mean ± SD. Figure from (6). .......................................................................... 23	
Figure 13. Plasma total protein and albumin in Skylab crewmembers before flight and after landing (R+0, 
landing day) (39). ................................................................................................................................. 23	
Figure 14. Plasma insulin (N=22) and glucose (N=33) in Apollo crewmembers before and after flight 
(104). .................................................................................................................................................... 25	
Figure 15. Plasma glucose in Skylab crewmembers before, during, and after flight (39). ......................... 26	
Figure 16. Plasma insulin in Skylab crewmembers before, during, and after flight (39). .......................... 26	
Figure 17. Plasma triglycerides in Skylab crewmembers before and after flight (39). ............................... 29	
Risk Factor of Inadequate Nutrition 
 
 232
Figure 18. Serum high-density lipoproteins (HDLs) in ISS crewmembers before and after flight. Unless 
otherwise noted, data are from R+0/1. Because HDLs are not routinely measured at landing, some 
data were available only at the next medical exam. In these cases, the date is denoted on the chart as 
R+X days (2). ....................................................................................................................................... 30	
Figure 19. Serum low-density lipoproteins (LDLs) in ISS crewmembers before and after flight. Because 
LSLs are not routinely measured at landing, some data were available only at the next medical exam. 
In these cases, the date is denoted on the chart as R+X days (2). ........................................................ 30	
Figure 20. Relationship between the loss of body mass post flight and the change in serum LDLs in ISS 
crewmembers. Because LDLs are not routinely measured at landing, some data were available only at 
the next medical exam, which ranged from 50 to 257 days after landing. ........................................... 30	
Figure 21. Relationship between fish intake during flight and whole-body bone mineral density loss after 
flight. Figure adapted from (147). ........................................................................................................ 31	
Figure 22. Serum (N=33) and urinary (N=30) sodium from Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). ..................................... 37	
Figure 23. Serum (N=33) and urinary (N=30) chloride from Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). ..................................... 38	
Figure 24. Plasma sodium of Skylab crewmembers (N=9) before, during, and after flight (39). .............. 38	
Figure 25. Plasma chloride of Skylab crewmembers (N=9) before, during, and after flight (39). ............. 39	
Figure 26. Serum sodium (left panel) and chloride (right panel) of Shuttle crewmembers (N=2-6) during 
and after flight, expressed as a percentage change from preflight values (208). .................................. 39	
Figure 27. Inflight dietary sodium intake (mg/d) across space programs. .................................................. 40	
Figure 28. Urinary C-telopeptide (CTX) excretion in bed rest subjects on high-sodium (open triangles) or 
low-sodium (filled squares) diets. Bed rest began on day 4, indicated by the vertical line. Adapted 
from (241, 242). .................................................................................................................................... 42	
Figure 29. Proposed mechanism of the effects of high dietary sodium on bone loss (6). ........................... 42	
Figure 30. Serum (N=33) and urinary (N=30) potassium of Apollo crewmembers. Numbers in bars 
represent the percentage change from preflight values. Adapted from (104). ..................................... 44	
Figure 31. Exchangeable potassium of Apollo 15, 16, and 17 crewmembers after flight, as the percentage 
change from preflight values (104). ..................................................................................................... 44	
Figure 32. Plasma potassium of Skylab crewmembers (N=9) before, during, and after flight (39). .......... 45	
Figure 33. Serum potassium of Shuttle crewmembers (N=2-6) during and after flight, expressed as the 
percentage change from preflight values (208). ................................................................................... 45	
Figure 34. Serum retinol and retinol-binding protein in ISS crewmembers before and after long-duration 
spaceflight.  Adapted from (31). ........................................................................................................... 47	
Figure 35. Serum retinol (left) and β-carotene (right) in ISS crewmembers before, during, and after long-
duration spaceflight.  Dashed lines represent the normal range for retinal.  Figure from (6). ............. 48	
Figure 36. Vitamin D synthesis, activation, and catabolism. Adapted from (278). .................................... 50	
Figure 37. Plasma 25-hydroxyvitamin D of Skylab crewmembers (N=9) before and after flight (39). ..... 51	
Figure 38. Serum 25-hydroxyvitamin D concentrations before and after 4- to 6-month spaceflights on the 
International Space Station. Each line represents one crewmember. The “Pre Mean” point on each 
line is the average of data collected about 6 months and 6 weeks before launch. R+0 = Recovery plus 
zero days, that is, landing day. These samples are typically collected 2-8 hours after landing. The 
dashed line shows the (outdated) lower limit of normal range, and the solid horizontal line shows 
what many considered to be the “optimal” concentration of vitamin D in the circulation. From (1, 31).
 .............................................................................................................................................................. 52	
Figure 39. Serum 25-hydroxyvitamin D and parathyroid hormone (PTH) concentrations before (average 
of data from samples collected about 6 months and 6 weeks before launch) and after (landing day, 
typically collected 2-8 hours after landing) 4 to 6-month spaceflights on the International Space 
Station. Each symbol represents one crewmember. From (1, 31). ....................................................... 52	
Risk Factor of Inadequate Nutrition 
 
 233
Figure 40. Pre- and postflight data from testing required for medical operations show that vitamin D 
status decreased after long-duration spaceflight, despite vitamin D supplementation with 400 IU/d 
(black dashed line, N=16). In-flight data (purple line) show that 800 IU/d is enough vitamin D3 to 
maintain status during long-duration spaceflight (N=26). Red lines depict Institute of Medicine-
defined lower acceptable limits (with respect to bone health), and upper advised limit (279). The 
green line at 80 nmol/L reflects what many perceive as an optimal level with respect to parathyroid 
hormone suppression and non-bone health outcomes. Figure adapted, and data updated, from Smith et 
al (314). ................................................................................................................................................ 55	
Figure 41. Effect of long-duration spaceflight on vitamin K status of 15 ISS crewmembers. 
Undercarboxylated osteocalcin (left) and urinary -carboxyglutamic acid (GLA, right) are shown 
here. There were no significant changes as a result of spaceflight (341). ............................................ 60	
Figure 42. Red blood cell (RBC) (left) and serum folate (right) before, during, and after long-duration 
spaceflight (data are mean ± SD). Note: RBC folate data are not available during flight because of 
sample processing requirements. .......................................................................................................... 62	
Figure 43. Plasma vitamin C in 7 subjects during 21 d of bed rest. Data are expressed as the percentage 
change (mean±SD) from before bed rest (356). The vertical dotted line marks the end of bed rest. ... 68	
Figure 44. Plasma methylmalonic acid data collected on ISS astronauts. Each point represents an 
individual test point, and the horizontal bars represent mean ± SD. Dashed lines represent normal 
ranges (Smith and Zwart, unpublished observations). ......................................................................... 72	
Figure 45. Plasma calcium of Skylab crewmembers (N=9) before and after flight (39). ........................... 77	
Figure 46. Serum calcium of Shuttle crewmembers (N=2-6) during and after flight, expressed as 
percentage change from preflight values (208). ................................................................................... 77	
Figure 47. Plasma parathyroid hormone (PTH) concentrations of Skylab crewmembers (N=9) before and 
after flight (39). .................................................................................................................................... 77	
Figure 48. Plasma total alkaline phosphatase of Skylab crewmembers (N=9) before and after flight (39).
 .............................................................................................................................................................. 78	
Figure 49. Plasma phosphate of Skylab crewmembers before, during, and after flight (2). ....................... 81	
Figure 50. Urinary phosphorus of ISS crewmembers (N=11) before and after long-duration spaceflight. 
Adapted from (31). ............................................................................................................................... 82	
Figure 51. Serum (N=32) and urinary (N=23) magnesium levels in Apollo crewmembers. Numbers in 
bars represent the percentage change from preflight values. Adapted from (104). .............................. 83	
Figure 52. Serum magnesium levels of Shuttle crewmembers (N=2-6) during and after flight, expressed 
as a percentage change from preflight (208). ....................................................................................... 84	
Figure 53. Plasma magnesium levels of Skylab crewmembers (N=9) before and 0, 1, 3-4, and 14 days 
after flight (2). ...................................................................................................................................... 84	
Figure 54. Serum (left panel) and urinary (right panel) magnesium before and after 4- to 6-month 
spaceflights on the International Space Station. Each line represents one crewmember. The “Pre 
Mean” point on each line is the average of data collected about 6 months and 6 weeks before launch. 
R+0 = Recovery plus zero days, i.e., landing day. These samples are typically collected 2-8 hours 
after landing. From (1, 31). .................................................................................................................. 85	
Figure 55. Red blood cell mass (mL/kg body mass) after spaceflight. Each point represents one 
crewmember. Data are expressed as the percentage change from preflight values. From (493). ........ 88	
Figure 56. The percentage change from preflight in serum ferritin (red circles, solid line) and urinary 
8OHdG (blue squares, dashed line) before, during, and after long-duration spaceflight (N=23). “Pre” 
was determined from the mean of preflight data points (3 for ferritin, 4 for 8OHdG), and percentage 
change was calculated from that average. Adapted from (498). .......................................................... 88	
Figure 57. Relationship between iron stores and oxidative damage in three NEEMO missions, where 
crewmembers were exposed to saturation dive conditions for 10-12 days. The panel on the left 
presents data from 12 crewmembers on the NEEMO 12 and 13 missions (507), and the panel on the 
Risk Factor of Inadequate Nutrition 
 
 234
right presents data from 6 crewmembers on the NEEMO 5 mission (358). The regression line in both 
graphs is significant (P<0.05). Adapted from (2, 507). ........................................................................ 89	
Figure 58. Serum copper before and after 4- to 6-month missions on the International Space Station. Each 
line represents one crewmember. The “Pre Mean” point for each line is the average of data collected 
about 6 months and 6 weeks before launch. R+0 = Recovery plus zero days, i.e., landing day. These 
samples are typically collected 2-8 hours after landing. From (1, 31). ................................................ 91	
Figure 59. Serum ceruloplasmin before and after 4- to 6-month missions on the International Space 
Station. Each line represents one crewmember. The “Pre Mean” point on each line is the average of 
data collected about 6 months and 6 weeks before launch. R+0 = Recovery plus zero days, i.e., 
landing day. These samples are typically collected 2-8 hours after landing. From (1, 31). ................. 92	
Figure 60. Serum and urinary zinc status from 11 ISS crewmembers before and after flight (2, 31). ....... 96	
Figure 61. Toenail selenium content and relative risk of prostate cancer (adapted from (549)). ............... 97	
Figure 62. Urinary iodine excretion of ISS crewmembers before and after long-duration spaceflight (31).
 .............................................................................................................................................................. 99	
Figure 63. Serum 2-methylcitric acid (2-MCA), methylmalonic acid (MMA), homocysteine, and 
cystathionine before, during, and after long-duration spaceflight in crewmembers who have 
experienced ophthalmic changes during flight and those who have not. Figure adapted from Zwart et 
al (349). .............................................................................................................................................. 103	
Figure 64. The absolute refractive change in the right eye after flight relative to before flight was 
significantly associated with mean preflight homocysteine, cystathionine, and 2-methylcitric acid, and 
with mean in-flight serum folate. A Somers’ D measure of association was used for analysis. Raw 
data are presented in the graphs. One crewmember with visual or intracranial pressure issues did not 
experience refractive changes after flight, and that crewmember had the highest preflight 
homocysteine and the highest in-flight serum folate, and was the only crewmember with visual or 
intracranial pressure issues to have reported taking multivitamin supplements during the 6-month 
mission. This individual also had the highest grade of disc edema of all crewmembers to date. The 
data from that subject are included in the graphs above (N=20 in all graphs above). Data from Zwart 
et al (349). ........................................................................................................................................... 104	
Figure 65. Bone mineral density and body composition (expressed as % change per month) in 
crewmembers on the Russian space station Mir, and on ISS flights with exercise on the iRED or 
ARED. Figure from (41). ................................................................................................................... 106	
Figure 66. Bone mineral density (BMD) loss after flight in men (N=33, open bars) and women (N=9, 
solid bars) who used either the iRED or ARED exercise device. Data are expressed as percentage 
change per month of flight. Figure adapted from (58). ...................................................................... 107	
Figure 67. The percentage change in ferritin and urinary 8OHdG before, during, and after long-duration 
spaceflight (N=23). “Pre” was determined from the mean of preflight data points (3 for ferritin, 4 for 
8OHdG), and percentage change was calculated from that average (498). ........................................ 109	
Figure 68. Characterization of cytokine changes during (and after) flight, based on data from (577). 
Arrows indicate changes observed during flight (except for IL-6, where increases were noted at 
landing). .............................................................................................................................................. 110	
Figure 69. In-flight body mass measured by the BMMD (black lines) or SLAMMD (gray dashed lines), 
expressed as percentage change from before flight (N=25). Adapted from (60). .............................. 111	
Figure 70. Comparison of in-flight body mass data from the SLAMMD and BMMD. For the linear 
relationship (dashed line), the Pearson r= 0.9829. The solid black line is a line of unity for 
comparison. Adapted from (60). ........................................................................................................ 112	
Figure 71. Pre- and postflight data from MedB8.1 show that vitamin D status decreased after long-
duration spaceflight, despite vitamin D supplementation with 400 IU/d. In-flight data from SMO 
016E showed that 800 IU/d was enough vitamin D to maintain status during long-duration 
spaceflight. Red lines depict Institute of Medicine-defined lower acceptable limits (with respect to 
bone health), and upper advised limit (279). The green line at 80 nmol/L reflects what many perceive 
Risk Factor of Inadequate Nutrition 
 
 235
as an optimal level with respect to parathyroid hormone suppression and non-bone health outcomes. 
Figure adapted from (31, 41). ............................................................................................................. 113	
Figure 72. Data from long-duration spaceflight showing that consumption of more servings of fish per 
week was related to less bone resorption after flight, as indicated by resorption marker urinary n-
telopeptide (NTX) on the left, and greater bone density, as indicated by whole-body bone mineral 
density (BMD) on the right). Data are adapted from Zwart et al, 2010 (147). ................................... 114	
Figure 73. Urinary calcium concentration before and during flight, by year of collection. Each symbol 
represents a 24-h urine collection (N=23, up to five 24-h collections/subject), mean ± SD. The 
horizontal green dashed line represents a calcium concentration of 28.3 mg/dl, the expected calcium 
precipitation point for UPA water recovery at 70% (new set point), and the red dashed line represents 
calcium concentrations of 14.2 mg/dl, the expected calcium precipitation point for UPA water 
recovery at 85% (the original set point). ............................................................................................ 115	
Figure 74. Concentration of calcium in urine voids relative to the time of day when they were collected. 
Filled circles represent crewmembers who were taking bisphosphonates during their mission. These 
data were evaluated to see if operational decisions (such as excluding the first morning void or 
prescribing bisphosphonates) could decrease the risk of calcium precipitating in the UPA. SV = single 
void (as opposed to 24-h pool data). .................................................................................................. 115	
Figure 75. In-flight urinary calcium concentration versus in-flight mean fluid intake (estimated from the 
food frequency questionnaire). The green dashed lines represent the calcium concentration required to 
maintain 70% or 75% water recovery from the UPA system. 70% represents the conservative lower 
recovery rate adopted after system failure in 2009, and 75% the adjustment after revisiting these data 
in 2012. Figure from (191). ................................................................................................................ 116	
Figure 76. Estimated risk of brushite and calcium oxalate supersaturation from the Renal Stone Risk 
Profile. Each symbol represents an individual 24-h urine collection, and the solid black line represents 
the group mean. The red dashed line at 2 is the point above which the risk of supersaturation is 
greater than in the general population. ............................................................................................... 117	
Figure 77. Total testosterone concentrations before, during, and after flight. Although circulating 
concentrations decreased significantly after flight (at R+0), no other time point differed significantly 
from the preflight mean. N=15. Data adapted from Smith et al (583). .............................................. 118	
Figure 78. Effect of long-duration spaceflight on vitamin K status of 15 ISS crewmembers. 
Undercarboxylated osteocalcin (left) and urinary -carboxyglutamic acid (GLA, right) are shown 
here. No significant changes resulted from spaceflight (341). ........................................................... 119	
Figure 79. Serum α-tocopherol (top left) and γ-tocopherol (top right), and total vitamin E:lipid ratio 
(bottom) before, during, and after long-duration spaceflight. All data are mean ± SD. (6) ............... 131	
Figure 80. Bone resorption (as indicated by urinary n-telopeptide [NTX], left panel) and bone formation 
(as evaluated by serum bone-specific alkaline phosphatase [BSAP], right panel) during 17 weeks of 
bed rest with (solid line) or without (dashed line) heavy resistance exercise. Data are expressed as 
percentage of pre-bed rest values, and are mean ± SD. The vertical line separates the bed rest and post 
bed rest periods. Data adapted from (564). ........................................................................................ 137	
Figure 81. Bone resorption (as indicated by urinary n-telopeptide, left panel) and bone formation (as 
indicated by serum bone-specific alkaline phosphatase, right panel) during 60 days of bed rest with 
(solid line) or without (dashed line) a combination of resistance exercise and supine treadmill/LBNP 
exercise. Data are expressed as percentage of pre-bed rest values, and are mean ± SD. Data adapted 
from (81). ............................................................................................................................................ 137	
Figure 82. Body composition changes (left panel, lean body mass; right panel, total body fat) in astronauts 
on Mir and ISS missions. ISS crews had access to either iRED or ARED exercise devices. Data are 
expressed as percentage change per month of flight. Figure adapted from (41). ............................... 138	
Figure 83. Bone mineral density loss in astronauts on Mir and ISS missions. ISS crews had access to 
either iRED or ARED exercise devices. Data are expressed as percentage change per month of flight. 
Figure adapted from (41). ................................................................................................................... 138	
Risk Factor of Inadequate Nutrition 
 
 236
Figure 84. Bone mineral density (BMD) loss after flight in men (N=33, open bars) and women (N=9, 
solid bars) who used either the iRED or ARED exercise device. Data are expressed as percentage 
change per month of flight. Figure adapted from (58). ...................................................................... 139	
Figure 85. Relationship between omega-3 fatty acid consumption and bone resorption during bed rest (left 
panel), and relationship between fish consumption and percentage change in whole-body bone 
mineral density at landing in astronauts (right panel). Figures adapted from (147). .......................... 142	
Figure 86. Serum phylloquinone before launch (launch minus 180 d, or L-180, L-45, and L-10), during 
flight (flight days 15, 30, 60, 120, and 180), on landing day (R+0), and 30 days post landing (R+30). 
The dashed lines indicate the normal range for phylloquinone. Data are mean ±SD, N=26 (6). Data 
and N are expanded from the original publication of these findings (341). ....................................... 144	
Figure 87. Dietary phosphorus:calcium ratio in ISS crewmembers during flight (approximate flight days 
15, 30, 60, 120, and 180). The dashed line indicates a ratio of 1.5. Data are mean ±SD, N=9. ......... 145	
Figure 88. The bone resorption marker n-telopeptide (NTX) was positively correlated with the ratio of 
animal protein to potassium intake (APro/K) during weeks 3 and 4 of bed rest in sedentary (SED) bed 
rest subjects but only during week 1 in exercising (EX) bed rest subjects. The ratio of vegetable 
protein to potassium intake (Vpro/K) was correlated with urinary NTX excretion before bed rest but 
was not associated with NTX during bed rest (774). ......................................................................... 147	
Figure 89. Urine pH (mean ± SD) of amino acid-supplemented (AA, ■) and placebo (CON, ○) groups 
during 4 weeks of bed rest. *Significantly different from pre-bed rest, P < 0.05. #Significant 
difference between groups, P < 0.05 (778). ....................................................................................... 149	
Figure 90. Urinary n-telopeptide (NTX) excretion (mean ± SD) of amino acid-supplemented (AA, ■) and 
placebo (CON, ○) groups during 4 weeks of bed rest. *Significantly different from pre-bed rest, P < 
0.05 (no significant difference between groups) (778). ...................................................................... 149	
Figure 91. Urinary calcium excretion (mean ± SD) of amino acid-supplemented (AA, ■) and placebo 
(CON, ○) groups during 4 weeks of bed rest. #AA values were significantly different from pre-bed 
rest, P < 0.05 (778). ............................................................................................................................ 149	
Figure 92. Urinary n-telopeptide (NTX) excretion was positively correlated with net acid excretion (NAE) 
during but not before bed rest. NAE was estimated from the diet (357). ........................................... 150	
Figure 93. Protein synthesis and energy deficit. Adapted from Stein et al (69). ...................................... 154	
Figure 94. Urinary amino acid excretion by Apollo crewmembers (N=12) before and after flight (2, 104).
 ............................................................................................................................................................ 154	
Figure 95. Total serum testosterone concentrations before, during, and after flight. Although circulating 
concentrations decreased significantly after flight (at R+0), no other time point differed significantly 
from the preflight mean. N=15. Data are from Smith et al (583). ...................................................... 158	
Figure 96. Total serum testosterone concentrations in subjects before, during, and after bed rest with 
(dashed line and open circles) or without (solid line and filled squares) an artificial gravity 
countermeasure. These data have been published (356), although the pre-bed rest data were combined 
as an average in the original manuscript. In this figure, the 2 pre-bed rest data points are graphed 
separately, as reported in (583). ......................................................................................................... 159	
Figure 97. Relationship between energy intake (kcal/kg body mass/d) and plasma volume loss (mL/d) 
during Apollo missions. N=21. Data are courtesy of William Carpentier (6). ................................... 163	
Figure 98. Postflight heart rate under 3 conditions, predicted (from factors including plasma volume loss) 
versus actual measured heart rate. These data are based on the following equations: ....................... 164	
Figure 99. Postflight heart rate, predicted (from factors including energy intake) versus actual measured 
heart rate. These data are based on the following equations: ............................................................. 165	
Figure 100. Energy intake during spaceflight on ISS missions (N=56). Each point represents an individual 
crewmember, and is their reported average daily energy intake over the course of the mission. Lines 
represent the mean ± 1SD (6). ............................................................................................................ 166	
Figure 101. Overview of 1-carbon metabolism. AA, amino acids; CBS, cystathionine β-synthase; CYS, 
cystathionine; FA, fatty acids; HCY, homocysteine; αKBT, α-ketobutyrate; MCA, methylcitric acid; 
Risk Factor of Inadequate Nutrition 
 
 237
MM-CoA, methylmalonyl coenzyme A (CoA); MMA, methylmalonic acid; MS, methionine 
synthase; 5-MTHF, 5-methyltetrahydrofolate; 5,10-MTHF, 5,10-methylenetetrahydrofolate; MTHFR, 
methylenetetrahydrofolate reductase; MTRR, 5-methyltetrahydrofolate homocysteine 
methyltransferase reductase; PRP-CoA, propionyl CoA; SAH, S-adenosylhomocysteine; SAM,S-
adenosylmethionine; SUC-CoA, succinyl CoA; THF, tetrahydrofolate ............................................ 170	
Figure 102. Artistic depiction of the vision issues related to spaceflight, and the potential for genetic 
influences on the understanding of this problem. The depiction of a different DNA base pair in the 2 
strands reflects genetic polymorphisms, or multiple forms, of the DNA. Inset imagery includes ISS, 
and a Hubble Space Telescope image of the Cat’s Eye Nebula, to reflect that these issues are relevant 
not only for ISS missions, but for exploration-class missions as well. .............................................. 170	
Figure 103. This figure shows how diet and exercise can ultimately affect cognitive function through 
BDNF, a signaling molecule that can alter synaptic plasticity.  (Figure is from (917).) .................... 172	
Figure 104. An interaction between serum cortisol, vitamin D status, and the probability of EBV 
shedding. Data from all 41 participants in the Antarctic study are included in the graph, and the data 
were statistically analyzed using the continuous data set of cortisol data. The data are split into the 2 
subgroups here for presentation purposes. The graph is from Zwart et al (312). ............................... 179	
Figure 105. Estimated supersaturation risk from the Renal Stone Risk Profile before, during, and after 
spaceflight. Each symbol represents a 24-h urine pool, and the solid black line represents the group 
mean. The red dashed line is the point above which the risk is greater than in the non-stone-forming 
population (2, 6). ................................................................................................................................ 184	
Figure 106. Relationship between urinary citrate and sodium urate supersaturation. The dashed line at 2 
represents the average risk of sodium urate stone formation for the general population, with numbers 
above 2 being higher than average risk. Citrate, which typically protects against renal stone risk, is 
actually positively correlated with sodium urate supersaturation (Pearson r = 0.065; P < 0.016). Data 
are from 1399 24-h urine collections (2, 6). ....................................................................................... 185	
 
  
Risk Factor of Inadequate Nutrition 
 
 238
 
XXI. Appendix C. Abbreviations 
 
8OHdG 8-hydroxy-2'-deoxyguanosine 
ACP  acyl carrier protein 
ADP  adenosine diphosphate 
AI   adequate intake 
AME  annual medical examination 
AMP  adenosine monophosphate 
ARED  Advanced Resistance Exercise Device 
BDNF  brain-derived neurotrophic factor 
BHP  Behavioral Health and Performance Element (of the Human Research Program) 
BMD  bone mineral density 
BMMD Body Mass Measuring Device 
BSAP  bone-specific alkaline phosphatase 
cal   calorie 
CoA  coenzyme A 
d   day 
DFE  dietary folate equivalent(s) 
DLR  German Aerospace Center 
DNA  deoxyribonucleic acid 
DRI  dietary reference intake 
DXA  dual-energy x-ray absorptiometry 
EBV  Epstein-Barr virus 
EER  estimated energy requirements 
EGR  erythrocyte glutathione reductase 
Eq   equivalent 
ESA  European Space Agency 
EVA  extravehicular activity (space walk) 
FAD  flavin adenine dinucleotide 
FD   flight day 
g   gram 
g   acceleration due to gravity (1g = Earth gravity) 
GLA  -carboxyglutamic acid 
GPX  glutathione peroxidase 
Gy   Gray 
h, hr  hour  
HDL  high-density lipoprotein 
HRP  Human Research Program 
Hz   hertz 
IFN  interferon 
IL   interleukin 
IOM  Institute of Medicine 
iRED   interim resistance exercise device 
ISS  International Space Station 
IU   international unit 
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J   joule 
K   kilo 
KCit   potassium citrate 
L   liter 
LDL  low-density lipoprotein 
LBNP  lower-body negative pressure 
LH   luteinizing hormone 
µ   micro 
m   meter, milli 
MCA  methylcitric acid 
MDA  malondialdehyde 
MMA  methylmalonic acid 
mol  mole 
N   number of subjects in a sample of a population 
NAD  nicotinamide adenine dinucleotide  
NADH  reduced form of nicotinamide adenine dinucleotide 
NADP  nicotinamide adenine dinucleotide phosphate 
NADPH reduced form of nicotinamide adenine dinucleotide phosphate 
NASA  National Aeronautics and Space Administration 
NE   niacin equivalent 
NEEMO NASA Extreme Environment Mission Operations 
NF-κB  NF-kappa B protein complex, which functions as a nuclear transcription factor 
NK  natural killer 
NTX  n-telopeptide 
P   probability 
PGF2α  8-iso-prostaglandin F2α 
PL   pyridoxal 
PLP  pyridoxal 5'-phosphate 
PM  pyridoxamine 
PMP  pyridoxamine 5'-phosphate 
PN   pyridoxine 
PNP  pyridoxine 5'-phosphate 
psia  pound(s) per square inch absolute 
PTH  parathyroid hormone 
PUFA   polyunsaturated fatty acid 
r   bivariate correlation coefficient 
R+0  0 days after landing (recovery) 
RBC  red blood cell 
RDA  recommended dietary allowance  
RE   retinol equivalent 
RNA  ribonucleic acid 
ROS  reactive oxygen species 
SAM  S-adenosylmethionine 
SD   standard deviation 
SLAMMD Space Linear Acceleration Mass Measuring Device 
SMO  Supplemental Medical Objective  
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TEE  total energy expenditure 
THF  tetrahydrofolate 
TPP  thiamin pyrophosphate 
U   unit 
ULLS  unilateral limb suspension 
UPA   Urine Processor Assembly 
UV-B  ultraviolet B 
VDR   vitamin D receptor 
WHO  World Health Organization 
y   year 
 
 
 
